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Abstract 
i 
 
Oxidative stress is a key feature of inflammatory diseases. Reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) are generated by many cell types during 
inflammation. ROS are known to induce chemokines, however it is increasingly 
apparent that RNS also impact on inflammation. This study was designed to 
investigate the effects of tissue stress on both chemokine production and function.  
How stress alters chemokine production in epithelium was established by qPCR. A 
distinct tissue, stress and chemokine specific response was elicited; of those 
studied, CXCL8 showed the greatest induction. The chemokines produced by 
epithelial cells were functional but post-translational modification occurred and so 
these chemokines may not have their predicted function. The effects of stress in 
vivo were also assessed. Immunohistochemistry showed association between RNS 
activity and ischaemic time in a model of kidney ischaemia-reperfusion injury. 
These observations were extended to human inflammatory liver disease, with 
increased RNS activity at sites of inflammation, a situation in which chemokines 
such as CCL2 are also present.  
RNS also modulates inflammation by post-translational modification. CCL2 was 
nitrated by RNS creating a chemokine, nCCL2, with decreased chemotactic activity 
in a diffusion gradient. Similar results were seen for nCCL5 and nCXCL8. 
Recruitment of HEK-CCR2b cells was decreased following CCL2 nitration and 
radio-ligand binding experiments confirmed there was some loss of receptor 
binding. However, the biological significance of this was uncertain. 
Glycosaminoglycan interactions were prevented by CCL2 nitration as was 
proportion of transendothelial migration. The ability of nitration to decrease the 
chemotactic potential of CCL2 was confirmed by in vivo assays.  
These data show the complexities of the chemokine system. Increased chemokine 
production by oxidative stress and concurrent modification of those chemokines 
by RNS represents a powerful paradigm for the regulation of inflammation. 
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1 GENERAL INTRODUCTION 
1.1 BACKGROUND TO THIS STUDY 
Inflammation, often resulting from tissue stress, is a significant clinical problem. 
Oxidative stress has a major role in inflammation, especially following organ 
transplantation, and can also lead to premature tissue ageing or senescence, 
contributing to loss of organ function. Chemokines are involved in the initiation 
and maintenance of both these pathologies and so this study looks at the 
relationship between oxidative stress and chemokine regulation. This is in terms of 
production of chemokines and their post-translational modifications.  
1.2 TISSUE INFLAMMATION  
Inflammation is a complex response to both infection and tissue injury and is a 
considerable burden to public health; inflammatory diseases were estimated to 
cause 44.5% of global mortality in 2008 (World Health Organisation). The cardinal 
signs of inflammation (rubor, calor, tumor and dolor) were first described in 
Roman times (Celsus, c. A.D. 25). These symptoms are due to a number of 
responses aimed to limit infection and damage. Redness and pain are caused by 
vasodilation increasing blood flow to the site of injury. Heat and further pain are 
due to the actions of pyrogens causing local tissue destruction and nerve irritation. 
Swelling results from oedema due to leukocyte infiltration and an increase in 
extravascular fluid. Later a fifth important consequence of inflammation was 
described, the loss of function of inflamed areas. This is particularly detrimental if 
crucial organs become inflamed.  
Inflammation is a double edged sword. Its purpose is to limit and eliminate the 
agent causing inflammation and to remove damaged tissue, however an 
inappropriate and unregulated immune response can be damaging. Acute 
inflammation, directed by the innate immune system, is short lived and is generally 
beneficial in the resolution of damage. It focuses, for example, antimicrobial factors 
at the site of infection, helping remove the cause of inflammation. Some injury can 
occur, for instance from oxidative stress, but generally is not as severe as that 
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caused by prolonged inflammation. This response needs to be actively terminated 
as failure to resolve results in chronic inflammation.  
Uncontrolled chronic inflammation can promote damage by the sustained 
recruitment of leukocytes, particularly monocytes and lymphocytes, causing 
persistent inflammation. Oxidative stress, produced by both infiltrating leukocytes 
and some surrounding cells, as discussed in section 1.4.1, can lead to tissue 
destruction and the resulting functional impairment. Both apoptotic and necrotic 
cell death occurs, the latter itself a strong inducer of inflammation by cell content 
release, and neutrophil recruitment to phagocytose debris. Tissue repair and 
regeneration following inflammation must also occur and if unsuccessful, fibrous 
scarring can result. Tight regulation of inflammation is crucial.  
Inflammation occurs in a range of diseases, including cancers, rheumatoid arthritis 
and tuberculosis. Relevant to this study, inflammation is a problem at all stages of 
organ transplantation. Ischaemia-reperfusion injury (IRI) occurs when the blood 
supply returns to tissue after a period of ischaemia (Eltzschig and Eckle, 2011). 
This can occur for example following organ transplantation when organs are 
surgically isolated from the blood system until reperfusion in the recipient. IRI is 
also a major cause of organ dysfunction following surgery such as heart bypass 
(Hammond et al., 2011). Intracellular oxidative stress under these conditions can 
be generated in the mitochondria and by oxidases in epithelial and endothelial 
cells. It causes both cellular and molecular damage as will be discussed in section 
1.4.1. However the initial hypoxia followed by reperfusion is not the only source of 
oxidative stress in this situation. Initial stress causes the infiltration of immune 
cells capable of performing oxidative burst, a secondary source of oxidative stress. 
A study in hepatocytes demonstrated that this stress induces liver inflammation 
and may cause apoptosis and necrosis (Bhogal et al., 2010). The Banff system 
(Demetris et al., 1997) for grading liver allograft rejection highlights the role of 
such stress and inflammation in acute rejection. The three categories of the 
rejection activity index are portal inflammation, bile duct inflammation and 
damage, and venous endothelial inflammation. IRI not only has adverse effects in 
early transplantation but also has a major impact on chronic rejection (Gueler et 
al., 2004). 
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Chemokines are prime drivers of inflammation and cell recruitment and will now 
be discussed in detail. These, like oxidative stress, can be produced by both the 
cells of the affected organ, including stressed epithelium, and by infiltrating 
leukocytes.  
1.3 CHEMOKINES 
Chemokines, chemoattractant cytokines, are small (8-14kDa) proteins secreted by 
many cell types to direct leukocyte navigation. The chemokine system, present in a 
primitive form in Drosophila (Gerard and Rollins, 2001), evolved with immune 
cells to mediate their migration. Cells move along a concentration gradient 
towards high chemokine concentrations; chemotaxis. Gene duplication throughout 
evolution has created a large family consisting of at least 45 ligands and 20 
receptors. Many chemokines interact with multiple receptors, which in turn can 
interact with more than one chemokine as shown in Table 1, the system is 
however non-redundant.  
Chemokines are classified by both structure and function. Functionally they are 
classed as inflammatory or homeostatic (Zlotnik and Yoshie, 2000). Homeostatic 
chemokines have various roles including regulating angiogenesis, directing 
lymphocytes to the lymph nodes for immune surveillance, and cellular maturation. 
These chemokines are secreted without any specific stimulus and are generally 
selective in receptor binding (Rot and von Andrian, 2004). Inflammatory 
chemokines however are produced and released in response to infection or 
damage, and function to recruit leukocytes from the blood to the site of injury. 
These chemokines are more promiscuous, often binding multiple receptors (Rot 
and von Andrian, 2004). It is the regulation of these chemokines which is crucial 
for resolving inflammation. Although the categorisation of chemokines in this 
manner is useful, the distinction between homeostatic and inducible chemokines is 
increasingly blurred. For example CCL19 and CCL21 are all critical for the 
development and function of lymphoid tissues but are also induced during 
inflammation (Marsland et al., 2005). 
Structurally, the human chemokine family is divided into four classes (Zlotnik and 
Yoshie, 2000; 'Chemokine/chemokine receptor nomenclature,' 2002) defined by 
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the position and spacing of the N-terminal cysteine residues: C, CC, CXC and CX3C, 
and receptors are named accordingly (see Figure 1-1). Within the CXC class there 
is further functional classification based on presence or absence of an ELR motif 
(glutamic acid-leucine-arginine) immediately adjacent to the CXC motif. ELR 
positive chemokines bind CXCR1 and/or CXCR2 and are potent angiogenic factors 
(Strieter et al., 1995), and ELR negative chemokines bind CXCR3 and inhibit 
angiogenesis. CXCL12 is the exception, it binds CXCR4 and despite lacking  the ELR 
motif can be pro-angiogenic (Verbeke et al., 2012). Genetically the chemokine 
groups are also distinct (O'Donovan et al., 1999; Mortier et al., 2012). The genes for 
CXC chemokines are located on chromosome 4, with ELR positive and negative 
chemokines in separate subclusters. CC chemokines are in are two clusters on 
chromosome 17. 
 
Figure 1-1 The four structural chemokine families 
Schematic showing the peptide chains and connecting disulphide bonds in the four chemokine 
families – C, CC, CXC, CX3C.   
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Name Other names Typical Receptor Atypical 
Receptor 
C family    
XCL1 Lymphotactin, SCM-1α XCR1  
XCL2 SCM-1β XCR1  
CC family    
CCL1 I-309 CCR8  
CCL2 MCP-1 CCR2 ACKR1, ACKR2  
CCL3 MIP-1a CCR1, CCR5 ACKR2 
CCL4 MIP-1β CCR1, CCR5 ACKR2 
CCL5 RANTES CCR1, CCR3, CCR5 ACKR1, ACKR2 
CCL7 MCP-3 CCR1, CCR2, CCR3, CCR5 ACKR1, ACKR2 
CCL8 MCP-2 CCR1, CCR2, CCR3, CCR5 ACKR2 
CCL11 Eotaxin CCR3 ACKR1, ACKR2 
CCL13 MCP-4 CCR2, CCR3 ACKR1, ACKR2 
CCL14 HCC-1 CCR1, CCR5 ACKR1, ACKR2 
CCL15 HCC-2 CCR1, CCR3  
CCL16 HCC-4 LEC CCR1, CCR2, CCR5  
CCL17 TARC CCR4 ACKR1, ACKR2 
CCL18 PARC, DC-CK1   
CCL19 ELC, Exodus-3, MIP-3β CCR7 ACKR4 
CCL20 LARC, Exodus-1, MIP-3α CCR6  
CCL21 SLC, 6Ckine, exodus-6 CCR7 ACKR4 
CCL22 MDC CCR4 ACKR2 
CCL23 MPIF-1, Ckβ8 CCR1  
CCL24 Eotaxin-2, MPIF-2, Ckβ6 CCR3  
CCL25 TECK CCR9 ACKR4 
CCL26 Eotaxin-3, MIP-4α CCR3  
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CCL27 CTACK, ILC CCR10  
CCL28 MEC CCR3, CCR10  
CXC family    
CXCL1 Gro-α CXCR2 ACKR1 
CXCL2 Gro-β, MIP-2α CXCR2 ACKR1 
CXCL3 Gro-γ, MIP-2β CXCR2 ACKR1 
CXCL4 PF-4 CXCR3b  
CXCL5 ENA-78 CXCR2 ACKR1 
CXCL6 GCP-2 CXCR1, CXCR2 ACKR1 
CXCL7 NAP-2 CXCR2  
CXCL8 IL-8, NAP-1 CXCR1, CXCR2 ACKR1 
CXCL9 MIG CXCR3  
CXCL10 IP-10 CXCR3  
CXCL11 I-TAC CXCR3 ACKR1, ACKR3 
CXCL12 SDF-1 CXCR4 ACKR3 
CXCL13 BCA-1 CXCR5  
CXCL14 BRAK, bolekine   
CXCL16 SRPSOX CXCR6  
CXCL17 DMC, VCC-1   
CX3C family    
CX3CL1 Fractalkine, Neurotactin CX3CR1  
 
Table 1 Human chemokines and receptors 
The members of the four chemokine families and the receptors they bind. Atypical receptors have 
recently changed nomenclature, former names are given in brackets - ACKR1 (Duffy 
antigen/chemokine receptor; DARC), ACKR2 (D6), ACKR3 (CXCR7), ACKR4 (CCRL1, CCR11). This 
lsit is non-exhaustive and is adapted from the Subcommittee on Chemokine Nomenclature, 2003 
and Bachelerie et al., 2014. 
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CCL2, formerly known as monocyte chemotactic protein-1 (MCP-1), is the main 
chemokine studied in this thesis and will be used to demonstrate multiple aspects 
of chemokine biology including structure and function throughout the 
introduction. It is a widely expressed prototypical inflammatory chemokine 
produced by multiple cell types and is able to induce migration of many cells, 
predominantly monocytes.  
CCL2 is an 8.7kDa protein encoded by the three exon CCL2 gene on chromosome 
17 (Shyy et al., 1990) and like many chemokines has an N-terminal signal sequence 
which is cleaved forming the 76 amino acid mature protein (see Figure 1-6), first 
sequenced in 1988 (Robinson et al., 1989). CCL2 has a discrete receptor system, 
binding only CCR2, although it can also bind the atypical receptors ACKR1 and 
ACKR2. Of interest for this study, CCL2 has roles in inflammation and 
transplantation, discussed in more detail in section 1.3.3. For example it is 
associated with acute kidney transplant rejection with increasing levels 
corresponding to increased severity of rejection (Robertson et al., 2000). 
CCL2 has multiple roles in immunity. It can influence innate immunity by the 
recruitment of monocytes, and also adaptive immunity by the control of T helper 
cell polarisation, skewing responses towards Th2 (Gu et al., 2000). This Th2 
polarisation is thought to be exploited by HIV to enhance viral replication by 
recruiting target cells, increasing disease progression (Ansari et al., 2011). CCL2 is 
predominantly thought of as a monocyte recruiter, however not all monocytes are 
CCR2+. CCR2+ monocytes are classed as the inflammatory subset with CCR2- 
monocytes found to be recruited to non-inflamed tissues (Geissmann et al., 2003). 
Expression of the chemokine receptor CX3CR1 is inversely correlated with CCR2 
expression in such cells. Another example of the diverse effects of CCL2 is cancer 
metastasis, for example metastatic breast cancer. Inflammatory monocytes, 
recruited to the tumour by CCL2, promote the extravasation of tumour cells using 
monocyte-derived vascular endothelial growth factor (Qian et al., 2011). 
Other chemokines examined in this study include CCL5, CXCL8 and CXCL10. CCL5 
is a potent chemoattractant for cells including monocytes, T cells and eosinophils 
and is associated with multiple pathologies including allograft rejection 
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(Robertson et al., 1998) and also suppresses HIV replication (Coffey et al., 1997). 
CXCL8 is produced by many cells types including both epithelial and endothelial 
cells as well as leukocytes. Although predominantly thought of as a neutrophil 
attractant, CXCL8 can recruit other cells including macrophages, and like many 
chemokines has a role in cancer (Verbeke et al., 2012). CXCL10 is the final 
chemokine considered in this study. It is an interferon inducible chemokine 
(Luster et al., 1985) involved in the recruitment of numerous cell types and the 
inhibition of angiogenesis (Angiolillo et al., 1995; Dufour et al., 2002), and is a 
predicator of response to therapy in hepatitis C patients (Falconer et al., 2010). 
1.3.1 REGULATION 
Chemokine regulation is highly complex (Mortier et al., 2012) and, due to their role 
in leukocyte recruitment, this tight regulation is crucial. This ensures, for example, 
that inflammation does not become uncontrolled and pathogenic. The regulation is 
both temporal and spatial and occurs at multiple levels as shown in Figure 1-2 and 
described in detail in later sections of this introduction.  
The production of chemokines is a major level of regulation (section 1.3.2) but 
once produced, the functions of chemokines can be modified by post-translational 
modification (section 1.6), the main focus of this study. Many stresses mentioned 
in sections 1.2 and 1.4 are able to affect this, and other areas of chemokine biology, 
creating tighter regulation during times of inflammation when chemokine function 
is crucial.  
Signalling is another level of regulation. Chemokines bind and signal through G-
protein coupled receptors (see section 1.3.6.2) but atypical receptors (Bachelerie 
et al., 2014) can also bind chemokines, generally with anti-inflammatory effects 
(O'Boyle et al., 2011). They are scavenger receptors, down-regulating the 
bioavailability of chemokines in specific microenvironments. Biased agonism 
exists within the chemokine system as do synergy and antagonism (Gouwy et al., 
2012). The multimerisation of both chemokines and receptors also plays an 
important role (section 1.3.5.2).  
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Figure 1-2 Mechanisms of chemokine regulation 
Chemokine function is regulated at many levels. Protein production is regulated at both the 
transcriptional and translational level, with some microRNAs regulating mRNA levels. Chemokine 
post-translational modification occurs both intra- and extra-cellularly for example nitration, 
citrullination and protein cleavage, all of which can alter chemokine function. Chemokines bind and 
signal through ‘typical’ G-protein coupled receptors, this triggers downstream signalling and causes 
cell migration. Atypical receptors, including ACKR1 (DARC), however bind chemokine, reducing 
bioavaliability, but do not signal in the normal manner. Chemokines need to bind 
glycosaminoglycans (GAGs), for example heparan sulphate, for in vivo function. GAGs are presented 
on the endothelium and bind chemokine, enabling cell migration. N- chemokine nitration, Cit- 
chemokine citrullination, scissors – enzymatic cleavage. From Barker et al., 2014. 
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In order to form the chemokine gradients needed for in vivo function (Weber et al., 
2013), chemokines bind to glycosaminoglycans (GAG) such as heparan sulphate. 
This chemokine immobilisation increases the concentration at the site of 
production, thus aiding the recruitment and infiltration of cells in vivo (section 
1.3.4). GAG expression is increased during inflammation (Ali et al., 2005a), and 
binding to GAGs affects other levels of regulation, further complicating the process. 
Chemokine cooperativity is also dependant on GAG binding (Verkaar et al., 2014).  
1.3.2 CHEMOKINE EXPRESSION 
Chemokine function is strictly regulated at many levels, the first being expression. 
As mentioned, inflammatory chemokines are inducible and are produced in 
response to infection, tissue injury or stress, with regulation at both the 
transcriptional and translational level. The availability of chemokines is controlled 
by both temporal and spatial expression. Some chemokines can be preformed and 
are stored in endothelial cells in secretory granules including Weibel-Palade 
bodies, for a rapid response to insult (Øynebråten et al., 2005) whereas in other 
situations de novo  synthesis is required.   
Many stimuli trigger the production of chemokines. For example through pattern 
recognition receptors (PRRs), such as Toll-like receptors (TLRs), which recognise 
highly conserved pathogen-associated molecular patterns (PAMPs), including 
lipopolysaccharide (LPS), and danger-associated molecular patterns (DAMPs), 
including RNA and heat shock proteins as reviewed by Piccinini and Midwood, 
2010 and Mortier et al., 2012. PRRs are therefore able to induce chemokine 
production in response to both infection and sterile inflammation. The activation 
of these receptors often induces the transcription of chemokines via NFκB 
pathways, as is described in detail for CCL2 in section 1.3.2.1. Synergy between 
proinflammatory factors also occurs in the induction of chemokines. For CCL8 
production the effects of IL-1β and IFNγ are synergistic but are additive for the 
production of CCL2 (Struyf et al., 1998b). However the effects of this synergy are 
not always simple. Exposing fibroblasts and endothelial cells to proinflammatory 
cytokines and TLR ligands dramatically increases the production of CCL8. These 
same conditions also increase proteolytic cleavage of the chemokine (a post-
translational modification described in detail in section 1.6), creating an antagonist  
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(Struyf et al., 1998b). One chemokine can also influence the expression of others. A 
study in CCL2-/- mice showed decreased levels of several other chemokines during 
acute inflammation. Importantly this finding is not purely due to a failure to recruit 
inflammatory cells able to produce further chemokines to the site of inflammation, 
but is also seen in isolated macrophages from knock-out mice (Ferreira et al., 
2005).  
Post-transcriptional control of chemokines also occurs. Many gene transcripts are 
innately unstable due to the presence of AU-rich elements (AREs) in their 3′-
untranslated regions (3′-UTR) which are targeted for decay by RNA-binding 
proteins (Hitti and Khabar, 2012). These include chemokines and cytokines which 
require only transient expression (Bakheet et al., 2006). Both the upregulation and 
downregulation of chemokines is crucial to preventing excessive chemokine 
production and hence uncontrolled inflammation. Increased stabilsation of CXCL8 
mRNA occurs following IL-1 treatment (Winzen et al., 1999) and in THP-1 cells on 
differentiation to macrophages (Mahmoud et al., 2014). MicroRNA involvement in 
chemokine regulation is being increasingly studied (Tano et al., 2011; van Solingen 
et al., 2011; Kim et al., 2012; Arabanian et al., 2014). Pathogens also exploit 
microRNA modulation of chemokine production as a mechanism to evade the 
immune system, for example human cytomegalovirus can increase CCL5 mRNA 
degradation (Kim et al., 2012).    
Alternative splicing of both chemokines and receptors occurs, further adding to the 
complexity of the system. Six splice variants of CXCL12 have been identified (Yu et 
al., 2006). CXCL12γ has an extended C-terminus and increased GAG binding affinity 
(Laguri et al., 2007; Rueda et al., 2008). Maintaining chemokines at the site of 
production is crucial for function and is achieved by GAG binding as discussed 
further in section 1.3.4.   
1.3.2.1 Induction of CCL2  
The induction of CCL2 is complex and not yet fully understood, with most 
regulation occurring at the level of transcription initiation. Mechanisms of 
induction are cell type and stimulator specific. Expression is regulated by distal 
and proximal promoters, separated by 2.2kb DNA; κB and SP-1 sites in these 
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regions are crucial for activation (Ping et al., 1996; Ping et al., 1999). TPA (PMA) 
responsive elements (TRE) are also present. Phosphorylation and subsequent 
ubiquitin-mediated degradation of IκB (Alkalay et al., 1995), allowing NFκB to 
translocate to the nucleus and bind to the distal region (Boekhoudt et al., 2003) is 
therefore critical for CCL2 transcription. This can be triggered by protein kinase C 
(PKC) activation (Ghosh and Baltimore, 1990) or tumour necrosis factor (TNF) 
induced phosphorylation (Miyamoto et al., 1994), which, like LPS activation, can be 
PKC independent (Shyy et al., 1993). LPS triggers CCL2 via NFκB (Shyy et al., 1990) 
and unlike chemokines including CXCL10, CCL2 induction in response to LPS is 
mediated in a MyD88-dependant manner (Bandow et al., 2012) in macrophages. 
NFκB binding leads to recruitment of CREB-binding protein and p300, leading to 
histone acetylation and chromatin remodelling, opening the structure allowing 
recruitment of transcription machinery and eventual gene expression. As with 
several TNF induced genes the arginine methyltransferase CARM1 is needed 
although its exact role is not understood (Teferedegne et al., 2006). A p53 binding 
site has been identified and functional p53 is required for CCL2 expression (Hacke 
et al., 2010), this may be connected to findings that TNF can activate p53 via NFκB 
and provides another possible link between oxidative stress, senescence and CCL2 
production. Highlighting the need for tight regulation of this protein is the finding 
that a SNP in the distal promoter is associated with increased CCL2 production and 
inflammation. This A/G polymorphism creates an extra binding site for the TALE 
family of transcription factors (Page et al., 2011).  
1.3.3 CHEMOKINES IN TRANSPLANTATION  
Problems at all stages of transplantation involve the chemokine system. As liver 
and kidney epithelial cells have chemokine-producing ability, these sites are 
particularly susceptible to increased lymphocyte recruitment, causing the bile-duct 
and peritubular inflammation seen in rejection (Hancock et al., 2000). Tissue stress 
as early as brain death of the donor can lead to endothelial dysfunction and 
chemokine release, and IRI also causes the production of proinflammatory factors. 
Upon reperfusion, proinflammatory cytokines are produced, such as TNFα and IL-
1β. These stimulate the release of preformed chemokines from vascular 
endothelium, including CCL2 and CXCL8, recruiting macrophages and neutrophils 
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respectively to the graft (El-Sawy et al., 2002); increased CXCL8 expression in 
kidney correlates with ischaemia time (Lo et al., 2011). CCR1 knockout mice have 
decreased recruitment of both neutrophils and macrophages in a model of kidney 
IRI. The temporal pattern of recruitment however is unaltered with rapid 
neutrophil recruitment peaking at 24hr, and more gradual monocyte recruitment 
throughout the seven days of the model used in this study (Furuichi et al., 2008). 
The IFNγ-inducible chemokines CXCL9, CXCL10 and CXCL11 are rapidly increased 
following reperfusion (Lo et al., 2011), and are abundant in rejecting allografts. 
Controversy however surrounds the role of their receptor, CXCR3, in 
transplantation (Halloran and Fairchild, 2008).  
As well as ligands, chemokine receptors are also increased. CXCR1 and CXCR2 
expression on hepatocytes increases in hepatic IRI but a murine study shows that 
their effects differ. CXCR2 is associated with delayed recovery, whereas CXCR1 
seems to aid repair (Clarke et al., 2011). Later stages of transplant rejection 
including arteriosclerosis (Gerard and Rollins, 2001) and fibrosis are increased by 
chemokines and growing research suggests that chemokine levels could be used as 
biomarkers, such as CXCL10 for monitoring graft inflammation and predicting 
fibrosis (Berres et al., 2011; Romagnani and Crescioli, 2012).  
CCL2 production is upregulated by epithelial cells in liver fibrosis (Kruglov et al., 
2006), this CCL2 may then ‘activate’ portal fibroblasts; an example of paracrine 
signalling. Studies report that blocking CCL2 decreases hepatic macrophage and 
monocyte recruitment and ameliorates steatosis (Baeck et al., 2012). Chemokines 
are also involved in senescence (discussed further in section 1.5), with particular 
focus placed on the CXCR2 ligands CXCL1 and CXCL8 (Acosta et al., 2008b), further 
increasing inflammation, senescence, and in the case of transplantation, organ loss.   
As with all transplant immunology, the picture is further complicated as 
chemokines can be donor or host derived, and determining which has most 
significant effects is important both clinically and in understanding the system. A 
study by Melzi et al. suggests that for islet transplantation a strategy to selectively 
decrease recipient, but not donor CCL2 will have the most benefit (Melzi et al., 
2010).  
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1.3.4 GLYCOSAMINOGLYCAN BINDING 
For migration in vivo cells need vectoral cues. These come in the form of 
chemokine gradients, immobilised by binding to GAGs. GAGs, including heparin 
and heparan sulphate, are complex acidic polysaccharides both within the 
extracellular matrix and at the cell surface conjugated to proteins (proteoglycans). 
The main families of proteoglycans are syndecans, glypicans and perlecans. 
Syndecans are transmembrane molecules and there are four members of the 
mammalian family. Glypicans however are attached to the cell surface by a 
glycosylphosphatidylinositol anchor. The heparan sulphate chains attached to 
glypicans are closer to the cell surface than those attached to syndecans. The 
attachment of perlecans is different again. Cell adherence is by binding to integrins, 
not cells directly (Celie et al., 2009).  
These surface GAGs are important biological mediators for multiple fundamental 
cell processes including proliferation, cell death, haemostasis, adhesion and 
migration (Simon Davis and Parish, 2013). Chemokines bind GAGs by electrostatic 
interaction (Proudfoot et al., 2003) and binding adds both another level of 
specificity to interactions and also immobilises chemokines, increasing 
concentration at the site of production (Whitelock and Iozzo, 2005). This forms a 
haptotactic chemokine gradient needed for in vivo chemokine function. Chemokine 
gradients have been visualised in vivo in numerous papers by the Sixt lab 
(Schumann et al., 2010; Weber et al., 2013; Stoler-Barak et al., 2014).  
GAG structures are complex but all contain disaccharide repeat units. The 
disaccharides for heparin and heparan sulphate (collectively HSGAGs) are shown 
in Figure 1-3. The different combinations of these units, combined with a number 
of modifications such as sulphation and acetylation, creates remarkable structural 
heterogeneity (Simon Davis and Parish, 2013). Variations are found in other GAGs 
for example chondroitin sulphate and dermatan sulphate. The strongly polyanionic 
nature of GAGs allows interaction with the basic amino acids found in the GAG 
binding sites of chemokines. These are not just non-specific electrostatic 
interactions however, structure and oligomerisation state alters the ability of GAGs 
to interact with proteins (section 1.3.5.2).  
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Figure 1-3 Glycosaminoglycan subunits for heparin and heparan sulphate 
Each disaccharide repeating subunit contains a uronic acid (β-D-glucuronic acid or α-L-iduronic 
acid), with 2-O possible sulphation sites, and a β-D-glucosamine, with possible sulphation sites at 
the 3-O and 6-O positions, with additional sulphation or acetylation possible at the N position. All of 
these combinations result in 48 disaccharide building blocks for HSGAGs. The most common 
subunits in heparan sulphate are glucuronic acid and N-acetylglucosamine, however heparin has a 
higher level of sulphation with the predominant unit being iduronic acid(2S) and N-
acetylglucosamine(6S). Red – possible sulphation sites, Blue – possible sulphation or acetylation 
site. 
 
GAG distribution is relatively even across the surface of endothelium as shown in 
Figure 1-4 but chemokines bind to discrete regions due to multimerisation. Both 
heparin and heparan sulphate have been used in assays in this study to model 
chemokine-GAG interactions. Both GAGs are present in vivo; heparin is produced 
by mast cells and predominantly functions as an anti-coagulant, where as heparan 
sulphate can be produced by numerous cell types and is involved in chemokine 
immobilisation. Heparan sulphate is therefore the more physiologically relevant of 
the two for this work.  
The importance of GAG binding is highlighted by studies showing that increasing 
the GAG binding ability of chemokines which lack signalling capabilities is anti-
inflammatory (Piccinini et al., 2010). Anti-inflammatory properties are also seen in 
the reverse mutation chemokines that signal normally but cannot bind GAGs (Ali et 
al., 2005b; O'Boyle et al., 2009). As well as forming in vivo chemokine gradients 
GAGs have other roles in chemokine biology. GAG binding can protect chemokines 
from proteolysis (Sadir et al., 2004) (seezz section 1.6.1) and encourage 
chemokine oligomerisation, another fundamental part of chemokine biology, as 
discussed further in section 1.3.5.2. Endothelial expression of these GAGs increases 
during the stresses produced by transplantation, altering the potential to bind 
chemokines and so altering chemokine function (Ali et al., 2005a). This is yet 
another level of chemokine regulation during stress.  
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Figure 1-4 Chemokine-GAG interaction 
Confocal microscopy image from Hardy et al., 2004 showing immunofluorescence detection of CCL2 
(red) binding to heparan sulphate (green) on EA.hy926 cells following incubation of the 
endothelium with 12.5nM CCL2 for 1hr at 37°C. X-Z sectional image shows characteristic 
distribution of CCL2 associated with single cells and concentrated to discrete regions of the apical 
cell surface.  
1.3.5 STRUCTURE 
Structurally the human chemokine family is divided into four classes, listed in 
Table 1, and defined by the position and spacing of the N-terminal cysteine 
residues. Despite relatively low sequence homology, chemokines have several 
highly conserved structural regions and all have basic domains for GAG binding. 
Chemokines contain the common tertiary fold, a Greek key motif (Richardson, 
1977). In chemokines this contains three antiparallel β-sheets stabilised by 
multiple hydrogen bonds and hydrophobic interactions (Handel and Domaille, 
1996). There is also a C-terminal α-helix, and the whole structure is stabilised by 
disulphide bonds between the conserved cysteine residues (Schwiebert, 2005) 
(see Figure 1-5). The N-terminus plays a crucial role in receptor binding and 
activation. It is generally disordered and the well ordered regions, although not 
being directly involved in binding, create a scaffold to ensure protein correct 
conformation (Clark-Lewis et al., 1995).  
1.3.5.1 Structure of CCL2   
The structure of CCL2 has been determined (Handel and Domaille, 1996; 
Lubkowski et al., 1997), greatly helping identification of the functional role of 
specific residues. What is known about these residues is shown in Figure 1-6 and 
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will now be discussed. Due to differences between techniques, the exact 
importance of each residue in a given aspect of biology, both in vitro and in vivo, is 
not definitive.  
 
Figure 1-5 Chemokine structure 
Cartoon of general chemokine structure. The spacing between the cysteine residues highlighted in 
yellow determines the chemokine family. The Greek key like motif containing three antiparallel β-
sheets and an α-helix is shown. 
 
In keeping with the two site model for receptor activation described in section 
1.3.6.2, the N-terminus is crucial for signalling but contributes little to the binding 
affinity (Chakravarty et al., 1998; Hemmerich et al., 1999), deletion of residues 2-8 
creates a potent antagonist (Jarnagin et al., 1999). The exact N-terminal residues 
are not important suggesting receptor interaction may be with backbone atoms. 
Iso5Pro, a mutation predicted to disrupt helix formation also has little effect on 
binding, indicating that the secondary helical structure is also not crucial (Jarnagin 
et al., 1999). The multiconformation hypothesis was suggested: the core domain of 
CCL2 is needed for G protein activation but the N-terminal is needed to create a 
conformation able to trigger calcium influx (Jarnagin et al., 1999). 
Most mutants alter CCL2 signalling to an extent which correlates with alteration in 
receptor binding but some, known as active triggering residues, have decreased 
signalling to a much greater extent than the decrease in affinity. Mutations 
including deletion of residues 2-8 and mutation of Tyr13 (Jarnagin et al., 1999) 
demonstrate these two regions are crucial for signalling. 
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Figure 1-6 CCL2 amino acid sequence and function of specific residues 
Shown is the amino acid sequence of mature human CCL2. References: aBeall et al., 1996, 
bChakravarty et al., 1998, cGong and Clark-Lewis, 1995, dHemmerich et al., 1999, e Jarnagin et al., 
1999, fLau et al., 2004, gPaavola et al., 1998 and Uniprot. 
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The C-terminal region contains the positive residues Lys58 and His66, likely sites 
for binding of negative GAGs (Chakravarty et al., 1998). Arginine and lysine are the 
residues normally associated with GAG binding but the participation of histidine is 
in agreement with the pH dependence of CCL2 GAG binding. A study by Lau et al., 
2004, shows some involvement of these residues depending on the technique used 
but finds that Arg18>Arg24>Lys19>Lys49 are the key residues in GAG binding, 
Arg18Ala/Lys19Ala mutants cannot recruit cells in vivo but are functional in vitro 
fitting with data previously discussed in section 1.3.4 regarding the importance of 
GAG binding in vivo.  
Quaternary structure formation is important for function. The two monomers of 
the CCL2 homodimer are held together by hydrogen bonds which form between 
both Tyr13 residues via a water molecule. Val9 and Thr10 also interact via their 
hydroxyl groups (Paavola et al., 1998). The mutation Pro8Ala creates an obligate 
CCL2 monomer, receptor binding is unaltered but it cannot recruit leukocytes in 
vivo (Paavola et al., 1998; Lau et al., 2004). Analysis of CCL2 structure shows that 
receptor and GAG binding cannot occur concurrently due to the proximity of the 
binding sites if present as a monomer (Lau et al., 2004) and is confirmed by a 
recent study which created an obligate dimer (Tan et al., 2012). Upon GAG binding, 
CCL2 forms a tetramer, allowing both GAG and receptor binding to occur. As a 
tetramer the residues important in GAG binding form a ring creating a positive 
surface for GAG binding (Lau et al., 2004). 
1.3.5.2 Multimerisation 
Many chemokines can form oligomers, especially at the high chemokine 
concentrations reached at inflammatory sites on interaction with GAGs. Despite 
the similarity in tertiary structure there is great diversity in the quaternary 
interactions formed. For some chemokines, including CCL2, formation of higher 
order structures is necessary for function in vivo (Paavola et al., 1998; Lau et al., 
2004). Not all chemokines however can form dimers. CCL7 for example lacks the 
conserved proline residue involved in CC dimerisation, Pro8 in CCL2 (Key-Sun et 
al., 1996). In vitro chemically obligate monomers can still induce chemotaxis, in 
vivo but oligomerisation is needed (Proudfoot et al., 2003; Campanella et al., 2006). 
This requirement for oligomerisation is not fully understood but GAG binding is 
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involved. Wild type, not monomeric, CXCL10 is retained on endothelial surfaces, 
inducing transendothelial migration (Campanella et al., 2006), presumably due to a 
difference in GAG binding. The natural obligate monomer CCL7 has multiple GAG 
binding sites so can function in vivo despite lack of dimerisation ability (Salanga et 
al., 2014).  
Crucial differences are seen between CC and CXC chemokines in their dimerisation 
biology. CC chemokine dimers are sterically blocked from binding their receptors 
due to important binding residues being situated on the dimer interface (Jin et al., 
2007; Tan et al., 2012). CXC chemokines however are able to bind chemokine 
receptors while dimerised (Veldkamp et al., 2008; Gangavarapu et al., 2012). 
As well as homodimers chemokines can form heterodimers, the CCL2-CCL8 
heterodimer forms in preference in homodimers, and like homodimers can be 
influenced by GAGs (Crown et al., 2006). CXCL4 and CXCL8 interact to form 
heterodimers, increasing the anti-proliferative effects, and ability to cause cell 
migration via CXCR2 (Nesmelova et al., 2005).  
1.3.6 SIGNALLING 
For leukocyte recruitment during inflammation to occur the target cells need to 
come in contact with GAG bound chemokines. For this to occur cells must first 
adhere to the endothelium; this process is initially mediated by selectins.  
1.3.6.1 Selectins 
Shear forces in blood flow force cells to roll along the surface of blood vessels, 
allowing leukocytes to make contact with the endothelium. Weak associations are 
formed due to interaction with selectins (calcium dependent lectins), tethering 
lymphocytes to the inflamed endothelium, which in shear vascular flow results in 
leukocyte rolling. The three types of selectin are lymphocyte (L-selectin), 
constitutively expressed on leukocytes, platelet (P-selectin) and endothelial cell (E-
selectin), the latter two being expressed on cytokine activated endothelial cells. P-
selectin is pre-formed and is released from Weibel-Palade bodies in response to 
cytokines including IL-1β and TNFα; E-selectin is regulated by these at the level of 
transcription (Lowe, 2003). Initial adhesion is through P-selectin then L-selectin 
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reduces the leukocyte rolling allowing signalling through chemokine receptors 
(Parish, 2006). This then causes integrin activation and subsequent leukocyte 
migration as discussed in section 1.3.7.    
Selectins are heavily glycosylated cell surface proteins which bind other cell-
surface glycoproteins or glycolipids. For example the P-selectin counter receptor, 
P-selectin glycoprotein ligand-1 (PSGL-1) is expressed on neutrophils and other 
leukocytes and is characterised by abundance of a specific O-glycan. This is 
opposed to the broader range of polypeptides and glycolipids which E-selectin 
interacts with (Lowe, 2003). As well as aiding cell migration by immobilising 
chemokines, as discussed in section 1.3.4, heparan sulphate is a major L-selectin 
ligand especially during acute inflammation (Giuffre et al., 1997; Wang et al., 
2005). During chronic inflammation however, the mucin 6-sulpho sialyl Lewis X is 
thought to play a more important role (Parish, 2006). The importance of selectins 
in the complex regulation of leukocyte rolling and potential subsequent 
inflammation is demonstrated by Ali et al., 2008. α-L-Fucosidase is an enzyme able 
to cleave fucosylated residues from, for example, P-selectin ligands, and can 
therefore decrease cell rolling and subsequent cell migration. This enzyme can be 
upregulated by chemokines, a regulatory cycle. 
Selectin – ligand interaction is biphasic. Increasing tensile force initially prolongs 
interactions but when the force becomes too great the interactions decrease again. 
This is a mechanism to regulate cell adhesion under varying levels of mechanical 
stress and is due to the nature of the interaction being both ‘catch’ and ‘slip’ bond 
like (Konstantopoulos et al., 2003; Marshall et al., 2003). 
1.3.6.2 Chemokine Receptors 
Chemokines signal by binding class A, rhodopsin-like, seven transmembrane 
domain G protein coupled receptors (GPCRs) (Gether, 2000). Upon chemokine 
binding there is coupling between the receptor and heterotrimeric G proteins. 
Receptor activation induces conformational changes and increased affinity of 
leukocyte integrins for their adhesion molecules, eliciting adhesion to the 
endothelium (Ward and Marelli-Berg, 2009).  
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Chemokine receptors couple via a Gαi subunit, inhibiting adenylyl cyclase and 
decreasing intracellular cAMP levels, they are pertussis toxin sensitive. Gαi is 
necessary but not sufficient for chemotaxis (Neptune and Bourne, 1997). The 
release of the Gβγ subunit alone can trigger chemotaxis (Neptune et al., 1999) but 
it has to be from Gαi, release of Gβγ from Gαs or Gαq trimers is not functional 
(Neptune and Bourne, 1997). 
The two-site model is the current model for receptor activation (Monteclaro and 
Charo, 1996; Wells et al., 1996; Crump et al., 1997). A high affinity and specificity 
interaction between the chemokine and receptor, normally the N-terminal, allows 
chemokine docking and determines ligand specificity. The N-terminal of the 
chemokine then flips into the receptor binding groove, inducing a conformational 
change and allowing G protein binding. Whether the receptor needs to be present 
as a monomer or dimer for activation is yet to be fully determined (Thelen and 
Stein, 2008).  
Following receptor activation, Gβγ (Thelen, 2001; Thelen and Stein, 2008) 
activates numerous downstream effectors including phospholipase C (PLC) and 
phosphotidylinositol-3-OH kinase (PI3K), leading to the activation of PKC and 
recruitment of signal transducers including protein kinase B (PKB) and PTEN. The 
later can also activate the mitogen activated protein kinase (MAPK) pathway via 
Shc and Ras. Most chemokines can interact with multiple receptors, which in turn 
can interact with more than one chemokine, often causing ligand specific effects. 
CCR2 for example has multiple ligands. CCL2, but not CCL8, induces ERK1 nuclear 
translocation and c-Myc expression (O'Boyle et al., 2007) and  CCL11, a CCR2 
antagonist, also produces its effects via ERK but has different downstream 
pathways to the agonist CCL2 (Ogilvie et al., 2004).  
This downstream signalling results in an increase in cell movement and 
directionality but this is not due to receptor accumulation at the leading edge 
although there is an accumulation of membrane (Xiao et al., 1997; Servant et al., 
1999). There is however an asymmetric distribution of intracellular proteins 
including PKB which are needed for signal transduction (Parent et al., 1998; Meili 
et al., 1999). Cholesterol is required for polarised redistribution of factors 
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including PI3K but is not needed for early events such as calcium flux (Rose et al., 
2008).  
Chemokine receptors, like many other GPCRs can form homo and heterodimers 
and can also interact with, for example, opioid receptors (Suzuki et al., 2002). 
These interactions have functional consequences. Receptor oligomerisation can in 
some pairs cause negative cooperativity but in others enhance signalling or 
activate new, specific signalling pathways (Stephens and Handel, 2013). The 
receptors CCR5 and CCR2 can form heterodimers but the exact functional 
consequence is unclear. One study suggests that the dimer can only bind a single 
chemokine, creating competition between ligands (El-Asmar et al., 2005). A second 
study shows signalling through the dimer is pertussis toxin insensitive and triggers 
cell adhesion instead of chemotaxis (Mellado et al., 2001).  
Further complexity is added by the level of receptor expression. LPS signals via 
TLR4 to augment, but not directly induce, monocyte migration in response to CCL2 
by modulating CCR2 surface expression in a G protein-coupled receptor 2 (GRK2) 
dependent manner (Liu et al., 2013). 
Chemokine receptors are internalised, and subsequently recycled or degraded. 
This mostly occurs following chemokine stimulation but is also constitutive. 
Receptor internalisation is predominantly β-arrestin-mediated following receptor 
phosphorylation and is reviewed by Borroni et al., 2010. Many receptors reach the 
endosomal compartment by clathrin-coated pits and are then recycled to the 
surface but the rate is receptor dependant. CXCR3 is degraded and so for new 
surface CXCR3, de novo synthesis is required (Meiser et al., 2008).    
1.3.6.3 CCL2 Receptor   
CCR2 is the only known receptor for CCL2. A study suggested CCR4 may be a 
receptor (Power et al., 1995) but problems with the specificity of the transfectants 
used have since been established and it has been shown that CCL2 does not bind 
CCR4 (Imai et al., 1998). Numerous, more recent studies also propose other 
receptors but none have been confirmed. Portal fibroblasts were reported to not 
express CCR2 and therefore effects on these cells must be via another receptor 
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(Kruglov et al., 2006). Later studies however show that CCR2 expression on liver 
cells promotes fibrosis in mice and that CCR2-/- HSC are unresponsive to CCL2 in 
vitro (Seki et al., 2009), suggesting that the findings of the earlier study are due to a 
lack of CCR2 detection rather signalling via another means. CCL2 
heterodimerisation with other chemokines could explain the apparent existence of 
a second receptor. CCR2 itself can dimerise with CCR5 (Mellado et al., 2001; El-
Asmar et al., 2005). 
CCR2 has two isoforms, CCR2a and CCR2b, with alternatively spliced carboxyl tails 
(Charo et al., 1994). The 47 amino acid carboxyl tail of CCR2b is in the same exon 
as the transmembrane domains, whereas the 61 amino acid tail of CCR2a is in a 
downstream exon. It is thought that the C-terminal is important in receptor 
trafficking as in monocytes CCR2a is found in low levels on the cell surface but is 
present in the cytoplasm (Wong et al., 1997). The difference in C-terminal leads to 
a difference in G-protein coupling between the isoforms. CCR2a can bind Gα14 and 
Gα16 but CCR2b can bind neither (Kuang et al., 1996), both receptors can couple to 
Gαi and so are pertussis toxin sensitive (Kuang et al., 1996). Another functional 
difference between the two isoforms is the finding that Jurkat cells expressing 
CCR2a are chemotactic in response to CCL2 without calcium flux whereas CCR2b 
causes flux (Sanders et al., 2000).  
1.3.7 CHEMOKINE FUNCTION 
Having discussed the regulation of chemokine production, their ability to bind 
GAGs and form gradients, and signalling through GPCRs, how do these proteins 
perform their main function: directing leukocyte migration into extravascular 
tissues? The key steps in this process are tethering, rolling, adhesion and 
diapedesis, each step being a prerequisite for the next (Schenkel et al., 2004) and 
can be seen in Figure 1-7.  
1.3.7.1 Polarisation 
Polarisation occurs when leukocytes are stimulated, for example by chemokines.  
Two regions are created, the leading edge and the uropod, by cytoskeletal 
rearrangement (del Pozo et al., 1995). To do this they must be able to detect 
differences in concentration across a very small distance indeed. A lot of work in 
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this field has been carried out using the amoeba Dictyostelium discoideum which 
use cAMP secretions from bacteria as a chemotactic signal (Devreotes and 
Janetopoulos, 2003). Accumulation of PIP3 at the anterior is an early sign of 
polarisation (Devreotes and Janetopoulos, 2003). These physical changes occur by 
re-arrangement of the F-actin filaments throughout the cell (Coates et al., 1992). 
The importance of this cytoskeletal rearrangement is highlighted by studies 
showing inhibition of actin polymerisation causes cells to lose both morphology 
and polarised sensitivity to chemoattractants (Devreotes and Janetopoulos, 2003). 
Polarisation leads to the re-distribution of many cell-surface molecules important 
for migration. These include chemokine and integrin receptors (del Pozo et al., 
1995).  
1.3.7.2 Integrins 
After tethering to, and rolling along the endothelium via selectins, as described in 
section 1.3.6.1, leukocytes use integrins for firm adhesion. Integrins are 
transmembrane heterodimers which not only attach the migrating cells to the 
vessel wall but activate intracellular signalling pathways. They consist of two 
noncovalently attached glycoproteins subunits, α and β. There are at least 18 α 
subunits and 8 β, combining to form 24 distinct integrins. Each of these has a 
specific function with β6 thought to have an important role in inflammation, and 
αL, αM, αE, β2, β7 knockout mice have defects in leukocyte function (Hynes, 2002).  
Integrin α4β1 binds vascular cell adhesion molecule 1 (VCAM-1) and is important 
for leukocyte migration. Intracellular adhesion molecule-1 (ICAM-1) is the 
endothelial expressed molecule which interacts with the integrin αLβ7, or 
CD11a/CD18, expressed on numerous leukocytes. The expression of ICAM-1, like 
most, if not all, integrin ligands is regulated. In this case glycosylation is crucial for 
expression (Diamond et al., 1991) and a failure to glycosylate leads to a decrease in 
cell migration and resulting recurrent infection (He et al., 2014).  
Integrins must become activated for firm adhesion to occur; this is by ‘inside-out’ 
signalling. Upon activation, integrins straighten, forming an open conformation 
with increased ligand affinity (Beglova et al., 2002; Shimaoka et al., 2002). The 
resting, or closed conformation only binds ligands with low affinity (Adair et al., 
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2005). Integrin valency also increases upon activation by clustering. Positive 
feedback occurs with clustering increasing upon activation and binding (Welf et al., 
2012). The change of state to high-affinity, and lateral mobility of integrins, overall 
increases the avidity of the molecules and is triggered by chemokines (Constantin 
et al., 2000). This activation is both rapid and transient. 
1.3.7.1 Migration into Tissues 
Following adhesion, leukocytes have to cross the endothelium. The majority of 
cells cross through endothelial cell junctions (para-cellular migration) but can also 
pass through the endothelial cells themselves (trans-cellular migration) 
(Hashimoto et al., 2012). The latter has more recently been discovered and the 
exact signalling pathways involved have still to be fully identified (Muller, 2014). 
For para-cellular migration, cells need an additional step, termed locomotion, to 
efficiently move to cell junctions (Schenkel et al., 2004). Interactions between 
platelet-endothelial cell adhesion molecule-1 (PECAM-1; CD31) on leukocytes and 
endothelium and similar interactions of CD99 are crucial for diapedesis. PECAM-1 
blockade arrests cells mainly on the apical surface but CD99 inhibition arrests cells  
partially though the junction (Schenkel et al., 2002). Junctional adhesion molecule 
(JAM) is also important in regulating para-cellular migration (Martin-Padura et al., 
1998).  
Cells then cross the basal lamina and enter the tissue. Once in the affected tissue 
cells continue to migrate along a chemotactic gradient towards the site of infection 
or damage. Collagen networks increase during inflammation and this remodelling 
provides physical guidance to direct cells to the site of action. MMPs and other 
proteases are crucial for extravasation but the exact role of such enzymes in 
extravascular motility remains unclear (Lerchenberger et al., 2013). 
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Figure 1-7 Leukocyte transendothelial migration 
Leukocytes are recruited from the circulation to sites of inflammation by a series of distinct 
processes: tethering, rolling, adhesion and diapedesis, followed by chemotaxis through the tissue to 
the affected area. The initial interactions between leukocytes and the endothelium are transient 
low-affinity adhesions between selectins and their ligands, brought into contact by the shear forces 
in blood flow, and result in the rolling of leukocytes along the endothelial surface. Leukocytes 
rolling along the endothelium encounter GAG bound chemokines which bind and signal through 
appropriate receptors leading to the activation of integrins. Activated integrins then mediate high-
affinity adhesive interactions between the leukocytes and the endothelium, by binding endothelial 
adhesion molecules such as ICAM, resulting in firm adhesion and arrest of rolling leukocytes. 
Following arrest, leukocytes extravasate through the endothelium into the tissue, either by a para-
cellular route as depicted or through the endothelial cells directly (trans-cellular). Once in the 
tissue leukocytes migrate to sites of inflammation by following a chemokine concentration gradient 
and secreting proteases to aid movement through the tissue.    
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1.4 TISSUE STRESS  
There are many causes of stress and damage to tissues which link to inflammation 
and chemokine biology. As previously mentioned oxidative stress has an important 
role in transplantation and so is used in this study. To model stress and 
inflammation in this study phorbol 12-myristate 13-acetate (PMA) and LPS were 
also used. These can activate numerous pathways shared with oxidative stress 
(Numata et al., 1998; Gopalakrishna and Jaken, 2000). 
1.4.1 OXIDATIVE STRESS 
Oxidative stress is the accumulation of reactive oxygen species (ROS), and the 
related reactive nitrogen species (RNS). It arises due to an imbalance in ROS 
producers, including oxidases, and scavengers (or antioxidants) such as 
superoxide dismutase (SOD), altering the normal redox state of cells. This stress 
can be pathological as it has the potential for cellular dysfunction and tissue 
damage. ROS are oxygen based free radicals, or molecules involved in their 
formation as shown in Figure 1-8. Although closely related species, all have 
different effects, functions and half-lives.  For example superoxide is often the first 
radical produced. It is short lived, damaging only macromolecules in the 
immediate vicinity. In contrast, hydrogen peroxide has a longer half-life and can 
act as a signalling molecule as well as effecting molecules directly.  
Oxidative stress can be cell intrinsic as well as produced during inflammation and 
IRI as discussed in section 1.2. A major source of reactive species is electron 
leakage from the mitochondria during aerobic respiration (Bokov et al., 2004; 
Ďuračková, 2010; Papadopoulos et al., 2013). Other sources include peroxisomes, 
the site of lipid metabolism, xanthine oxidase (Ďuračková, 2010) and NADPH 
oxidase in the plasma membrane of activated macrophages (Dröge, 2002). 
Vascular adhesion protein-1, an amine oxidase present at increased levels on 
inflamed endothelium, for example in the liver, produces hydrogen peroxide and is 
linked to leukocyte recruitment during inflammation (Weston and Adams, 2011). 
Infiltration of immune cells able to perform oxidative burst, for example 
macrophages and neutrophils, is a further source of stress during inflammation by 
the release of multiple reactive species. This is an innate immune effector 
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mechanism to aid the killing of pathogens but can contribute to inflammation and 
stress with excess release of reactive species. Sufficient antioxidants are crucial to 
prevent damage by oxidative stress. Sod1-/- mice are deficient in the antioxidant 
CuZnSOD and although apparent normality in early life, have reduced lifespan and 
develop hepatocellular carcinoma (Elchuri et al., 2005). 
DNA, proteins and lipids are all affected by ROS. DNA damage due to oxidative 
stress includes both single–base damage and strand breaks (Rai, 2010; Woodbine 
et al., 2011). The most common DNA modification is the oxidation of 
deoxyguanosine to 8-oxoG (Nakabeppu et al., 2007). Detrimental double stranded 
breaks also occur if radicals cluster near the DNA, effectively causing multiple 
single strand breaks. This can introduce genetic mutations, cause downstream 
signalling effects and activate DNA damage repair mechanisms, potentially 
resulting in apoptosis or senescence (Rai, 2010). The damage is further worsened 
if proteins involved in DNA repair pathways are those damaged.  
To proteins, oxidative stress can cause both conformational and covalent change, 
by alteration of protein folding and amino acids respectively (Cole et al., 2010), as 
will be discussed in more detail in section 1.6.2, and this can alter function. 
Oxidation can also alter the oligomerisation states of proteins. Peroxynitrite, along 
with other reactive species can cause oxidative cross-linking leading to the 
formation of higher order structures (MacGregor et al., 2011; Wang and Barger, 
2012). Such damaged proteins need to be repaired. If repair is unsuccessful there 
are two mechanisms of degradation: the ubiquitin-proteosome system and the 
lysosomal, or autophagic, system. Protein aggregates, which can for example 
accumulate during cell ageing, resist degradation, blocking the proteosome and 
chaperones, further interfering with protein homeostasis (Martinez-Vicente et al., 
2005).  
Peroxidation is the main form of lipid damage; the removal of hydrogen from 
unsaturated fatty acids creating radicals that react with oxygen (Lambert and Elias, 
2010). This causes cell death both by peroxidation of membrane lipoproteins, 
disrupting membrane integrity, and by generation of reactive aldehydes including 
4-hydroxynonenal (4-HNE), which  interact with Fas pathways, including JNK, 
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leading to apoptosis (Ďuračková, 2010). This lipid modification is crucial in the 
pathogenesis of multiple diseases including atherosclerosis (Dröge, 2002). 
Chronic oxidative stress causes considerable damage to cell structure and function, 
with further amplification by recruitment of inflammatory cells. Alteration to 
transcription factors such as NFκB, HIF-1α and p53 further develop the stress 
response and can lead to apoptosis of the parenchyma (Reuter et al., 2010). 
Oxidative stress also reversibly increases mitochondrial permeability, allowing 
signalling molecules to transition to the nucleus and vice versa (Cole et al., 2010). 
The regulation of levels of reactive species is crucial as at high levels, in 
pathological states, they are damaging, but some are necessary in steady states as 
signalling molecules.  
Multiple, often age related, diseases including many cancers are associated with 
oxidative stress. Tissue injury, for example in the liver, generates oxidative stress 
(Urtasun et al., 2009) and hepatocytes produce low levels of ROS, as can Kupffer 
cells. Oxidative stress is not only a consequence of injury but contributes to fibrosis 
and pathogenesis in multiple liver diseases (Nitti et al., 2008). Fibrosis can be 
mediated by ROS via increased levels of TGFβ (Urtasun et al., 2008), however 
oxidative stress is not always pro-fibrogenic. The antioxidant CuZnSOD increases 
active matrix metalloproteinase (MMP) levels, via TGFβ1, leading to the 
breakdown of scar tissue, decreasing fibrosis (Vozenin-Brotons et al., 2001; 
McCord and Edeas, 2005) and in neuroinflammatory disorders ROS can activate 
MMPs (Haorah et al., 2007). Some RNS may also reverse fibrosis as they upregulate 
MMPs (Urtasun et al., 2008).  
1.4.1.1 Peroxynitrite and associated radicals 
Peroxynitrite is formed by the rapid reaction of nitric oxide and superoxide at a 
rate approaching the diffusion limit (Huie and Padmaja, 1993). This rate is 3 to 8 
times faster than superoxide is degraded by SOD, or other biological sinks (Dedon 
and Tannenbaum, 2004) and therefore can evade decomposition by the 
antioxidant enzyme. Figure 1-8 shows peroxynitrite and related species including 
nitric oxide which is formed from the oxidation of the amino acid arginine by NOS, 
with the stable end product of L-citrulline  (Marletta, 1993).  In vivo production of 
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peroxynitrite has been estimated at 50-100µmoles per minute and due to its short 
half-life of only 10ms at physiological pH, peroxynitrite is generally spatially 
associated with sites of superoxide production such as the plasma membrane 
(Szabo et al., 2007); it can however affect cells up to 20µm away (Szabo et al., 
2007). Peroxynitrite exists in cis and trans forms with the former being more 
stable and the latter having greater reactivity, this isomerisation creates complex 
kinetics (Beckman et al., 1992).  
The exact biological effects of peroxynitrite are hard to determine due to its short 
half life. For this reason the reactions and effects attributed to peroxynitrite in this 
study are likely to actually be caused by breakdown products and associated 
 
Figure 1-8 Reactive species in oxidative stress 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) can both be formed from 
superoxide, itself a ROS and a byproduct of aerobic respiration. Antioxidant enzymes reduce the 
oxidative stress. Superoxide dismutase turns the highly reactive superoxide into the slightly less 
damaging hydrogen peroxide. ROS are turned to water to further remove damaging species. This is 
for example by the NADH dependant glutathione peroxidase or catalase. A non-exhaustive list of 
involved species include: •O2- -superoxide, H2O2 – hydrogen peroxide, •OH - hydroxyl radical, ONOO- 
- peroxynitrite, NO• - nitric oxide, ONOOH - peroxynitrous acid, ONOOCO2 - nitrocarbonate ion, •NO2 
– nitric dioxide, •NO3 - nitrate, •CO3 – carbonate radical. Antioxidant enzymes (green): superoxide 
dismutase (SOD).  
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radicals, for ease however they will be credited to peroxynitrite or RNS (Halliwell, 
1997; Eiserich et al., 1998; Pfeiffer et al., 2000; Pfeiffer et al., 2001; Thomas et al., 
2002). The protonated form of peroxynitrite is peroxynitrous acid, the proportion 
of which is determined by pH (pKa=6.8). A crucial reaction for the in vivo effects of 
peroxynitrite is with carbon dioxide, forming the nitrocarbonate ion which can 
then undergo homolysis, creating the numerous reactive species shown in Figure 
1-8 (Beckman et al., 1990; Pryor et al., 1997; Murphy et al., 1998). 
Macrophages produce nitric oxide and superoxide by inducible NOS (iNOS) and 
NADPH oxidase which react to form peroxynitrite. This aids macrophage 
antimicrobial function (Xia and Zweier, 1997; Bokov et al., 2004) and is triggered 
by L-Arginine depletion occurring in inflammation. This is an innate immune 
effector mechanism to aid the killing of pathogens but contributes to inflammation 
and stress with excess release of reactive species. During chronic inflammation 
nitric oxide synthase 2 (NOS2) is upregulated in almost all liver cells (Urtasun et 
al., 2008), further increasing the potential for peroxynitrite formation.  
a) Effects on biomolecules 
Peroxynitrite, or derivatives, can selectively oxidise or nitrate many molecules 
with wide ranging effects. In DNA, peroxynitrite reacts mainly with guanine to 
form 8-nitrodG, by nitrosation, or 8-oxodG (Dedon and Tannenbaum, 2004) as well 
as attacking the DNA backbone causing strand breaks (Dedon and Tannenbaum, 
2004) and deoxyribose oxidation.  
In proteins, peroxynitrite can spontaneously nitrate aromatic amino acids 
including tyrosine and tryptophan but SOD and Fe can also act as catalysts 
(Beckman et al., 1992; Alvarez et al., 1996), with the optimal pH reported to be 
pH7.5 (Beckman et al., 1992). For tyrosine the sole nitration site is the third carbon 
however tryptophan has numerous reactive sites and can undergo oxidation, 
nitration and nitrosation (Nuriel et al., 2011). Oxidation of the thiol group of 
methionine and cysteine to sulfoxide also occurs (Vogt, 1995). The short half-life of 
peroxynitrite prevents its detection in vivo, but it is generally accepted that the 
biomarker 3-nitrotyrosine (3-NT) is indicative of peroxynitrite presence. 
Antibodies have been raised against 3-nitrotyrosine and are used to identify 
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nitrated proteins and the presence of peroxynitrite or related species (Szabo et al., 
2007). I have previously shown that addition of peroxynitrite alone drastically 
increases levels of 3-NT in cells using such antibodies (Barker, 2011). 
3-NT is not recognised during normal protein synthesis but can be incorporated 
both post-translationally and co-translationally by specific enzymes (Souza et al., 
2008). Nitration is not a silent modification and can have profound effects on 
protein function. Alteration of protein function occurs and if this leads to 
attenuation of antioxidants, a positive feedback loop is created further increasing 
peroxynitrite levels. Tyrosine nitration inactivates MnSOD by blocking the active 
site, and this has been observed in human renal allografts undergoing chronic 
rejection (Macmillan-Crow et al., 1996). Peroxynitrite inactivation of CuZnSOD, 
however, is by oxidation of a histidine residue in the active site (Souza et al., 2008). 
Lipid peroxidation by peroxynitrite not only alters lipids themselves but can also 
aid tyrosine nitration and oxidation (Szabo et al., 2007). Nitrated lipids can also 
exert anti-inflammatory effects via PPAR-γ (Szabo et al., 2007). Many of these 
modifications have been demonstrated in vitro but their relevance in vivo is 
unknown.   
b) Cellular effects 
The effects of peroxynitrite can be both damaging and beneficial, synergising with 
or antagonising the effects of ROS. This is dependent on the peroxynitrite 
concentration and surrounding  microenvironment, but also the activation state of 
the cells involved and the antioxidant levels, specifically the peroxynitrite 
scavenger glutathione (Urtasun et al., 2008). Peroxynitrite produces cell type 
dependant activation or inhibition of multiple signalling molecules including NFκB, 
phosphoinositide 3-kinase (PI3K), PKC, MAPK and histone deacetylase 2  (Szabo et 
al., 2007). Peroxynitrite can be pro-apoptotic, triggering the release of 
mitochondrial apoptosis factors (Szabo et al., 2007), but at low concentrations it 
initiates survival signals (Urtasun et al., 2008), and is also involved in senescence 
induction. Nitric oxide and peroxynitrite are pro-apoptotic in neutrophils by 
triggering the release of cytochrome c from mitochondria (Meguro et al., 2003), 
activating caspases 2 and 3, but macrophages are resistant to NO induced 
apoptosis (Shaw et al., 2011).  
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As well as altering protein function, tyrosine nitration can also effect tyrosine 
phosphorylation, altering intracellular signalling. Generally, high peroxynitrite 
concentrations inhibit phosphorylation, possibly by direct competition between 
nitration and phosphorylation, but low concentrations lead to an increase in 
phosphorylation either by activation of tyrosine kinases or irreversible inhibition 
of phosphatases (Pacher et al., 2007). There has also been a suggestion that 
nitration can mimic phosphorylation (Souza et al., 2008) and can inhibit 
phosphatases, therefore increasing phosphorylation levels (Takakura et al., 1999).  
A study by Urtasun et al., 2009, suggests that peroxynitrite is protective in early 
stages of injury, although this is likely to be cell type and situation dependant. 
Treatment of hepatic stellate cells (HSC) with peroxynitrite leads to decreased cell 
activation and reduces the pro-fibrogenic effects of TGFβ. Peroxynitrite also 
increases MMP1 and MMP13 function by nitration and so decreasing fibrosis. 
However if HSC are activated prior to peroxynitrite treatment these anti-fibrogenic 
effects are not seen due to increased levels of glutathione, TGFβ and ROS. 
Peroxynitrite can also inhibit tissue inhibitor of metalloproteinase-1 function and 
therefore further increase the effects of MMPs (Frears et al., 1996). 
c) Involvement in disease 
Peroxynitrite is toxic to pancreatic β-cells and there is increased 3-NT in the 
autoimmune attack of type 1 diabetes (Szabo et al., 2007). As mentioned in section 
1.4.1.1a, peroxynitrite in renal transplantation can further increase oxidative 
stress by inactivating MnSOD (Macmillan-Crow et al., 1996). Peroxynitrite toxicity 
is increased by depletion of its scavenger glutathione, and this is associated with 
neurodegenerative disorders such as Parkinson’s disease (Pacher et al., 2007). 3-
NT can also be seen in numerous cancers including colon, liver and prostate (Kasic 
et al., 2011; Molon et al., 2011) 
Numerous vascular and cardiac conditions have been linked to peroxynitrite. The 
nitration of proteins including creatine kinase and voltage-gated potassium 
channels are important targets as well as nitration of structural proteins including 
desmin and myosin which can have damaging effects on cardiac contractility 
(Pacher et al., 2007). At low levels however, peroxynitrite offers protection against 
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myocardial ischaemia-reperfusion injury by triggering cell survival signals 
(Urtasun et al., 2008), in keeping with ideas that low level oxidative stress is 
protective.  
1.4.2 PMA 
PMA, a tumour promoting phorbol ester, is a potent, although not physiological, 
activator of PKC. Using a PKC activator is a relevant model to this study as PKC is 
one of several redox sensitive signalling molecules and so is involved in oxidative 
stress pathways. PKC is a superfamily of serine-threonine kinases which are 
involved in the stress response, cell growth and cell death. The isoform and 
location within the cell contributes to creating a cell or tissue specific response. 
PMA stimulates PKC by binding its regulatory domain and mimicking the second 
messenger diacylglycerol (DAG) (Gopalakrishna and Jaken, 2000). Oxidative stress 
can have the same effect by oxidising cysteine (present as zinc-thiolates) in the 
zinc fingers which make up the PMA/DAG binding site. This alters conformation, 
relieving autoinhibition in the regulatory domain and causing PKC to be constantly 
active. High concentrations of oxidative stress however can inactivate the enzyme 
via alterations to cysteines in the catalytic domain (Gopalakrishna and Jaken, 
2000), and chronic PMA exposure leads to a decrease in PKC due to proteosomal 
degradation. 
PKC is also involved in the NFκB pathway which is important for redox-sensitive 
gene control. Superoxide increases NFκB DNA binding activity. In endothelial cells 
at least this is PKC dependent (Ogata et al., 2000) and a study in T cells showed 
that PKC synergises with calcineurin to phosphorylate IκBα, activating the 
pathway (Steffan et al., 1995). Hydrogen peroxide can activate tyrosine kinases 
which go on to regulate PKC-δ phosphorylation, further amplifying the effects of 
oxidative stress (Gopalakrishna and Jaken, 2000; Nitti et al., 2008). Of importance 
to this study, as mentioned in section 1.3.2.1, CCL2 transcription can be triggered 
by PKC activation (Ghosh and Baltimore, 1990). 
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1.4.3 LPS 
LPS, or endotoxin, is an essential component of the outer membrane of gram-
negative bacteria. It is a ligand for Toll-like receptor 4 (TLR4), stimulating the 
production of proinflammatory cytokines by both MyD88 dependent and 
independent pathways, activating downstream signalling cascades including NFκB 
and MAPK. The chemokine CCL2 is induced in response to LPS in a MyD88-
dependant manner in macrophages, however CXCL10 is independant (Shyy et al., 
1990; Bandow et al., 2012). 
LPS can therefore induce inflammation and can upregulate iNOS  resulting in the 
production of radicals including peroxynitrite (Numata et al., 1998). Previous 
studies have shown that LPS treatment of H69, the cholangiocyte cell line used in 
this study, induces cell proliferation by increasing production of the mitogen IL-6 
(Park et al., 1999).  
1.5 SENESCENCE 
Senescence is cell ageing, and premature, or accelerated senescence can be 
inflammation associated, contributing to the functional decline of tissues. 
Senescent cells are irreversibly arrested in the G1 phase of the cell cycle; the cells 
are not apoptosing but cannot divide further. Senescent cells generally have an 
enlarged and flattened morphology. Alterations in chromatin and transcription 
lead to the senescence associated secretory phenotype (SASP). Cellular senescence 
is implicated in the pathophysiology of multiple liver diseases, with increasing 
numbers of senescent cells seen in bile duct fibrosis (Sasaki et al., 2010; Chiba et 
al., 2011).   
There are two categories of senescence, replicative and premature. Replicative 
senescence is associated with the Hayflick limit (Hayflick and Moorhead, 1961) 
and is determined by telomere length (Harley, 1991). Premature senescence 
however is linked to stress, including oxidative stress, and is independent of 
telomere length. Replicative senescence however, is not independent of oxidative 
stress as ROS damage can cause DNA breaks to accumulate in telomeres leading to 
accelerated shortening (von Zglinicki et al., 2000). It is thought that senescence 
excludes cells from proliferation if there is a high chance of mutation; a tumour 
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suppressive mechanism (Laberge et al.). Due to other aspects of the biology of 
senescent cells however, this ‘anti-tumour’ effect is not clear cut. 
Oxidative stress is involved in both establishing and maintaining senescence 
(Passos et al., 2010). Chronic activation of p21WAF1/Cip1 (p21; CDKN1A) causes 
mitochondrial dysfunction and ROS production. ROS then cause further DNA 
damage, reinforcing the phenotype. A minimum level of damage is needed to enter 
permanent senescence, although the damage itself does not have to be permanent 
(Passos et al., 2010). Chronic activation of DNA damage repair pathways can lead 
to both senescence and apoptosis, depending on the degree of damage (Rai, 2010) 
and signalling through p21, MAPK and TGFβ are all important in linking 
senescence and ROS production. PKCδ is a downstream mediator of TGFβ-induced 
senescence (Katakura et al., 2009). 
1.5.1 SENESCENCE ASSOCIATED SECRETORY PHENOTYPE (SASP) 
The exact components of SASP vary between situations and cell types (Coppe et al., 
2008), but generally includes increased levels of proteases, matrix components, 
growth factors, for example TGFβ, and proinflammatory cytokines. Examples of 
such cytokines include the chemokines CXCL1 and CXCL8 which can both activate 
CXCR2, reinforcing senescence via activation of the p53 pathway (Acosta et al., 
2008b; Acosta and Gil, 2009). Downregulation of CXCR2 extends cellular lifespan 
(Acosta et al., 2008a). SASP allows senescent cells to alter the surrounding 
microenvironment, spreading senescence by the bystander effect. This is generally 
via autocrine signalling and can be tumour suppressive, but paracrine signalling 
can be pro-tumourigenic (Coppe et al., 2008). SASP also induces epithelial-to-
mesenchymal transition (EMT), linking it to fibrosis (Laberge et al.; Coppe et al., 
2008). The nature of molecules in SASP means tissue repair may initially be 
stimulated but chronic secretion can be deleterious, disrupting tissue structure 
and decreasing the functional mass of the organ. This is in contrast to apoptosis 
which disrupts tissue integrity.  
1.6 CHEMOKINE POST-TRANSLATIONAL MODIFICATIONS 
The function of chemokines, as with many proteins, can be profoundly altered by 
post-translational modification. These modifications can abrogate or enhance, and 
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in a few cases are mandatory for, chemokine function and thus act as a powerful 
regulatory mechanism to fine tune chemokine function. This has been previously 
reviewed by myself and others (Mortier et al., 2008; Moelants et al., 2013a; Barker 
et al., 2014). Modification can be both enzymatic and chemical, altering both 
peptide length or modifying amino acids directly. These modifications can 
profoundly alter chemokine behaviour, changing which receptors they target, their 
presentation by GAGs and our ability to detect them with current antibodies. 
Chemokine receptors may also be modified, for example tyrosine sulphation of 
CXCR4 stabilises CXCR4:CXCL12 interaction (Rapp et al., 2013; Ziarek et al., 2013). 
Examples of different types of modification will now be given but these are not 
exhaustive.  
1.6.1 PROTEOLYSIS  
Multiple enzyme families can cleave chemokines, particularly at the disordered N-
terminus although some examples of C-terminal cleavage have been found.  
1.6.1.1 Matrix metalloproteinases (MMPs) 
MMPs, zinc dependant endopeptidases, are involved in extracellular matrix 
degradation and remodelling. Multiple members of the family are upregulated 
following transplantation and during inflammation. MMP-2 and MMP-9, for 
example, are upregulated during ischaemia-reperfusion (Falk et al., 2002; 
Kuyvenhoven et al., 2004). Other MMPs are strongly associated with immune cells 
including the neutrophil associated MMP-8 and the macrophage specific MMP-12 
(Dean et al., 2008). Reactive nitrogen species can also upregulate MMPs (Urtasun 
et al., 2009). As well as involvement in tissue remodelling these enzymes also have 
important roles in modifying bioactive molecules such as chemokines.  
MMP-8 is released from inflammatory cells including infiltrating neutrophils. N-
terminal cleavage of CXCL5 and CXCL8 by this enzyme increases chemotactic 
activity (Tester et al., 2007). CXCL8 further increases MMP release from 
neutrophils and matrix component degradation by the enzyme further facilitates 
cell migration into the tissue, creating a feedback loop, amplifying cell recruitment 
and potentially leading to worsening damage if unresolved. MMP-1 and -9 also 
cleave CXCL8 (Van Den Steen et al., 2000; Van Den Steen et al., 2003b).  
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Chemokine inactivation also occurs by MMP cleavage. MMP-12 cleaves and 
inactivates ELR+ CXC chemokines, including CXCL8 (Dean et al., 2008), at the 
important E-LR motif. Later in inflammation, cleavage of CCL2, 7, 8 and 13 results 
in loss of activity and the formation of potent antagonists (Dean et al., 2008) that 
may actively suppress macrophage recruitment, promoting resolution and 
preventing damage. There is specificity between ligand and substrate, indicating 
tight control of chemokine regulation. An example of this is CCL2 and CCL7 which 
are co-expressed and share the receptor CCR2. CCL2 can be cleaved by MMP-1 and 
MMP-3 but not by MMP-2 (McQuibban et al., 2002). MMP-2 however can cleave 
and inactivate several chemokines including CCL7 (McQuibban et al., 2001). These 
are all examples of N-terminal processing but MMP-8 and MMP-9 can also cleave 
C-terminal amino acids in CXCL9 and CXCL10, downregulating the function of both 
chemokines (Van den Steen et al., 2003a).   
1.6.1.2 CD26 
The serine protease CD26 (dipeptidyl peptidase-4; DPP4) can also cleave many 
chemokines. CD26 is a membrane glycoprotein expressed by numerous cell types. 
It is highly expressed on T cells and is associated with several aspects of immune 
regulation including T cell proliferation. Inhibition of this enzyme has been 
investigated as a therapy for transplant rejection (Ohnuma et al., 2008). CXCL11 
cleavage by CD26 prevents chemotaxis but the chemokine is still able to 
desensitise the receptor CXCR3 and so can decrease the local activity of full-length 
CXCL11 (Ludwig et al., 2002). CCL5 is also subject to post-translational processing 
by CD26, which cleaves the first two N-terminal amino acids (Lim et al., 2005), 
preventing binding to CCR1 (Oravecz et al., 1997) and CCR3 (Struyf et al., 1998a), 
but CCR5 signalling is still intact, skewing the chemokine towards T cell 
recruitment. Interestingly, CD26 cleavage increases the anti-viral properties of 
CCL5 against HIV (Oravecz et al., 1997). CCL4 also has altered receptor usage 
following CD26 cleavage, it still binds CCR5 but unlike the full length form also 
binds CCR1 and CCR2 (Guan et al., 2002), altering the cell types it can recruit.  
CD26 truncated CXCL10 has been isolated from patients with hepatitis C and is a 
negative prognostic factor in response to treatment (Albert et al., 2011; Casrouge 
et al., 2011; Ragab et al., 2013; Riva et al., 2014). This is presumably because of the 
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antagonistic properties of the truncated form of the chemokine, it has a 10-fold 
decrease in chemotactic potency (Proost et al., 2001).   
1.6.1.3 Other enzymes 
Other enzymes can also alter chemokines. As well as CD26, CCL5 is subject to post-
translational processing by cathepsin G which cleaves the first three N-terminal 
amino acids (Lim et al., 2006). This variant has a 10 fold decrease in CCR5 binding 
and 100 fold lower chemotactic ability. This enzyme can also cleave platlet basic 
protein, forming the chemotactic CXCL7 (Walz and Baggiolini, 1990). C-terminal 
clipping of CCL1 by carboxypeptidase M results in increased signalling and anti-
apoptotic activity but reduced CCR8 binding (Denis et al., 2012).  
The exact importance of this proteolytic activity in vivo however is uncertain as 
GAG binding can prevent chemokine cleavage. GAG binding protects CXCL8 and 
CXCL12 from proteolysis by elastase and CD26 respectively (Webb et al., 1993; 
Sadir et al., 2004) and cleavage of CCL11 by plasmin is also reduced (Ellyard et al., 
2007). This protection is not a universal finding however as CCL20 cleavage by 
cathepsin D still occurs to chemokine when GAG bound (Hasan et al., 2006).  
1.6.1.4 Infection   
As well as enabling fine tuning of the chemokine system during inflammation, 
chemokine cleavage has been utilised by bacteria to evade the immune response. 
The pathogen Streptococcus pyogenes can express SpyCEP (Streptococcus pyogenes 
cell envelope protease) which cleaves ELR+ chemokines, including CXCL8 
(Edwards et al., 2005). This cleavage inactivates the chemokine, unusually at the C-
terminus, with functional effects most likely due to disruption of GAG binding and 
dimerisation rather than receptor binding. SpyCEP is a potent virulence factor, 
helping the bacteria evade immune response by decreasing neutrophil 
recruitment, and is crucial to aggressive bacterial dissemination (Kurupati et al., 
2010). This can lead to increasing disease, for example, lethal necrotising fasciitis 
(Edwards et al., 2005).  
Porphyromonas gingivalis, a bacterium implicated in periodontal disease, also 
produces enzymes capable of chemokine cleavage called gingipains (Mikolajczyk-
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Pawlinska et al., 1998; Moelants et al., 2014). These enzymes can both cleave 
CXCL8 into more potent forms of the chemokine and degrade it, abrogating 
function, depending on whether the enzyme is soluble or membrane bound.  
1.6.2 RESIDUE MODIFICATION   
Modification of chemokines by direct alteration of amino acid residues will now be 
discussed, focusing on the two examples used in this study – nitration and 
citrullination. These are non-enzymatic and enzyme-catalysed modifications 
respectively. Other chemokine modifications can occur, including glycosylation, for 
example to CCL2 and CCL11 (Jiang et al., 1990; Noso et al., 1998) but these will not 
be described in detail. 
1.6.2.1 Nitration 
As discussed previously in sections 1.2 and 1.4.1, transplantation and associated 
inflammation involve oxidative stress. The RNS peroxynitrite can selectively 
oxidise and nitrate several residues, including the oxidation of histidine and the 
nitration of tyrosine and tryptophan. As shown in Figure 1-9, nitration of tyrosine 
results in the formation of 3-nitrotyrosine. This gives the modified residue a 45Da 
mass increase but the overall charge remains unaltered. 3-nitrotyrosine is a 
marker of nitro-oxidative stress and antibodies have been raised against the 
modified residue (Szabo et al., 2007). 
Chemokines are present at increased levels during periods of oxidative stress, such 
as transplantation (see section 1.3.3), and so could be targets of modification. 
Several chemokines have been found to be targets of peroxynitrite modification 
including CCL2 (Sato et al., 1999a; Molon et al., 2011) and CCL5 (Sato et al., 1999b). 
Generally it is thought that modification of proinflammatory cytokines by 
peroxynitrite abrogates function, but this is dependent on numerous factors, 
including cell type. One study shows peroxynitrite-treated CCL2 loses its ability to 
recruit CD8+ T cells but the recruitment of myeloid-derived suppressor cells is 
unaltered (Molon et al., 2011). An earlier study however, shows CCL2 nitration 
impairs monocyte recruitment (Sato et al., 1999a).  Mechanisms of action have not 
been defined in these papers and this study aims to look at the effects in greater 
detail. 
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Figure 1-9 Tyrosine nitration 
Nitration of tyrosine by peroxynitrite results in the formation of 3-nitrotyrosine. This reaction can 
occur to both peptidyl and free tyrosine residues.  
 
Although not able to nitrate chemokines, the ROS hydrogen peroxide can modify 
chemokines by causing oxidative cross-linking of tyrosine residues in CCL5 
(MacGregor et al., 2011). This causes multimer formation of the chemokine but 
does not alter T cell chemotaxis or receptor usage. Interestingly, GAG binding 
prevents this modification occurring. 
1.6.2.2 Citrullination 
Enzymatic residue modification of chemokines includes citrullination. This is the 
formation of citrulline by the deimination of arginine, by peptidylarginine 
deiminase (PAD). This modification only occurs post-translationally as the enzyme 
substrate is peptidylarginine not free arginine.  
As shown in Figure 1-10, citrullination gives a 1Da mass reduction per arginine 
residue modified but more profound functional consequences are likely to result 
from loss of the basic charge. This is especially important for chemokines which 
strongly rely on their cationic residues for GAG interactions, as explained in section 
1.3.4. Arginine residues often play an important role in the structural integrity of 
proteins due to ionic interactions with negatively charged residues and cofactors, 
and by forming hydrogen bonds. Citrullination could logically therefore lead to 
changes in protein structure and hence function. 
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Figure 1-10 Citrullination 
Citrullination is the deimination of arginine to citrulline by peptidylarginine deiminase. The 
substrate for this enzyme is peptidylarginine, the reaction does not occur on free arginine. 
Production of free citrulline however can occur as a byproduct of NOS or the urea cycle. 
 
Five human PAD isoforms have been identified and their roles in pathology and 
chemokine interactions have been reviewed by Moelants et al., 2012. The isoforms 
have differing tissue expression patterns, and substrate specificity is also 
exhibited. For example only PAD2 citrullinates beta actin, and only PAD4 modifies 
histone H3 (Darrah et al., 2012). PAD are expressed by the epidermis, 
granulocytes, lymphocytes and some epithelial cells, with increased expression 
associated with a range of inflammatory diseases including rheumatoid arthritis 
and multiple sclerosis. Stress activated pathways involving p53 both regulate and 
are regulated by PAD4 citrullination (Tanikawa et al., 2009), with 
autocitrullination further controlling enzyme activity (Méchin et al., 2010). 
All human PAD isoforms are calcium binding, and so calcium levels are crucial in 
regulating enzyme activity (Moelants et al., 2012). Normal intracellular calcium 
levels are insufficient for function, but oxidative stress is known to cause an influx 
of cytoplasmic calcium, suggesting that PAD will be active in situations such as 
ischaemia-reperfusion and inflammation. Serum PAD has increased activity in 
rheumatoid arthritis patients (Basu et al., 2011). Citrullination of multiple protein 
families has been identified including the structural proteins actin and cytokeratin. 
Histone citrullination alters chromatin remodelling and so effects protein 
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expression. Citrullination is also needed for neutrophil extracellular trap formation 
and so is heavily involved in immune regulation (Moelants et al., 2012).    
Chemokines can be citrullinated and, as with nitration, this is not a silent 
modification; it affects function. All modifications found so far show citrullination 
to be an anti-inflammatory modification, decreasing in vivo chemokine function. 
Citrullination of both CXCL10 and CXCL11 does not alter CXCR3 binding but does 
result in a decrease in calcium signalling, chemotactic activity and heparin binding 
(Loos et al., 2008). Studies of CXCL12 show that PAD decreases function, with an 
increase in functional impairment correlated with an increased number of 
citrullinated arginines (Struyf et al., 2009). Such modified chemokine may occur in 
for example, Crohn’s disease, where co-expression of CXCL12 and PAD has been 
described (Struyf et al., 2009). CXCL8 has increased CXCR1 binding once 
citrullinated on specific arginines but decreased heparin binding so does not 
induce neutrophil chemotaxis in vivo (Proost et al., 2008). These modifications 
highlight important differences between in vivo and in vitro chemokine function.   
Bacterial PAD have also been identified, produced by P. gingivalis (PPAD). Unlike 
the human isoforms these can modify both free and peptidyl-arginine and are not 
calcium dependent. Chemokines are potentially subject to modification by these 
enzymes but as yet it is unconfirmed (Moelants et al., 2014). As well as modifying 
GAG binding, citrullination also has a role in preventing enzymatic cleavage. 
Citrullination of CXCL8 prevents cleavage by gingipains to more active forms of the 
chemokine, thus potentially dampening inflammation (Moelants et al., 2014). 
1.7 HYPOTHESIS 
Chemokine production following cellular stress and concurrent modification of 
those chemokines represents a powerful paradigm for the regulation of 
inflammation. Not all modifications can occur to all chemokines and not all affect 
function. It is this heterogeneity which makes understanding chemokine biology 
within the inflammatory environment crucial and it may offer better therapeutic 
options. 
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1.8 SPECIFIC AIMS OF THIS STUDY   
Chemokines play a crucial and complex role in inflammation. This study sets out to 
enhance the current understanding of chemokine regulation during inflammatory 
and stressful conditions. Three areas of study were focused on and work was 
carried out to: 
 To determine how tissue stress effects the production of the chemokines 
CCL2, CCL5, CXCL8 and CXCL10 
 
 To investigate which chemokines are subject to post-translational 
modification. Specifically if CCL2, CCL5 and CXCL8 undergo the oxidative 
stress associated modification, nitration, and  if CCL5 citrullination occurs 
 
 To characterise the functional effects of nitration, focussing on CCL2 
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2 GENERAL MATERIALS AND METHODS 
2.1 LABORATORY PROCEDURE 
All experimental procedures were conducted according to the Control of 
Substances Hazardous to Health (COSHH) regulations. All laboratory work was 
carried out in compliance with the University Safety Policy. Laboratory procedures 
were performed in accordance with the Newcastle University publications ‘Safe 
Working with Biological Hazards’, and ‘Safe Working with Chemicals in the 
Laboratory’. Tissue culture was carried out in compliance with the regulations for 
containment of class II pathogens. 
Unless otherwise stated all reagents used are from Sigma.  
2.2 CELL CULTURE 
All cells were grown in a humidified incubator at 37°C with 5% CO2 and tissue 
culture was carried out in a Class II containment cabinet. Cells were grown in 25, 
75 and 175cm2 tissue culture flasks or 6 well plates (Greiner Bio-One). Adherent 
cells were washed with phosphate buffered saline (PBS; Sigma) and detached by 
incubation with trypsin-EDTA (Sigma). Detached cells were then centrifuged 
(5min, 500xg), resuspended in tissue culture medium, counted by 
haemocytometer if necessary, and seeded into new flasks or plates. If cells were to 
be used for assays requiring immediate cell surface protein expression, cells were 
detached from the flask using EDTA-PBS (Sigma).    
2.2.1 CULTURE MEDIA  
All media were supplemented with 2mM L-glutamine (Sigma), 10% foetal bovine 
serum (FBS; Biosera) and 100U/ml penicillin and 100µg/ml streptomycin (Sigma). 
Other supplements were added as required.     
2.2.2 CELL STORAGE 
Cells were detached as described above and resuspended in 1ml freezing media 
(10% dimethylsulphoxide (DMSO; Sigma) in FBS) in a cryovial. Cells were cooled at 
1°C per minute in a “Mr Frosty” (Nalgene) overnight in a -80°C freezer to prevent 
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cryoinjury. Cells were transferred to liquid nitrogen for long term storage. Cells 
were retrieved from storage by rapid thawing in a 37°C water bath and washed 
with media to remove DMSO before seeding into flasks.  
2.2.3 CELL COUNTING AND VIABILITY 
To determine cell number and concentration, 10µl cell suspension was counted 
using an improved Neubauer chamber haemocytometer.  
If cell viability needed to be assessed, cell suspension was mixed 1:1 with 0.4% 
trypan blue (Sigma) prior to counting. Trypan blue cannot pass through viable cell 
membranes, but if the cell is necrotic, trypan blue crosses the membrane, staining 
the cell blue. Live and dead cells can therefore be distinguished, counted by 
haemocytometer, and the percentage viability calculated. 
2.2.4 CELL LINES 
2.2.4.1 H69 
The cholangiocyte cell line H69 was created by Grubman et al., 1994 from human 
intrahepatic biliary epithelial cells immortalised by transfection with SV40 large T 
antigen. Cells were cultured in complete low glucose Dulbecco’s Modified Eagle’s 
medium (DMEM)/Nutrient Mixture F12 Ham (3:1; Sigma) supplemented with: 
18mM adenine (Sigma), 2μM triiodothyronine (Sigma), 5.5µM adrenaline (Sigma), 
ITS-X supplement (10µg/ml insulin, 5.5µg/ml transferrin, 2µg/ml ethanolamine, 
6.7ng/ml sodium selenite; Gibco, Invitrogen), 1μM hydrocortisone solution 
(Sigma).  
2.2.4.2 HKC8 
The renal epithelial cell line HKC8 was created by Racusen et al., 1997 from adult 
human renal tubule epithelium and cells were immortalised using adenovirus 12-
SV40. Cells were cultured in complete DMEM F12 Ham (Sigma).  
2.2.4.3 EA.hy926 
EA.hy926 were created by the fusion of human umbilical vein endothelial cells 
with the human lung carcinoma cell line A549 (Edgell et al., 1983) and are used in 
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this study to model endothelium for in vitro transendothelial chemotaxis. Cells 
were cultured in complete DMEM (Sigma). 
2.2.4.4 THP-1 
THP-1 is a monocytic cell line derived from the peripheral blood of a 1 year old 
with acute monocytic leukemia (ATCC TIB-202). Cells were cultured in complete 
RPMI-1640 (Sigma).  
2.2.4.5 HEK-CCR2b 
Human embryonic kidney (HEK-293) cells have previously been transfected with 
the chemokine receptor CCR2b by our group (Wain et al., 2002) using a vector 
encoding the human chemokine receptor CCR2b and neomycin 
phosphotransferase, giving G418 resistance. Cells were cultured in complete 
DMEM (Sigma) with 800µg/ml G418 (Calbiochem) to maintain selection of the 
transfectants.  
2.2.4.6 CHO-CCR5 
Chinese hamster ovary (CHO-K1) cells previously transfected with the human 
chemokine receptor CCR5 (Ali et al., 2000) were cultured in complete DMEM F12 
Ham (Sigma) with 800µg/ml G418.  
2.2.4.7 Peripheral Blood Mononuclear Cells 
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood taken 
from healthy volunteers. Blood was thoroughly mixed with 1 unit heparin per ml 
blood to stop coagulation before dilution 1:1 with serum-free RPMI-1640 and 
carefully layering 10ml above 5ml Lympholyte-H (Cedarlane Laboratories). The 
blood was then separated using density gradient centrifugation (800xg, 20min). 
The interface containing PBMC was extracted and washed twice in serum-free 
RPMI-1640 (500xg, 5min) before counting. Cells were serum starved for 1hr prior 
to use in assays. CCR2 expression on T cells and monocytes was confirmed by flow 
cytometry (Figure 2-1). 
Ethical approval to obtain blood from healthy volunteers was granted by the 
County Durham and Tees Valley Research Ethics Committee (12/NE/0121). 
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2.2.4.8 Neutrophils 
Neutrophils were isolated from whole blood taken from healthy volunteers. All 
reagents were warmed to 37°C before use. 10ml blood was mixed with 1ml 3.8% 
sodium citrate (Sigma) as an anti-coagulant. The blood was then centrifuged for 
20min at 200xg, brake rate 0, and the plasma layer removed. 2.5ml of 6% dextran 
T-500 in 0.9% NaCl (Pharmacosmos) was added, the mix made up to the original 
blood volume with 0.9% saline solution and cells left to sediment for 30min. The 
leukocyte rich upper layer was removed and made up to 50ml with 0.9% saline 
solution and centrifuged at 200xg for 5min, brake rate 1. The pellet was then re-
suspended in 2.5ml 55% percoll plus (GE Healthcare) and layered on top of layers 
of 70% and 81% percoll plus before centrifugation at 700xg for 20mins, brake rate 
zero. Neutrophils were then collected from between the 70% and 81% layers, and 
washed in Hank’s Balanced Salt Solution (modified with NaHCO3, without phenol 
red, calcium chloride or magnesium sulphate; Sigma) with centrifugation at 200xg 
for 5min before use in assays. This work was performed under my supervision by 
the BSc project students P Milligan and F Tak. 
2.2.5 CHARACTERISATION OF CELL LINES 
Flow cytometry was used to establish which chemokine receptors are present on 
the epithelial cell lines (Figure 2-2 and Figure 2-3). This was performed to see if 
the epithelial cells were capable of chemokine scavenging. The antibodies used 
were all from R&D Systems, and cells were stained according to the manufacturer’s 
instructions, with appropriate isotype controls (see Table 2).  
H69 cells have previously been validated as epithelial cells using the markers E-
cadherin, cytokeratin-19 and zona occludens-1 (Barker, 2011). 
2.2.6 MYCOPLASMA TESTING 
Mycoplasma can alter cell responses but is not visible by light microscope. To 
ensure cells were not infected, cells were tested using MycoAlert™ mycoplasma 
detection kit (Lonza) in accordance with the manufacturer’s instructions.  
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Figure 2-1 Characterisation of CCR2 expression on monocytes and T cells.  
Upper panels show identification of monocytes and T cells using the markers CD14 (red) and CD3 
(blue) respectively. 
Lower panels show unstained control (left) and CCR2 staining (right) on monocytes and T cells. 
Representative of three experiments. 
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Figure 2-2 Chemokine receptor expression on H69 cells  
Representative flow cytometry staining of H69 cells for range of chemokine receptors (solid lines) 
and isotype controls (dashed lines). n=2  
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Figure 2-3 Chemokine receptor expression on HKC8 cells 
Representative flow cytometry staining of HKC8 cells for range of chemokine receptors (solid lines) 
and isotype controls (dashed lines). n=2 
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2.3 FLOW CYTOMETRY  
2.3.1 GENERAL PRINCIPLES 
Flow cytometry is a laser-based technique which uses principles of light scattering 
and, in many cases, emission from fluorochromes, to gain information on single 
cells as they pass through a laser in a fluid stream. 
Light is reflected and refracted by cells and their internal structures. This light is 
measured, detected, and converted into electrical pulses by optical detectors. This 
can give information on the physical characteristics of the cells. Light scattered in 
the forward direction of the laser beam is focused by a lens and converted into a 
parameter known as Forward Scatter (FSC). This gives information about the size 
and shape of the cell. Light scattered perpendicular to the plane of the beam is 
called Side Scatter (SSC) and is proportional to the granularity of the cell. The 
combination of these two parameters can help identify cell types. 
In addition to information on physical characteristics, cells can be labelled with 
dyes or fluorochrome-conjugated antibodies which allow detection of specific cell-
surface markers. When fluorochromes are stimulated at a particular wavelength 
they are excited but then return to their original unexcited state by emission of 
lower energy and longer wavelength light. This emitted light is detected, split in to 
specific colours by wavelength and digitised, as with FSC and SSC. Ideally, 
fluorochromes should be selected so that their emission and excitation 
wavelengths have sufficient spectral separation to allow fluorescence to be 
detected individually. If more than one fluorochrome is used per tube and this is 
not the case, there is a chance that the signal of one fluorochrome will be 
artificially increased by photons from the periphery of another fluorochrome’s 
spectrum. This is further complicated as fluorochromes emit a spectrum that will 
activate different detectors to different extents if they do not emit at a single 
wavelength. If needed, electronic compensation algorithms can be set up at the 
beginning of the experiment.  
In this study flow cytometry has been used to determine the presence of cell-
surface receptors, using fluorochrome-conjugated antibodies, and to count cells as 
Materials and Methods 
54 
 
a ratio to beads following chemotaxis, using the FSC and SSC characteristics of cells 
and beads (see section 2.8.1.1b).    
2.3.2 STAINING OF CELL-SURFACE ANTIGENS 
Cells were removed from culture, counted and resuspended in 2% FBS/PBS. 
250,000 cells in 50µl were stained per tube with the antibody concentration 
according to the manufacturer’s instructions (see Table 2). Unstained and 
appropriate isotype controls were also performed.  
Antigen Clone Isotype Label Manufacturer 
hCXCR1 42705 mIgG2a FITC R&D 
hCXCR3 49801 mIgG1 PE R&D 
hCXCR4 44717 mIgG2b APC R&D 
hCCR2  48607 mIgG2b PE R&D 
hCCR3  61828 rIgG2a FITC R&D 
hCCR5  CTC5 mIgG2b FITC R&D 
hCCR7  150503 mIgG2a PE R&D 
hCCR9  112509 mIgG2a FITC R&D 
hDARC 358307 mIgG2a FITC R&D 
hD6  196124 rIgG2a FITC R&D 
hCD3 OKT3 mIgG2a eFluor 450 eBioscience 
hCD14 61D3 mIgG1 APC eBioscience 
mCD3 17A2 rIgG2b eFluor 450 eBioscience 
mCD45 30-F11 rIgG2b PerCP-Cyanine5.5 eBioscience 
Table 2 List of antibodies used in flow cytometry 
 
2.3.3 INSTRUMENT AND ANALYSIS  
All flow experiments were performed using BD FACSCanto II flow cytometers and 
data recorded using BD FACSDiva software. Data were analysed using FlowJo 
software v.7.6.4 (Treestar). 
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2.4 REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN 
REACTION  
In order to decrease the risk of sample contamination, all reagents used were 
RNase free, only sterile filter tips were used and all tubes were autoclaved and/or 
treated with UV light exposure. 
2.4.1 RNA ISOLATION 
RNA was isolated using TRI-Reagent (Sigma) as per the manufacturer’s 
instructions, and my previous work (Barker, 2011), based on the method 
developed by Chomczynski (Chomczynski and Sacchi, 1987). All work was carried 
out on ice and centrifugation was at 4°C. Treated cells were lysed directly on the 
plate using 1ml TRI-Reagent, pipetted to form a homogeneous lysate and allowed 
to stand for 5min to allow nucleoprotein complex dissociation. 200µl chloroform 
(Sigma) was then added prior to vigorous shaking for 15sec and allowed to stand 
at room temperature (RT) for 15min. The lysate was then separated into three 
phases by centrifugation (12000xg, 15min). The upper colourless phase containing 
 
Figure 2-4 Representative plot from Nanodrop   
RNA quality was analysed using a Nanodrop Spectrophotometer. 260/280 and 260/230 ratios can 
be determined as well as RNA concentration.  
 
the RNA was transferred to a new tube and 0.5ml 2-propanol (Sigma) added. After 
standing for 10min the RNA precipitate was pelleted by centrifugation (12000xg, 
10min). The pellet was washed using 75% ethanol in DEPC-treated water, 
vortexed and centrifuged at 7500xg for 5min. The pellet was air dried before 
resuspending in 50µl DEPC treated water. The RNA was analysed using a 
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NanoDrop ND-1000 Spectrophotometer to determine concentration and purity 
(see Figure 2-4). 
2.4.1.1 Gel electrophoresis  
Gel electrophoresis was used to check the degradation state of the isolated RNA. 
2µl RNA with orange G loading buffer was run on a 1% agrose gel (50ml tris-
acetate-EDTA (TAE) buffer, 0.5g agrose and 0.5µg/ml ethidium bromide; TAE 
buffer contains 40mM Tris, 20mM acetic acid and 1mM EDTA at pH8.0; all Sigma) 
at 90V for approximately 45min. RNA was then visualised and imaged using an 
AlphaImager (Alpha Innotech Corporation) to demonstrate intact ribosomal RNA 
subunits, as shown in Figure 2-5.  
 
Figure 2-5 Confirmation of RNA integrity.  
Following RNA isolation using TRI-Reagent, RNA was run on a 1% agrose gel. The 2 bands show the 
RNA from the 18S and 28S ribosomal subunits, rRNA being the most abundant RNA and so the most 
apparent bands.  
2.4.1 FIRST STRAND COMPLEMENTARY DNA SYNTHESIS 
Complementary DNA (cDNA) was made from the RNA suspension using an 
AffinityScript Multiple Temperature cDNA synthesis kit (Aligent Technologies) or 
Tetro cDNA Synthesis Kit (Bioline) and a thermocycler (T100™ Thermal Cycler, 
Bio-Rad) according to the manufacturer’s instructions (Aligent – 5min at 65°C, 
10min at 25°C, 60min at 50°C and 15min at 70°C. Bioline - 30min at 45°C and 5min 
at 85°C). 2µg RNA was used per reaction and following synthesis short term 
storage of cDNA samples was at 4°C until PCR amplification.  
28S 
18S 
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2.4.2 TAQMAN REAL-TIME PCR 
2.4.2.1 General Principles 
Polymerase chain reaction (PCR) is a technique used to amplify a specific gene 
from a cDNA template, using primers specific to the gene of interest: the more 
abundant the starting template, the more product will be created. Conventional 
PCR is semi-quantitative as levels of product can be visualised by gel 
electrophoresis and compared; real-time PCR (qPCR) is quantitative. Both 
techniques require comparison to a housekeeping gene, for example GAPDH, 
which serves as an endogenous control.  
PCR is performed in a thermocycler which repeatedly heats samples to a range of 
temperatures allowing the reaction to occur. First, an initialisation step is needed 
to activate the polymerase, and then a series of steps are repeated, normally for 
forty cycles. Cycles are as follows: denaturing step - causes disruption of hydrogen 
bonds, creating single stranded DNA, annealing step - annealing of the primers to 
the single stranded template, elongation step – the optimal temperature for 
polymerase activity, allowing synthesis of a new strand of DNA. There is 
exponential amplification in which the amount of product doubles, followed by 
levelling off and plateauing in which no more product is formed due to exhaustion 
of reagents.   
qPCR allows the detection of PCR products during their formation by the 
generation of a fluorescent signal. In this study Taqman probes were used, which 
have a high energy fluorescing dye (reporter; 6-carboxyfluorescein) at the 5’ end 
and a low energy quencher (non fluorescence quencher-minor groove binder; 
NFQ-MGB) at the 3’ end of the probe, as shown in Figure 2-6. If the probe is intact, 
when the reporter is excited by light it does not fluoresce as energy is transferred 
to the quenching molecule (fluorescence resonance energy transfer). The probe 
anneals to specific sequences between the forward and reverse primers and as the 
polymerase extends the primers, the 5’ exonuclease of the enzyme cleaves the 
probe, separating the reporter and quencher. This allows the reporter to fluoresce, 
and fluorescence increases with every cycle, proportional to the accumulation of  
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Figure 2-6 Taqman qPCR schematic 
Steps of qPCR - initial denaturation of the cDNA followed by annealing of PCR primers and probe to 
complementary regions of DNA. The polymerase then extends the strand using the cDNA template,  
and the exonuclease activity displaces and cleaves the probe. This allows the reporter and quencher 
to be separated resulting in reporter fluorescence. The increase in fluorescence is directly 
proportional to the amount of PCR product. 
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PCR products. An important parameter for quantification is the threshold cycle 
(Ct), this is the cycle number at which the fluorescence level passes a fixed 
threshold, set within the lower third of the exponential phase of increasing 
fluorescence (see Figure 2-7). The lower the Ct, the higher the initial amount of 
template. 
 
Figure 2-7 Real-time PCR amplification plot 
The threshold is placed in the lower third of the linear phase of the amplification curve, establishing 
the threshold cycle (Ct) for each sample. This allows calculation of the fold increase relative to the 
housekeeping gene GAPDH using ddCt. The plot shows amplification of cDNA from H69 cells both 
untreated and following treatment with the positive control LPS. The lower the Ct value, the higher 
the starting level of gene specific mRNA and so CXCL8 expression is increased following LPS 
treatment.    
 
2.4.2.2 Method 
Real-time PCR (qPCR) was performed to quantify the alteration in mRNA 
expression of various chemokines and enzymes following cell treatment. 20µl 
reactions were performed in MicroAmp Optical 96 well reaction plates (Applied 
Biosystems). Each reaction contained: 1µl cDNA, 8µl sterile water, 1µl TaqMan 
primer-probes (shown in Table 3) and 10µl 2xBrilliant II QPCR Master Mix (Aligent 
Technologies) or SensiFast Probe Hi-ROX Mix (Bioline). Reactions were carried out 
in triplicate in a StepOnePlus real-time PCR machine (Applied Biosystems).  
In this study two protocols were used for qPCR, a normal and a fast cycle (times in 
brackets). In order to activate the Taq polymerase, the reaction was first heated to 
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95°C for 10min (20sec). Then a step of 95°C for 15sec (1sec) followed by 60°C for 
1min (20sec) was repeated 40 times. 
Target Assay ID 
CCL2 Hs00234140_m1 
CCL5 Hs00174575_m1 
CXCL8 Hs00174103_m1 
CXCL10 Hs00171042_m1 
CD26 Hs00175210_m1 
PADI2 Hs00247108_m1 
PADI4 Hs00202612_m1 
GAPDH Hs02758991_g1 
Table 3 List of primers used in real-time PCR 
All are TaqMan® Gene Expression Assays from Applied Biosystems with FAM dye. 
 
 
Prior to reactions primers were validated (see Figure 2-9). The house-keeping 
gene used was GAPDH (Que et al., 1999). ΔΔCt value, error and significance were 
calculated as described by Yuan et al. (Yuan et al., 2006) and shown in Figure 2-8.  
 
                                                       
                                            
                   
Figure 2-8 Equations for fold change calculation in real-time PCR 
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CCL2 -3.33 100% 
CCL5 -3.50 93% 
CXCL8 -3.32 100% 
CXCL10 -3.14 108% 
GAPDH -3.46 94% 
 
 
 
Figure 2-9 Validation of TaqMan primers for realtime PCR.  
A serial dilution of sample template cDNA gave increasing threshold cycle (Ct) values with 
decreasing cDNA levels. The table shows the gradient of each line and calculated reaction efficiency.  
Plotted is mean Ct ± SEM  
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2.5 PROTEIN DETERMINATION BY IMMUNOASSAY 
Levels of chemokine were generally quantified using enzyme linked 
immunosorbent assay (ELISA).  
2.5.1 ENZYME-LINKED IMMUNOSORBENT ASSAY 
ELISA is a widely used technique to determine protein levels in a sample. It is an 
antibody based technique in which the final antibody is conjugated to an enzyme, 
usually horse radish peroxidase (HRP), and the final step involves adding the 
enzyme’s substrate in a buffer, which will develop colour if the enzyme is present. 
This level of colour change can then be quantified by spectrophotometry.   
Two forms of ELISA have been used in this study – sandwich and direct. In a 
sandwich ELISA an antibody against the protein of interest is coated on to a 96 
well microtitre plate. The sample is then added, followed by a second antibody 
against the protein. This is then detected by an enzyme conjugated antibody and a 
colour change reaction. Direct ELISAs are detected in the same way but the protein 
of interest is directly bound to the plate. In both cases, quantification is achieved 
by comparison to a standard curve.  
2.5.1.1 General ELISA protocol 
For sandwich ELISAs, a 96-well plate (Immulon HBX or Costar) was coated with 
100µl monoclonal antibody in PBS overnight at 4°C and then blocked with PBS 
containing protein (casein or BSA) for 1-2hr. This is to reduce non-specific binding. 
Plates were washed three times between every step with 150µl 0.05% Tween/PBS 
and antibodies diluted in block buffer. 100µl sample was then incubated for 1-2hr 
prior to incubation with a second protein specific antibody, normally polyclonal. If 
this second antibody is biotinylated it can be detected using streptavidin-HRP. If 
not a HRP conjugated antibody against the polyclonal can be used. The ELISA is 
then developed using one of two colour change reactions: tetramethylbenzidine 
(TMB) or o-phenylenediamine (OPD). TMB (Sigma) was dissolved in 250µl DMSO, 
added to 25ml TMB buffer (0.1M sodium acetate, pH adjusted to 4.9 with 0.1M 
citrate) and 3.7µl H2O2, the colour change reaction was then stopped with 50µl 1M 
H2SO4 and measured at 450nm. For OPD, 100µl OPD was added to 12.5ml citrate 
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buffer (0.1M citric acid, pH5) with 5µl H2O2. The reaction was again stopped with 
50µl 1M H2SO4 but colour change measured at 490nm. Plates were read using an 
Opsys MR plate reader (DYNEX Technologies) or a Synergy plate reader (BioTek). 
For some assays wavelength correction at 595nm was also performed. 
For direct ELISAs the detection protocol was the same but sample was bound to 
the plate in carbonate buffer (15mM Na2CO3, 35mM NaHCO3, pH9.6) overnight 
prior to blocking so a capture antibody is not required.  
2.6 PROTEIN NITRATION 
The basic nitration protocol was received from Prof. Antonella Viola, University of 
Milan, and further optimisation performed previously (Barker, 2011). 
Chemokine nitration was achieved by adding peroxynitrite (Cayman Chemical) at a 
final concentration of 1mM, to 1µM chemokine in deionised water (dH2O) and 
incubating at 37°C for up to 10min. Chemokine was freshly nitrated for each 
experiment and all chemokines purchased from Almac unless otherwise stated. 
Peptides were nitrated by the same method. 
Peroxynitrite concentration was established according to the manufacturer’s 
instructions. Stock peroxynitrite was diluted 40-fold with 0.3M NaOH and 
absorbance at 302nm measured using a Nanodrop. The concentration was then 
calculated using the peroxynitrite extinction coefficient (1670M-1cm-1).   
2.7 PROTEIN LEVEL DETERMINATION 
Protein concentration was determined using a Pierce BCA protein assay kit 
(Thermo Scientific) as per kit instructions, using the microplate procedure. The 
bicinchoninic acid (BCA) assay is a commonly used method which combines the 
biuret reaction with colourimetric detection using BCA. Proteins in an alkaline 
solution can reduce Cu2+ to Cu1+ and BCA chelation by Cu1+ results in a colour 
change from green to purple which can be measured at 562nm (nearest 
wavelength available on the plate reader used is 595nm).  
Due to the oxidative potential of peroxynitrite (see Figure 2-10), for accurate 
quantification of samples containing peroxynitrite, dialysis was needed. Samples 
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were dialysed against 500ml PBS overnight using Slide-A-Lyzer MINI Dialyse Units, 
2000 molecular weight cut-off (MWCO) (Thermo Scientific).  
Blank NaOH Peroxynitrite
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Figure 2-10 BCA assay showing peroxynitrite can give false positives 
A BCA assay (Thermo Scientific) was performed using water, peroxynitrite, or NaOH (the 
peroxynitrite carrier) in the absence of protein to show that the oxidative potential of peroxynitrite 
can give false positives.    
2.8 CHEMOTAXIS 
Chemotaxis assays allow evaluation of the ability of chemokines to induce the 
chemotaxis of cells. In this study several forms of chemotaxis assay were used. 
Standard bare membrane assays determine the level of response to a chemokine, 
mainly dependent on chemokine-receptor interactions. As a more physiological 
assay, transendothelial chemotaxis was performed. For this chemokine-GAG 
interactions are also required to enable cells to migrate through the endothelial 
monolayer. To measure the number of cells recruited in vivo, a murine air-pouch 
model was used.     
2.8.1 IN VITRO 
In vitro chemotaxis assays were carried out using a transwell system as shown in 
Figure 2-11. Prior to chemotaxis, 24 well companion plates (BD Falcon) were 
blocked with 1ml 1% BSA/RPMI per well for 1hr to prevent chemokine binding 
and therefore lowering the concentration of available chemokine. FBS is not used 
as a blocking agent in chemotaxis as it contains bovine chemokines which may 
affect results (Struyf et al., 2001; De Buck et al., 2013). After this, 800µl chemokine 
in 1% BSA/RPMI was added to each well and a cell culture insert (BD Falcon) 
containing cells in 0.5ml 1% BSA/RPMI carefully lowered into each well. Wells 
Materials and Methods 
65 
 
containing 1% BSA/RPMI only were performed as a negative control. The plate 
was then incubated at 37°C and cells counted. See Table 4 for individual conditions 
for each cell type.  
Some cell types need fibronectin coated filters to encourage adherence to the filter 
for counting. For such assays the underside of filters was coated with 80µl 
2.5µg/ml fibronectin (Sigma) for 30min. The excess fibronectin was then removed 
and filters allowed to dry for a further 30min. 
Cell type Filter size Fibronectin Cell 
number 
Migration 
time 
Counting method 
PBMC 3µm No 500 000 90min Flow cytometry 
Filter staining 
Neutrophil 3µm No 500 000 90min Haemocytometer 
HEK-CCR2b 8µm Yes 200 000 6hr Filter staining 
CHO-CCR5 8µm Yes 100 000 5hr Filter staining 
Table 4 Chemotaxis conditions for different cell types 
Cells require different conditions dependent on cell size and motility. 
 
2.8.1.1 Transendothelial chemotaxis  
In order for more physiological conditions to be created in vitro, transendothelial 
chemotaxis assays were performed. This was as above except 72hr prior to the 
assay, 5x104 EA.hy-926 cells were cultured in 0.5ml complete RPMI-1640  in cell 
culture inserts. Media was only placed in the insert, not in the well underneath, to 
discourage cells from growing through the filter, forming a ‘double’ monolayer and 
making final cell counting more difficult. 
2.8.1.1 Counting migrated cells  
a) Filter staining 
Cells which adhered to the lower side of the filter were manually counted by 
microscopy. The upper side of filters were gently wiped with a cotton bud to 
remove non-migrated cells and then filters were fixed in methanol at -20°C (1hr to 
overnight). After fixation filters are washed in dH2O and stained using 
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haematoxylin (Sigma) for 10min. Tap water was then used to blue the stain before 
dehydration with 50%, 75%, 90% and 100% ethanol. After air drying, filters were 
mounted with DPX mountant (Sigma) and migrated cells counted (5 high power 
fields per filter), see Figure 2-11.    
 
Figure 2-11 Schematic of a chemotaxis experiment.  
Cells are placed in a filter above a well with or without chemokine. After incubation at 37°C for 
90min, T cells have migrated to the lower well where they can be counted by flow cytometry as a 
ratio to a known number of counting beads. Migrated monocytes are adhered to the underside of 
the filter and are counted using a microscope.  
 
b) Flow cytometry 
Cells which fully migrated through the filter into the well below were counted 
using flow cytometry. Well contents were transferred into appropriate tubes (BD 
Falcon), centrifuged at 500xg for 5min, and cell pellet resuspended in 50µl 1% 
BSA/RPMI. A known number of, normally 2000, counting beads (UltraRainbow 
calibration particles, Spherotech Inc) was then added and flow cytometery used to 
determine the number of migrated cells as a ratio to beads, see Figure 2-11.  
 
No chemokine Chemokine 
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Neutrophils migrated into the lower chamber were counted by haemocytometer 
under my supervision by the BSc project students P Milligan and F Tak. 
2.8.2 IN VIVO 
In vivo function of chemokines was assayed using an air pouch model. The 
generation of air pouches was described previously by (Ali et al., 2005b) and 
outlined in Figure 2-12, in full compliance with UK Home Office regulations for 
animal experimentation (licence PPL60/3786). Air pouches were created by 
injecting 3ml sterile air subcutaneously into the back of each animal under general 
anaesthetic (isofluorane). Pouches were then topped up with 1ml air injections on 
days 2, 4, and 5. This produced stable fluid-filled pouches (Figure 2-13). On day 6, 
each pouch was injected with 1ml chemoattractant or PBS negative control. After 
24hr recruited cells were recovered by lavaging the pouch twice with 0.75ml 3mM 
EDTA/PBS. Cells were then analysed by flow cytometry and counted by 
haemocytometer. 
 
Figure 2-12 Schematic of the air pouch in vivo chemotaxis model 
 
 
Figure 2-13 Air pouch  
Shown is a murine air pouch. On day 7 the pouch was lavaged to recover migrated cells, for this the 
back was shaved to allow clear access to the pouch. 
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2.9 MASS SPECTROMETRY 
Mass spectrometry (MS) measures the mass-to-charge ratio (m/z) of molecules, 
allowing calculation of the mass of the sample. Firstly the sample is ionised, in the 
simplest situation by adding or removing protons. In certain techniques for 
example electrospray ionisation (ESI), larger molecules, especially peptides and 
proteins can gain or lose numerous protons forming a variety of charged states. A 
protein with many lysine and arginine residues can easily gain extra protons, 
ranging from a single to tens of protons, and in positive mode mass spectrometry 
this adds one extra Dalton mass as well as charge, creating a large number of 
possible m/z values.  
The cloud of ionised molecules in the mass spectrometer is separated by m/z. In a 
simple machine the cloud of charged molecules is deflected round a bend and hits 
a detector. Ions of the same mass-to-charge ratio will undergo the same amount of 
deflection and hit the detector at the same time. For example a molecule of 500 
mass units with one proton attached and thus a +1 charge would have an m/z of 
500 but a molecule of 1000 mass units with two protons attached would also have 
an m/z of 500. Similarly, a mass difference of 45Da would be seen as an m/z 
increase of 22.5 for +2 ions and 15 for 3+. For analysis of more complex spectra, 
deconvolution algorithms can be applied to establish the monoisotopic masses of 
the proteins or peptides in the sample.    
ESI coupled to both MS and tandem MS (ESI-MS/MS) are the methods used in this 
study for the detection of post-translational modification. It has been used for 
establishing the mass of whole proteins, synthesised peptides and tryptic digests of 
proteins. The latter allows determination of which residues specifically are 
modified and not just the overall alteration in mass following post-translational 
modification. Specific details are given in the relevant chapters.    
2.10 STATISTICAL ANALYSIS 
Statistical analysis was carried out using GraphPad Prism 5.0. Unless otherwise 
stated, all graphed data depicts the mean value of three experiments, each 
performed in triplicate. ANOVA and Student’s t-test (abbreviated to t-test 
throughout) are the statistical analyses used.  
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Error bars on graphs illustrate the standard error of the mean. Dotted lines on 
graphs represent the negative control. P values on graphs are denoted by asterisks 
as follows: *= p<0.05, **= p<0.01, ***= p<0.001, ****= p<0.0001. 
2.11 IMAGES 
Chemical structures were drawn using ChemBioDraw Ultra 2012 (CambridgeSoft, 
PerkinElmer).  
Three dimensional protein structure images were created using Jmol. 
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3 ALTERATION OF CHEMOKINE EXPRESSION DURING STRESS 
3.1 INTRODUCTION 
The immune system has evolved to defend against numerous types of infection and 
malignancy. As a result there is a consequent need to elicit different responses 
based on the pathological stimulus in question. For this reason different cell 
activating stimuli will result in different ‘activated’ phenotypes.  
As discussed in section 1.3, chemokines have different and specific patterns of 
regulation. The chemokines involved in normal cell trafficking and tissue 
homeostasis, such as CXCL12, are constitutively expressed, whereas 
proinflammatory chemokines can be induced. Many of these chemokines are 
induced by cytokines including IL-1β or TNFα, and it was specific upregulation in 
response to IFNγ which lead to the discovery of the chemokines CXCL9 and 
CXCL10 (Luster et al., 1985; Liao et al., 1995). The expression of many 
proinflammatory chemokines involves the activation of numerous signalling 
pathways. These can be different for each stimulus, transcription factor and cell 
type, as well as the added complexity of cross talk between these pathways. This 
intricate system allows the fine tuning required for the signal and tissue specific 
biological responses needed. 
These different chemokine responses can be seen in vivo by considering specific 
chemokine involvements in disease models (Segerer et al., 2000). For example in 
models of kidney disease, CCL2 and CCL5 seem to be consistently involved whilst 
other chemokines play a role depending on the specific disease. Within the 
inflammatory environment certain chemokines can be produced by both the cells 
of the affected organ and infiltrating leukocytes, further complicating the picture. 
In the kidney CCL2 and CCL5 are generally thought to originate from the mesangial 
cells and infiltrating monocytes, whereas CX3CL1, another chemokine with some 
involvement in kidney disease, is predominantly bound to endothelial cells in the 
glomerulus (Anders et al., 2001; Panzer et al., 2006). In rats with cresentic 
glomerulonephritis, CCL2 is selectively expressed in the glomeruli and not the 
tubulointerstitium (Panzer et al., 2001). The effects of these chemokines also differ. 
Early studies showed CCL2 and CCL5 neutralising antibodies decreased monocyte 
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influx in a model of cresentic glomerulonephritis but only CCL2 had a role in the 
development of interstitial fibrosis (Lloyd et al., 1997). It is not just CC chemokines 
which have involvement in kidney diseases, CXCL9, but not CXCL10, is involved in 
the murine model, nephrotoxic serum nephritis (Menke et al., 2008). 
In the liver different chemokines have been found to be important, again 
highlighting both the different chemokines produced during inflammation and the 
differential chemokine expression within each organ. It is thought that CCR5 has a 
role in the recruitment of leukocytes to the portal tracts, and CXCR3 to the 
parenchyma as reviewed by Oo et al., 2010. The sources of CXCR3 ligands in liver 
inflammation include hepatocytes, stellate cells, sinusoidal endothelial cells and 
infiltrating leukocytes. These ligands are increased on hepatic endothelium during 
chronic hepatitis, and levels correlate with disease outcome (Curbishley et al., 
2005). As found in kidney inflammation, CX3CL1 can be involved in human liver 
disease; expression increases in biliary epithelial cells during primary biliary 
cirrhosis (PBC) (Isse et al., 2005). CC chemokines also have a role in liver 
inflammation. Plasma and hepatic levels of CCL2 correlate with alcoholic liver 
disease (ALD) severity, neutrophil infiltration and CXCL8 levels, however they do 
not correlate with steatosis (Degre et al., 2012). Sections from another 
inflammatory liver disease have been examined in this chapter, primary sclerosing 
cholangitis (PSC). Both PSC and PBC have increased levels of CCL26 but CCL11 was 
only found to be increased in PSC (Landi et al., 2014). The exact role of chemokines 
in inflammation is complex. In some mouse models of liver inflammation CCR5+ 
lymphocyte infiltration is characteristic, however CCR5-/- mice are more 
susceptible to Con A-induced hepatitis showing that this receptor is not simply 
pro- or anti-inflammatory (Ajuebor et al., 2005; Moreno et al., 2005). Con A 
induces liver specific inflammation which is driven by hepatic expression of IFNγ 
and mediated by activated T cells. In this model CCL3 blockade reduces disease, by 
reducing the infiltration of CCR1+ T cells (Ajuebor et al., 2004). 
During transplantation and inflammation the production of reactive species, both 
ROS and RNS, is a major source of stress as discussed in sections 1.2 and 1.4.1. 
These are produced following organ reperfusion, by mitochondria and oxidases in 
epithelial and endothelial cells, and by infiltrating leukocytes capable of oxidative 
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burst. As well as causing tissue damage, oxidative stress can also stimulate 
proinflammatory factors including chemokines, and is a major factor in their 
production in the situations discussed above.      
So far in this chapter, only transcriptional regulation of chemokines during 
inflammation has been described. However this is only one method for chemokine 
regulation during inflammation, as discussed earlier in sections 1.3.1 and 1.6. Post-
translational modifications are an important mechanism for modifying chemokine 
function, potentially causing abrogation, potentiation or alteration of function. In 
some cases these modifications can have wider effects, for example antagonists can 
be formed, decreasing the activity of wild type chemokines also present (Proost et 
al., 1998b). If there is loss of GAG binding function with unaffected receptor 
activating potential, an anti-inflammatory agonist could be formed (O'Boyle et al., 
2009), the biological implications of which are discussed later in this chapter.  
A key question is whether chemokine modification is cell intrinsic or extrinsic; can 
cells modify the chemokines they produce or are other modifiers needed? Data in 
this chapter shows that, at least in some circumstances, cells are capable of 
intrinsic modification. All of this complex regulation feeds together to allow the 
tight control of inflammation integral to the delicate control of leukocyte 
behaviour.  
3.1.1 SPECIFIC AIMS  
 Establish how chemokine gene expression and protein production alter in 
response to stress 
 Determine whether these chemokines are functional and if there is 
potential for alteration of function by post-translational modification during 
such stress 
 Demonstrate the presence of chemokine modification in an inflammatory 
environment 
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3.2 SPECIFIC MATERIALS AND METHODS 
3.2.1 CELL TREATMENT 
H69 and HKC8 cells were grown in 6 well plates (Greiner Bio One) or T25 tissue 
culture flasks (Greiner Bio One) for cell treatment for RNA isolation or collection of 
media for analysis of chemokine production. Treatments for qPCR analysis were as 
follows: 1µg/ml LPS-EB (E. coli 0111:B4; Invivogen), 6hr; 12.5-200ng/ml  PMA, 
6hr; 200µM hydrogen peroxide (Sigma), 6hr with media changed after 2hr; 600µM 
peroxynitrite (Cayman Chemicals), 6hr (all previously optimised Barker, 2011 or 
Brain, 2010). For serum starvation cells were grown in their normal media and 
then changed to serum-free media overnight prior to treatment. For cell treatment 
for ELISA analysis cells were treated for 24 or 48hr and a range of concentrations 
for each treatment used. 
For creation of a poly-chemokine stimulus for chemotaxis assays (section 3.2.3), 
H69 cells were treated with 1µg/ml LPS-EB for 6hr. Media was then removed, cells 
washed with PBS and new media added. Media was collected 18hr later and used 
in assays. 
For the purification of chemokine from cell treated media, 6 well plates were used 
to produce media for the ELISAs to determine the preferred cell line and 
treatment. For purification, 2 litre of HKC8 treated media was produced in T125 
flasks (Greiner Bio One).  
3.2.2 PROTEIN DETERMINATION BY IMMUNOASSAY 
3.2.2.1 ELISAs 
For the measurement of chemokine levels following cell stress various ELISAs 
were performed, all using the basic protocol previously outlined (section 2.5.1.1). 
CCL5 and CXCL8 were detected using Duosets (R&D Systems) according to the 
manufacturer’s protocol and for CCL2 an ELISA kit from Peprotech was used. 
Figure 3-1 shows the standard curves from these ELISAs used for quantification. 
Samples were assayed at 2 different concentrations, neat and 1/10 diluted in block 
buffer. CXCL12 levels were also determined using a Duoset (R&D Systems). 
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Figure 3-1 Elisa standard curves 
Example standard curves from chemokine ELISAs, performed in duplicate. CCL2 ELISA kit 
(Peprotech), CCL5 and CXCL8 Duoset (R&D Systems) 
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3.2.2.2 MesoScale Discovery 
Determination of the levels of CCL2, CCL4, CCL5, CCL11, CCL13, CCL17, CXCL8 and 
CXCL10 for chemotaxis assays was achieved using MSD® kits (Mesoscale 
Discovery, MD) as per the manufacturer’s instructions. A very similar method to an 
ELISA, Instead of the enzymatic reaction in ELISAs, the detection antibody in an 
MSD is coupled to an electrochemoluminescent label (‘sulfo-tag’) which emits light 
at a 620nm when an electric charge is applied to the carbon electrode in each well. 
This light is detected by a charge-coupled device (CCD) camera within the MSD 
Sector analyser and then protein concentrations calculated from the standard 
curve using MSD Workbench software (MesoScale). 
3.2.3 CHEMOTAXIS 
3.2.3.1 In vitro chemotaxis 
Transendothelial chemotaxis was performed as described in section 2.8.1.1. T cell 
migration in response to chemokines produced by LPS stimulated H69 was 
assayed. 800µl H69 conditioned media per well and 100nM PS372424 (Ligand 
Pharmaceuticals), a small molecule CXCR3 agonist (Stroke et al., 2006; Nedjai et al., 
2012), or 2µg/ml CXCR3 neutralizing antibody (clone 49801, R&D Systems) was 
added to appropriate filters immediately prior to lowering into well. The assay was 
incubated for 90min and migrated cells counted by flow cytometry (section 
2.8.1.1). 
3.2.3.2 In vivo air pouch 
Air pouch was created as in section 2.8.2 but the mice used were humanised as 
described by O’Boyle et al. 2012. Female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice 
(Charles River; 8 week old) were given 107 human PBMC in 0.5ml PBS by 
intraperitoneal injection. After 21 days air pouches were generated and six days 
after creation of air pouches, each pouch was injected with 1ml LPS treated H69 
media (see section 3.2.1). Animals received intravenously 0.1ml vehicle control, a 
CXCR3 agonist PS372424 (1μM in blood), or CXCR3 neutralizing antibody (25μg). 
The pouch was lavaged and human cells counted by flow cytometry. The in vivo 
model was established by Dr G O’Boyle and Mr C Fox, Newcastle University. 
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3.2.3.3 Determining level of LPS 
Quantifying the level of LPS in media used in the in vivo chemotaxis assay was done 
using HEK-BlueTM-hTLR4 cells (InvivoGen) as per the manufacturer’s instructions 
and was performed by Dr Jeremy Palmer, Newcastle University. HEK-BlueTM-
hTLR4 cells are a stably transfected HEK-293 cell line which expresses the LPS 
receptor complex TLR4, MD-2 and CD14. A secreted embryonic alkaline 
phosphatase (SEAP) reporter gene was co-transfected and placed under the 
control of an NFB promoter. Stimulation with LPS activates NFB inducing SEAP 
production and catalysis of a colour change reaction in the detection medium. This 
colour change is then quantified against a standard curve constructed using E. coli 
K12 LPS (Invivogen) by measuring absorbance at 620nm. 
3.2.4 CHEMOKINE PURIFICATION 
Natural chemokine was purified from HKC8 conditioned media. This was achieved 
using three types of chromatography for increasing purity, with ELISAs and silver 
stain SDS-PAGE performed between each purification step to identify positive 
fractions and determine purity.   
All purification work, with the exception of production of the original sample, was 
carried out in the Laboratory of Molecular Immunology, Rega Institute, Katholieke 
Universiteit, Leuven, Belgium with the help of Prof. Paul Proost and technicians 
Noëmie Pörtner and Lien Leutenez. NanoLC-MS was performed at the 
Gasthuisberg campus, Katholieke Universiteit, Leuven. 
3.2.4.1 Sample preparation 
Two litres of conditioned media from HKC8 cells which had been serum starved 
and treated with 5µM peroxynitrite for 48hr was produced. 
Prior to purification, the sample was centrifuged and 0.45µm filtered under 
vacuum to remove particulate. It was then diluted 1 in 3 with 50mM Tris to lower 
the salt concentration of the sample to approximately that of the loading buffer, 
ensuring protein binding to the column. 
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3.2.4.2 Affinity Chromatography 
Affinity chromatography separates proteins based on reversible interactions 
between the target proteins and a specific ligand attached to the chromatography 
matrix, in this case heparin. Unbound protein is then washed out and conditions 
changed to elute the proteins of interest which are bound to the column. For 
heparin the ionic strength is increased to disrupt the charge interaction between 
heparin and chemokines.  
Sample was loaded at 3ml/min on to a 20ml heparin-sepharose column (GE 
Healthcare) prior to eluting using a linear gradient (50mM-2M NaCl). 5-10ml 
fractions were collected; all steps were carried out at 4°C using an AKTA purifier 
(GE Healthcare). Eluent used: 50mM Tris, 50mM NaCl, pH7.4, protein eluted using: 
50mM Tris, 2M NaCl, pH7.4. 
3.2.4.3 Ion Exchange Chromatography 
Ion-exchange chromatography (IEX) separates proteins by differences in surface 
charge: positively charged chemokines reversibly bind the negatively charged 
cation exchanger, methyl sulfonate (Mono S). As pH alters the surface charge of 
proteins, IEX is performed at a pH significantly below the pI to ensure protein 
binding to Mono S.   
Following affinity chromatography fractions were still contaminated with many 
proteins and so IEX was performed to further purify samples. Fractions positive 
for the chemokine of interest were pooled and dialysed against 2l 50mM formic 
acid, pH4, 4°C with agitation in 3500 MWCO dialysis tubing (Spectrum). This was 
for both desalting and buffer exchange. Dialysis is needed as fractions are eluted 
from heparin-sepharose by increasing ionic strength, but for IEX samples need to 
be loaded at low ionic strength. The pI of many chemokines is around 9, so samples 
need to be at pH4, significantly below the pI to ensure binding to Mono S.   
Dialysed sample was 0.45µm filtered before loading in 50mM formic acid, pH4 
onto a 1ml Mono S column (5/5-GL; GE Healthcare). Samples were then eluted 
using a 1hr linear gradient increasing to 1M NaCl in 50mM formic acid. 1ml 
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fractions were collected and all steps were carried out at 4°C using an AKTA 
purifier (GE Healthcare). 
3.2.4.4 Reversed Phase - High Performance Liquid Chromatography 
As a final purification step a third chromatography method was used. Positive 
fractions from IEX were purified by reversed phase – high performance liquid 
chromatography (RP-HPLC). RP-HPLC separates proteins by hydrophobicity, 
proteins stick to the column in a highly aqueous mobile phase and are eluted using 
a highly organic mobile phase, in this case the organic solvent acetonitrile. The 
stationary phase of RP-HPLC columns is made of hydrophobic alkyl chains. The 
chain length used in this study was C8 as it is suitable for smaller proteins and 
peptides.  
Positive fractions following IEX were pooled and injected on to a 2.1x220mm 
Brownlee C8 Aquapore RP-300 column (PerkinElmer) in 0.1% TFA and run using 
an Aglient 1100 HPLC system. Samples were then eluted at 0.4ml/min using a 
three stage acetonitrile gradient: started in 0.1% TFA, increasing to 20% 
acetonitrile after 10min, then a flatter gradient, to increase chemokine separation, 
increasing to 40% acetonitrile after 85min. Column effluent was collected in 400µl 
fractions. 
3.2.4.5 Fraction Identification 
a) Gel Electrophoresis 
To visualise protein purity following chromatography, fractions were separated by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
silver stained.  SDS-PAGE is a technique which uses an electrical current to drive 
proteins though a gel with the rate of movement being influenced by the size, 
shape and charge of the molecule. SDS is an anionic detergent which in 
combination with reducing agents such as β-mercaptoethanol can denature 
proteins, forming linear structures with a negative charge proportional to length. 
This allows proteins to be separated by size and an estimation of molecular weight 
made by comparison to a protein ladder.   
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Large gels were made as shown in Table 5 using the Biorad Protean system. 
Running and spacer gels were poured one above the other and left to set, with the 
spacer covered with a layer of butanol to prevent oxidation. Butanol was then 
washed off, the stacking gel poured and left to set with a 25 well comb.  
20µl of each fraction were heated in sample buffer at 95°C for 5min to denature 
proteins and add a negative charge. Sample buffer was at a final concentration of: 
2% SDS, 6% glycerol, 1% β-mercaptoethanol, 0.005% brilliant blue G, 25mM Tris 
HCl pH6.8. Gels were run at 96V for 16hr with anode buffer (0.2M Tris base, pH8.9) 
and cathode buffer (20mM Tris base, 20mM tricine, 0.7mM SDS, pH8.2).  
b) Silver staining 
Gels were fixed for 1hr in 10% ethanol, 2.5% acetic acid, 1.25% sulfosalicylic acid 
and washed 3 times in 20% ethanol prior to incubation with ammonium hydroxide 
solution (163mM NH4OH, 14.7mM NaOH, 20% ethanol, 10% AgNO3, in degassed 
dH2O) for 1hr. Gels were washed in dH2O and 20% ethanol and developed for 5-
10min in 20% ethanol, 0.01% citric acid, 0.037% formaldehyde. When the bands 
had developed to the required density, gels were placed in stop solution (20% 
ethanol, 0.5% acetic acid) for 1min and washed in dH2O for 30mins. Gels were then 
shrunk using 50% ethanol overnight for imaging and storage at 4°C.  
 Running gel Spacer gel Stacking gel 
Acrylamide  9.75ml (5%) 7.50 ml (3.3%) 1.25 ml (5%) 
Gel buffer (3M Tris base, 
10mM SDS pH8.45) 
10.00ml 10.00ml 2.50ml 
Glycerol 3.20ml - - 
dH2O 7.05ml 12.50ml 6.25ml 
10% APS  200µl 200µl 100µl 
TEMED* 20µl 20µl 10µl 
Table 5 Components for large SDS-PAGE gels 
* TEMED - Tetramethylethylenediamine 
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c) ELISA 
ELISA were performed on fractions to determine which fractions contained the 
chemokines of interest. These were performed as described in section 2.5.1.1 with 
some modifications. The block buffer used was 0.1% casein/0.05% Tween/PBS, all 
subsequent incubation steps were carried out at 37°C. The final development was 
using TMB. Antibodies used are shown in Table 6. 
 Coating antibody Secondary antibody Detection  
CCL2 Mouse anti-hCCL2 (R&D 
clone 23007) 1/300 
Biotinylated goat anti-
hCCL2 (R&D #279) 
1/1000 
Streptavidin-HRP 
(R&D) 
CCL5 Mouse anti-hCCL5 (R&D 
Duoset) 
Biotinylated goat anti-
CCL5 (R&D Duoset) 
Streptavidin-HRP 
(R&D) 
CXCL8 Polyclonal anti-hCXCL8 
(Rega#4576) 1/300 
Mouse anti-hCXCL8 
1/2000 
Goat anti-mouse 
HRP 1/2500 
Table 6 Antibodies used in ELISAs for fraction identification  
 
d) Mass spectrometry 
HPLC fractions containing the highest concentrations of chemokine were analysed 
by nanoLC-MS using a Thermo Scientific Q Exactive mass spectrometer. Due to low 
chemokine concentration the nano column was needed to concentrate the sample 
sufficiently for identification.  
3.2.1 TISSUE STAINING  
3.2.1.1 Tissue Sections 
Formalin fixed paraffin embedded (FFPE) 4µm tissue sections were used for 
immunohistochemistry (IHC). Biopsies from human liver with a range of 
inflammatory conditions, or time-zero biopsies from liver transplants post 
reperfusion were stained.  Blocks from a mouse model of kidney ischaemia-
reperfusion injury were kindly donated by Prof N. Sheerin’s group, Newcastle 
University.  
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Ethical approval was obtained from a local regional ethics committee concerning 
the use of patient samples. Samples represented excess liver tissue that had been 
taken for diagnostic purposes; diagnosis and staging of disease in each sample was 
identified by means of a number allocated by the Cellular Pathology department. 
No patient identifiable information was used during the project. Approval 
reference REC 06/Q0905/150 Amendment 1; Date of amendment 09/01/2007 By 
the Newcastle and North Tyneside Local Research Ethics Committee 1. 
The kidney IRI animal work was carried out under Home Office license 
PPL60/3786. Tissue from a murine ischaemia-reperfusion injury model (De Vries 
et al., 2003) was used for IHC. Briefly, the left kidney was clamped for up to 45min 
and then both kidneys harvested 24hr post reperfusion, the right being used as the 
contralateral control. Surgical work was performed by Mr Christopher Fox, 
Newcastle Comparative Biology Centre.    
3.2.1.2 Immunohistochemical Staining 
Sections were dewaxed in xylene for 10min and rehydrated through 100%, 95%, 
70% ethanol to running water. Endogenous peroxidase activity was then blocked 
using 3ml H2O2 in 200ml methanol for 10min and sections washed in water 
followed by TBS (pH7.6; Tris-buffered saline). This is crucial as antigen detection is 
by a peroxidase based methods and so endogenous enzyme may lead to non-
specific background staining. The formalin used to fix tissue sections can cause 
protein crosslinking and prevent the epitope being accessed by antibodies, for this 
reason antigen retrieval is needed. This was carried out by pressure cooking slides 
in citrate buffer (pH6) for 1min at pressure then cooled rapidly in running water 
and washed in TBS. Biotin block (Vector Laboratories) was then performed 
according to the manufacturer’s instructions. This is especially important when 
staining liver tissue which has a high level of endogenous biotin. If this is not 
blocked then high background may occur as biotinylated antibodies are used in 
detection. Sections were then blocked for 1hr with 20% normal swine serum, 
incubated with primary antibody, biotinylated secondary antibody and then 
developed with TBS washes between each step. Vectastain ABC(Px) kit (Vector 
Laboratories) was then used as per manufacturer’s instructions prior to 
development with DAB (2.5ml DAB, 2µl H2O2) for 1min. Sections were finally 
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counterstained in haematoxylin Sigma), blued in Scott’s tap water and dehydrated 
through 70% to 99% ethanol, then into xylene before mounting using DPX. 
For 3-nitrotyrosine staining the primary antibody used was rabbit anti-
nitrotyrosine polyclonal (1/500, 1hr; Millipore, 06-284) as previously optimised 
(Barker, 2011). For CCL2 the antibody used was rabbit anti-CCL2 polyclonal 
(1/500, 1hr; Abcam, ab9669), previously optimised by Mrs B Innes. No primary 
antibody controls were also performed.  
3.2.1.3 Haematoxylin and eosin staining 
Sections were dewaxed and rehydrated as described in section 3.2.1.2. Slides were 
then stained with haematoxylin (Sigma) for 1min, rinsed, blued in Scott’s tap water 
for 30sec, rinsed and finally stained with eosin (1min; Sigma). Slides were then 
dehydrated and mounted as described in section 3.2.1.2. H&E staining was 
performed by Mrs B Innes. 
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3.3 RESULTS 
3.3.1 ALTERATION IN CHEMOKINE TRANSCRIPTION BY STRESSED EPITHELIUM 
To establish the different responses to stress of liver and kidney epithelium, 
appropriate cell lines were stressed with peroxynitrite, hydrogen peroxide, PMA or 
LPS, and the chemokines produced measured. Before measuring chemokine levels, 
cell viability following stress was assessed and none of the treatments were found 
to be cytotoxic (Figure 3-2).  
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Figure 3-2 Cell viability following stress 
H69 and HKC8 cells were untreated (UT) or treated with 600µM peroxynitrite (ONOO), 200µM 
H2O2, 1µg/ml LPS or 20ng/ml PMA for 6hr, as for subsequent real-time PCR analysis. Cell viability 
was then determined using Trypan Blue. n=3 
 
TaqMan qPCR was used to examine transcriptional changes in the inflammatory 
and senescence associated chemokines CCL2, CCL5, CXCL8 and CXCL10 following 
cell stress. Results were normalised to GAPDH and fold increase calculated by 
ddCt, compared to untreated cells. Figure 3-3 shows that PMA, hydrogen peroxide 
and LPS all increase CCL2 transcription in H69, hydrogen peroxide giving the 
greatest mean fold increase of 8. Only PMA however significantly increases CCL2 
levels in the kidney epithelium. The kidney cannot be stimulated to produce 
increased CCL5 under any of the conditions examined and the liver cells only 
produce increased CCL5 in response to LPS. The CXC chemokines CXCL8 and 
CXCL10 showed a greater potential for induction in response to stress (Figure 3-4) 
with PMA stimulating a 412 fold increase in CXCL8 mRNA levels in HKC8 cells and 
Chemokine Expression During Stress 
84 
 
39 fold in H69. CXCL10 had more specific induction, only being upregulated by LPS 
in H69 and PMA in HKC8.   
The effect of serum starvation, another form of cellular stress, on chemokine 
induction was also assessed. Figure 3-5 and Figure 3-6 show serum starvation 
stimulates chemokine production, with the largest effect being on CXCL10 mRNA 
levels in kidney cells. The combined stresses of PMA and serum starvation were 
also studied as shown in Figure 3-7 and Figure 3-8. The effect of PMA on 
chemokine production is far greater on serum starved cells than untreated (Figure 
3-3 and Figure 3-4), giving a greater fold increase compared to untreated and the 
starting levels of chemokine production is also higher than cells in sera.      
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Figure 3-3 Induction of CCL2 and CCL5 in H69 and HKC8 cells following stress 
Cells were treated with 600µM peroxynitrite (ONOO), 200µM H2O2, 1µg/ml LPS or 20ng/ml PMA 
for 6hr. Following RNA isolation using TRI-Reagent and cDNA synthesis, TaqMan qPCR was 
performed. Fold increase was calculated using ddCt relative to untreated cells, normalised to 
GAPDH. Shown is the mean fold change of four experiments, each performed in triplicate. Statistics 
denote a larger than 3 fold change which is significantly different to 1 (t-test). 
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Figure 3-4 Induction of CXCL8 and CXCL10 in H69 and HKC8 cells following stress 
Cells were treated with 600µM peroxynitrite (ONOO), 200µM H2O2, 1µg/ml LPS or 20ng/ml PMA 
for 6hr. Following RNA isolation using TRI-Reagent and cDNA synthesis, TaqMan qPCR was 
performed. Fold increase was calculated using ddCt relative to untreated cells, normalised to 
GAPDH. Shown is the mean fold change of four experiments, each performed in triplicate. Statistics 
denote a larger than 3 fold change which is significantly different to 1 (one sample t-test).  
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Figure 3-5 Induction of CCL2 and CXCL10 in H69 cells following serum starvation 
Cells were subject to serum starvation overnight. TaqMan qPCR was performed and fold increase 
calculated using ddCt relative to cells grown in serum, normalised to GAPDH. FBS-cells grown in 
10% serum, SS-serum starved cells. Results are from a representative experiment of three 
experiments, each performed in triplicate.  
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Figure 3-6 Induction of CCL2 and CXCL10 in HKC8 cells following serum starvation 
Cells were subject to serum starvation overnight. TaqMan qPCR was performed and fold increase 
calculated using ddCt relative to cells grown in serum, normalised to GAPDH. FBS-cells grown in 
10% serum, SS-serum starved cells. Results are from a representative experiment of three 
experiments, each performed in triplicate.  
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Figure 3-7 Induction of CCL2 and CXCL10 in serum starved H69 cells following PMA 
treatment 
Cells were treated with 20ng/ml PMA for 6hr following overnight serum starvation. TaqMan qPCR 
was performed and fold increase calculated using ddCt relative to untreated cells (UT), normalised 
to GAPDH. Results are from a representative experiment of three experiments, each performed in 
triplicate.  
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Figure 3-8 Induction of CCL2 and CXCL10 in serum starved HKC8 cells following PMA 
treatment 
Cells were treated with 20ng/ml PMA for 6hr following overnight serum starvation. TaqMan qPCR 
was performed and fold increase calculated using ddCt relative to untreated cells (UT), normalised 
to GAPDH. Results are from a representative experiment of three experiments, each performed in 
triplicate.  
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3.3.2 CHEMOKINES PRODUCED ARE FUNCTIONAL 
The qPCR data shows that stressed epithelium is able to upregulate transcription 
but to establish any potential physiological consequences the function of the 
chemokines needs to be determined. LPS treated H69 cells were chosen as the 
example treatment for this study as it was the only treatment which increased the 
transcription of all four chemokines evaluated in section 3.3.1. Cells were treated 
with LPS for 6hr, washed, fresh media added, and cells incubated for a further 18 
hours. This short LPS treatment was necessary as the aim was to produce a poly-
chemokine mix without high levels of LPS. Residual LPS could potentially be a 
confounding variable especially in subsequent in vivo assays. HEK-Blue-hTLR4 
cells were used to determine LPS levels and Figure 3-9 shows very low residual 
levels in the ‘LPS wash’ treated media.  
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Figure 3-9 Quantification of LPS in H69 supernatant using HEK-Blue-hTLR4 cells  
a) Standard curve constructed using E. coli K12 LPS. In the presence of LPS, secreted embryonic 
alkaline phosphatase (SEAP) causes a colour change reaction which can be detected by measuring 
absorbance at 620nm  
b) Concentration of LPS in samples. Samples were used neat and diluted 1 in 4. LPS – H69 cells 
treated with 1µg/ml LPS for 24hr, LPS wash – cells treated with LPS for 6hr, media changed and 
18hr later media was collected, UT – media collected from untreated H69 cells.  
 
To determine the chemokine concentration present in the media, ELISA and MSD 
were used (Figure 3-10). Serum starved cells were also tested in this assay. The 
data shows a range of chemokines are present in the LPS treated media. Both in 
vitro and in vivo chemotaxis assays were then performed to establish if these 
chemokines have chemotactic potential. Transendothelial chemotaxis was used to 
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assess the ability of T cells to migrate in response to the chemokines produced by 
H69 cells (Figure 3-11). The migration of these cells could be blocked using the 
small molecule CXCR3 agonist PS372424 but not by a CXCR3 blocking antibody. 
Supporting results were found in an in vivo air-pouch model (Figure 3-12).  
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Figure 3-10 Chemokine production following LPS treatment of H69 cells 
Cells were treated with 1µg/ml LPS for 6hr, media changed and 18hr later media collected. ELISA 
or MSD was used to quantify chemokine protein levels in this media. SS-cells were serum starved 
overnight, FBS-cells were grown in serum-containing media, UT-untreated cells. n=1 
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Figure 3-11 LPS treated H69 supernatant is chemotactic in vitro  
Transendothelial chemotaxis was performed to evaluate T cell migration in response to the poly-
chemokine stimulus produced by LPS treated H69 cells. T cells from PBMC were placed in a 3µm 
filter above a well containing media, ± 100nM PS372424, ± 2µg/ml CXCR3 blocking antibody (BAb), 
and incubated at 37°C for 90mins. Negative control is non cell treated media. Migrated cells were 
counted by flow cytometry as a ratio of cells to counting beads. Statistics – unpaired t-test - all 
p<0.0001, n=3 in triplicate.  
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Figure 3-12 LPS treated H69 supernatant is chemotactic in vivo  
Human cell migration into air pouches of humanised SCID mice 24hr following intrapouch 
administration of LPS-treated H69 supernatant and intravenous administration of PBS, 1μM 
PS372424 or 25μg CXCR3 blocking antibody (BAb). Shown is three independent experiments, each 
with >5mice per group. 
 
3.3.3 CHEMOKINES PRODUCED MAYBE MODIFIED 
As well as assessing the functional potential of chemokines produced by stressed 
epithelial cells, it was also determined if these chemokines had undergone 
modification. To do this chemokines needed to be purified and analysed by mass 
spectrometry.  
CCL2, CCL5 and CXCL8 ELISAs were used to determine a suitable cell type and 
treatment to use to produce the large amounts of conditioned media for this 
analysis (Figure 3-13 - Figure 3-18). However each ELISA was only performed 
once (in duplicate) and so robust conclusions cannot be drawn as to how each 
treatment effects chemokine production. For CXCL8, exact concentrations could 
not be reached for some samples as even diluted samples were above the top 
standard (Figure 3-18). 5µM peroxynitrite with serum starvation of HKC8 for 48hr 
was chosen as the treatment as it gave the highest levels of a range of chemokines 
and reducing the amount of serum present is of technical benefit for later 
purification.   
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Figure 3-13 CCL2 production by H69 cells 
H69 cells were treated with a range of concentrations of peroxynitrite, hydrogen peroxide, LPS and 
PMA for 24 and 48hr. CCL2 levels in supernatant was measured by CCL2 ELISA (Peprotech)  
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Figure 3-14 CCL2 production by HKC8 cells 
HKC8 cells were treated with a range of concentrations of peroxynitrite, hydrogen peroxide, LPS 
and PMA for 24 and 48hr. CCL2 levels in supernatant was measured by CCL2 ELISA (Peprotech)  
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Figure 3-15 CCL5 production by H69 cells 
H69 cells were treated with a range of concentrations of peroxynitrite, hydrogen peroxide, LPS and 
PMA for 24 and 48hr. CCL5 levels in supernatant were determined by CCL5 ELISA (Duoset, R&D 
Systems) using supernatant neat and diluted 1:10 with PBS.  
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Figure 3-16 CCL5 production by HKC8 cells 
HKC8 cells were treated with a range of concentrations of peroxynitrite, hydrogen peroxide, LPS 
and PMA for 24 and 48hr. CCL5 levels in supernatant were determined by CCL5 ELISA (Duoset, 
R&D Systems) using supernatant neat and diluted 1:10 with PBS.  
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Figure 3-17 CXCL8 production by H69 cells 
H69 cells were treated with a range of concentrations of peroxynitrite, hydrogen peroxide, LPS and 
PMA for 24 and 48hr. CXCL8 levels in supernatant were determined by CXCL8 ELISA (Duoset, R&D 
Systems) using supernatant neat and diluted 1:10 with PBS. 
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Figure 3-18 CXCL8 production by HKC8 cells 
HKC8 cells were treated with a range of concentrations of peroxynitrite, hydrogen peroxide, LPS 
and PMA for 24 and 48hr. CXCL8 levels in supernatant were determined by CXCL8 ELISA (Duoset, 
R&D Systems) using supernatant neat and diluted 1:10 with PBS.  
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To isolate the chemokines produced by stressed HKC8 cells filtered media was first 
purified by heparin-sepharose affinity chromatography. ELISAs were used to 
determine positive fractions and the concentrations of the chemokines CCL2, CCL5 
and CXCL8 (Figure 3-19 and Figure 3-20a). The CCL5 positive fractions were then 
further purified by ion-exchange chromatography and HPLC as shown in Figure 
3-20b. Chemokine concentrations were again determined by ELISA, and silver 
stain SDS-PAGE used to determine the level of contamination of other proteins 
remaining within the fractions. Chemokines are around 10kDa but due to low 
concentrations cannot positively be identified on the gels. The final stage of 
purification was HPLC (Figure 3-20c).  Positive fractions were analysed by mass 
spectrometry to determine is any of the CCL5 present in the media had been 
subject to post-translational modification. Figure 3-21 demonstrates the presence 
of truncated CCL5 as the molecular weight shows first two amino acids have been 
cleaved.  
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Figure 3-19 Purification of chemokines from HKC8 treated media 
ELISA data showing heparin-sepharose fractions containing CCL2, CCL5 and CXCL8 isolated from 
HKC8 media. 
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Figure 3-20 Purification of CCL5 from HKC8 treated media 
ELISA data and SDS-PAGE images for each step of purification. a) Heparin-sepharose, b) Ion 
exchange (Mono S), c) HPLC. 
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Figure 3-21 Identification by mass spectrometry of CCL5 isoforms produced by HKC8 cells 
Example MS plot from CCL5 positive HPLC fractions (Fraction 67) and table explaining the CCL5 
isoforms found. m/z – mass:charge ratio, MW – molecular weight. 
 
 
Previous studies have found the enzyme CD26 to be responsible for cleaving the 
first two amino acids of chemokines including CCL5. For this reason the presence 
of CD26 was analysed using Taqman qPCR and both HKC8 and H69 cells were 
found to express the enzyme (Figure 3-22). This data suggests that in this situation 
CD26 could be the enzyme responsible for the CCL5 modification but other 
proteases cannot be ruled out.    
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Figure 3-22 CD26 expression in H69 and HKC8 cells  
Upper - Real-time PCR amplification plots showing presence of CD26 in H69 and HKC8 cells 
Blue - CD26, Green – GAPDH. Lower - delta Ct values relative to GAPDH. n=2 
 
Chemokine Expression During Stress 
100 
 
3.3.4 OXIDATIVE STRESS IN VIVO 
The previous work in this chapter has been examining the effects of oxidative 
stress on chemokine production in vitro. This section aims to give evidence of 
chemokines and cellular stress in vivo in inflammatory and transplant situations.  
3-nitrotyrosine is a marker of the presence of reactive nitrogen species. Sections 
from a murine model of kidney ischaemia-reperfusion injury were stained for 3-NT 
and an increased level of staining was found in the ischaemic kidneys compared to 
control, but little difference between 35 and 45min ischaemia time (Figure 3-23). 
H&E staining shows loss of tubular cells, exudate and interstitial oedema with IRI, 
confirming that higher levels of tissue damage occur in association with increased 
levels of 3-NT.   
Figure 3-24 shows 3-NT levels in human liver biopsies. The upper four panels are 
from inflammatory liver disease and the lower two are time zero biopsies taken 
immediately post-transplant and after reperfusion. These images show high levels 
of peroxynitrite are associated with the inflammatory infiltrate and surrounding 
tissue has also been subject to protein modification by peroxynitrite although to a 
lesser extent.  
CCL2 is also expressed in the situations in which peroxynitrite is present (Figure 
3-25). Sections from patients with similar diseases to those stained in Figure 3-24 
were stained for CCL2 and results show low level expression in liver tissue with 
increased levels in inflammatory infiltrate, especially in the cirrhosis patients. 
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Figure 3-23 Effect of ischaemia-reperfusion injury on murine kidney  
Kidney sections from a murine model of ischaemia-reperfusion were stained by 
immunohistochemistry for 3-nitrotyrosine (3-NT; left) or H&E (right). The left kidney was 
ischaemic for 35 or 45min and organs harvested 24hr post reperfusion, the right kidney was used 
as a control. 3-nitrotyrosine staining was developed by DAB (brown) and counterstained with 
haematoxylin (blue). No primary antibody control (NPA) is shown. Four mice were tested for each 
time point and a representative image shown. Arrows highlight example areas of damage, for 
example tubular shrinkage. Original magnification x20.  
 
Chemokine Expression During Stress 
102 
 
 
 
 
 
 
 
 
 
Figure 3-24 Presence of 3-nitrotyrosine in inflammatory liver disease.  
4µm sections from human liver biopsies were stained for 3-nitrotyrosine by 
immunohistochemistry. The signal was developed by DAB (brown) and counterstained with 
haematoxylin (blue). The biopsies were from patients with primary sclerosing cholangitis (PSC), 
alcoholic liver disease (ALD) or time zero biopsies from newly reperfused transplants. No primary 
antibody control (NPA) is shown. Six disease samples and five time zero biopsies were stained and 
representative images are shown. Original magnification x20. 
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Figure 3-25 Presence of CCL2 in inflammatory liver disease.  
4µm sections from human liver biopsies were stained for CCL2 by immunohistochemistry. The 
signal was developed by DAB (brown) and counterstained with haematoxylin (blue). The biopsies 
were from patients with biliary cirrhosis, fatty liver, or time zero biopsies from newly reperfused 
transplants. Six disease samples and three time zero biopsies were stained and representative 
images are shown. Original magnification x20. 
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3.4 DISCUSSION 
The data in this chapter highlights the intricate regulation of the chemokine system 
in response to stress, a complexity which has evolved to allow the immune system 
to elicit different responses based on the pathological stimulus present and the 
time course of the damage. Such different ‘activated’ phenotypes are demonstrated 
by the PCR data in this chapter; there is not a binary response to stress. This study 
extends from my previous work demonstrating that oxidative stress increases 
CCL2 and CXCL8 transcription in H69 cells (Barker, 2011) to look at a wider range 
of stresses and a second tissue type, kidney epithelium. Epithelium was examined 
in this study rather than other cell types linked to oxidative stress and 
inflammation, such as macrophages or stromal cells. It was chosen as the focus due 
to its involvement in IRI and chemokine production and also the potential of these 
cells to be modified by long term stress. They can undergo EMT or become 
senescent, secreting more chemokines and spreading senescence, causing further 
functional loss of the tissue. Immunoassays were also performed to look at the 
alteration of chemokine levels during stress but this was only a single ‘snapshot’ 
due to the expense of MSD analysis and so robust conclusions cannot be drawn 
from these results. Initial findings however support the notion of cell, chemokine 
and stress specific responses.  
All the proinflammatory chemokines tested by qPCR were induced by at least one 
form of cellular stress, with CXCL8 having the greatest capacity for induction and 
CCL5 the lowest at the time point studied, in terms of both level of induction and 
breadth of inducers. CCL5 is thought to have a larger role in the amplification than 
the initiation of the immune response (Deckers et al., 1998) so a low level of CCL5 
induction at this early time point is not surprising. CXCL10, initially discovered as 
an IFN inducible gene can also be stimulated by other stresses. PCR data shows 
LPS can upregulate its production in liver cells and previous studies, although in 
murine macrophages, demonstrate this is through a MyD88 independent pathway 
involving both NF-κB and IFN-regulatory factor 3 (IRF-3) (Kawai et al., 2001). 
There is little, if no previous evidence for PMA stimulating CXCL10 production and 
defining the mechanism is beyond the scope of this study. PMA is a stimulator of 
the NF-κB pathway so this is a potential mechanism for CXCL10 induction (Mut et 
al., 2010).  
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A notable absence in response to stress is that of renal epithelia to LPS. However, 
HKC8 have previously been shown to lack TLR4 mRNA (Bland et al., 2001) and so 
the lack of chemokine induction is unsurprising. This finding highlights the 
limitations of work involving cell lines, or at least the extent of the conclusions 
which can be drawn. This lack of stress response is cell line specific and not the 
case for kidney epithelium as a whole. The opposite is actually the case as TLR4 is 
important in the production of proinflammatory chemokines in kidney IRI (Wu et 
al., 2007). Determining the extent to which the findings in this study are purely cell 
line dependant or a cell type specific response is important.  
The concentrations of the stress inducers used in this work are those previously 
optimised to give a chemokine response in the H69 cell line. Whether this level of 
stress is physiological is uncertain. Peroxynitrite cannot be detected in vivo (Szabo 
et al., 2007), as discussed in section 1.4.1.1, so the exact maximal concentration 
reached at a site of inflammation cannot be determined. Carbon dioxide and other 
molecules present can also affect the form and therefore effects of the reactive 
species. Metal ions are crucial for hydrogen peroxide chemistry and so it is not just 
the concentration of the reactive species that affects reactivity (Halliwell et al., 
2000). PMA is not a physiological inducer of stress but as discussed in section 1.4.2 
is an activator of PKC which is involved in numerous stress responses in vivo. 
These are all potential limitations of this study but it is an in vitro study using 
immortalised cell lines designed to model the differential stress responses rather 
than accurately represent possible in vivo conditions. 
Serum starvation increases the expression of both CCL2 and CXCL10, and along 
with PMA can synergistically increase the levels of both chemokines (cell line 
dependent). Different stresses acting synergistically to further increase chemokine 
production has been found in numerous other studies both in vitro and in vivo 
(Yasumoto et al., 1992; Dent et al., 2014) . The exact effects of serum starvation are 
undefined but induction of NF-κB has been found in some cell types (Kohno et al., 
2012). Effects could also be due to decreased antioxidant levels, therefore 
increased oxidative stress. Selenium is required for the antioxidants thioredoxin 
reductase and glutathione peroxidise and in a study evaluating the importance of 
differing selenium concentrations between batches of FBS, FBS with the highest 
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selenium levels gave the smallest increase in luciferase under control of an 
oxidative stress gene (Karlenius, 2011). Most cultures are thought to be selenium 
deficient despite the presence of serum. A complete absence of FBS and therefore 
selenium will presumably have a profound effect on antioxidant activity.  
The data discussed so far looks at the transcriptional regulation of chemokines 
during stress. To confirm this translated into functional chemokines, chemotaxis 
was performed. The mix of chemokines produced by LPS stimulated liver epithelial 
cells can elicit the migration of T cells both in vitro and in vivo. The use of both a 
CXCR3 blocking antibody and the small-molecule CXCR3 agonist PS372424 in 
these assays confirm the protein data of chemokine levels following LPS 
stimulation that a range of chemokines are produced. For these assays both human 
T cells and humanised mice were used as a Q196E amino acid change between the 
human and mice CXCR3 means the agonist PS372424 has no effect on the murine 
receptor (Nedjai et al., 2012). The blocking antibody gives some reduction in 
chemotaxis although this is not significant suggesting that although some CXCR3 
ligands are present, the blockade of chemokine function can be readily 
compensated for by other chemokines present in the poly-chemokine mixture. The 
agonist causes complete loss of migration, fitting with previous data from our 
group (O'Boyle et al., 2012). The agonist acts by similar mechanisms to non-GAG 
binding chemokine mutants which can activate the chemokine receptor but no 
directional cue is given as a GAG-bound gradient is absent (Ali et al., 2005b; 
O'Boyle et al., 2009). This receptor activation causes receptor internalisation, and 
so the cell is unable to respond to chemokine due to lack of cell surface receptor 
until surface receptor is regenerated. PS372424 administered i.v. can desensitise 
cells, preventing migration towards chemoattractant in the air pouch. This is 
particularly significant in the case of CXCR3 as this chemokine receptor requires de 
novo synthesis and is not simply recycled like other chemokine receptors (Meiser 
et al., 2008). The agonist is also capable of desensitising multiple chemokine 
receptors (O'Boyle et al., 2012) and so loss of response to other chemokines 
present is also achieved. Despite being counterintuitive, this explains the complete 
abrogation of transendothelial T cell migration by the CXCR3 agonist.  
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The focus of the next two chapters will be the post-translational modification of 
chemokines during stress, another mechanism for the fine tuning of chemokine 
responses. This chapter gives evidence of both the production and modification of 
CCL5 by HKC8 cells. The majority of CCL5 produced was in its wild type form but a 
truncated form, missing the two N-terminal amino acids, was also detected. This is 
a well characterised chemokine modification by CD26 (Oravecz et al., 1997; Proost 
et al., 1998a; Schols et al., 1998; Struyf et al., 1998a; Iwata et al., 1999; Lim et al., 
2005) and so no further functional studies have been carried out. The modification 
skews CCL5 towards a T cell chemoattractant by preventing CCR1 and CCR3 
binding but not altering signalling through CCR5. This is one of few examples of 
non-immune cell mediated chemokine cleavage (Struyf et al., 1998a) and gives 
direct evidence that cells are able to alter the chemokines they produce, an 
intrinsic mechanism for chemokine regulation. Although it cannot be ruled out that 
other proteases are responsible for the CCL5 processing in this situation, evidence 
from previous studies and data provided here showing production of CD26 by 
HKC8, builds a strong case that it is the enzyme responsible.    
As well as demonstrating the effects of cellular stress on chemokines, in vivo 
evidence of chemokines in an oxidative stress rich environment has been verified 
in this chapter. Inflammation and IRI are circumstances in which oxidative stress is 
known to be pathological. The biopsy staining carried out shows 3-NT, a marker of 
the reactive nitrogen species peroxynitrite, is markedly increased following 
ischaemia-reperfusion and is also at high levels in the inflammatory infiltrate of 
multiple inflammatory liver diseases. CCL2 is also present in these liver diseases. 
Although its unknown from this data if the chemokine presence is directly due to 
upregulation by oxidative stress, or if the source of the chemokine is liver cells or 
infiltrating immune cells, it provides evidence for concurrent protein modification 
by peroxynitrite in the presence of CCL2 in physiological setting which is 
important for the biological relevance of data in subsequent chapters. 
Tissue staining has also shown oxidative stress in time-zero biopsies, emphasising 
that even at the very beginning of the life of a transplant the organ has been 
subject to a large amount of oxidative stress. It is therefore likely to be damaged 
and have increased chemokine levels. Not only is this important in terms of 
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transplant biology but highlights a potential caveat in previous studies which used 
similar biopsies as ‘normal’ controls (Rygiel et al., 2010). This tissue has already 
undergone a number of processes which could be predicted to affect its ability to 
accurately represent normal tissue for example potential brain death of the donor 
(de Vries et al., 2011) and IRI. What can be classed as a normal control, especially 
when studying acute effects of oxidative stress is a complex argument, especially if 
it is for a human study. The human tissue staining carried out in this study has no 
‘normal’ comparison, instead animal models were used as the best alternative. 
Liver biopsies are a high risk procedure and so are not carried out unless deemed 
clinically necessary, for this reason no healthy tissue in available. Cancer resection 
biopsies contain areas of tissue distinct from the tumour. These could be argued to 
be healthy but due to the effects of the tumour microenvironment and previous 
evidence of the paracrine effects of this on spreading damage and senescence 
(Coppe et al., 2008; Leibovich-Rivkin et al., 2013) this cannot be guaranteed to be 
‘normal’. 
Overall this chapter highlights the complexity of regulation within the chemokine 
system. In vivo, chemokines are present at sites of inflammation and oxidative 
stress. Numerous stresses can alter both the transcription and production of 
chemokines in a tissue, stress and chemokine specific manner. The chemokines 
produced are functional but there is evidence of post-translational modification 
suggesting that the chemokines present may not all have their predicted function. 
These data show that a high level of regulation is necessary due to the numerous 
distinct situations to which chemokines and the immune system have to respond 
with minimal damage to the surrounding unaffected tissue.  
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4 CHEMOKINE POST-TRANSLATIONAL MODIFICATIONS 
4.1 INTRODUCTION 
Post-translational modifications of chemokines have previously been shown to 
diminish or potentiate the biology of said ligands. This occurs in a highly variable 
manner and so it is difficult to extrapolate a generalised paradigm. For this reason 
a careful ligand specific study is required. As discussed in section 3.3.1, oxidative 
stresses can alter the production of proinflammatory chemokines, and it is 
apparent that reactive species present in such stresses can directly modify 
proteins. This chapter sets out to examine the potential for chemokine 
modification within such inflammatory environments.  
Establishing which chemokines can be modified, and by which mechanisms is 
important in understanding the complexity within the chemokine system. As 
highlighted in section 1.3.1 there are many levels of regulation to finely tune the 
chemokine response and ultimately the body’s response to infection and injury. It 
is during these times of infection and inflammation that chemokines are both most 
abundant and most studied, however these are also the situations in which there is 
a higher potential for modification.  
Previous studies of chemokine modification have already been discussed in detail 
in section 1.6, and evidence of truncation found in section 3.3.3. Briefly, 
chemokines can be enzymatically truncated, both enhancing and abrogating their 
chemotactic potential, depending on the chemokine, enzyme and cleavage site. 
This chapter focuses on identifying targets of residue modifications, namely 
nitration and citrullination. Citrullination decreases the function of certain 
chemokines, with more substantial effects being seen in in vivo assays than in vitro, 
due to profound alteration in GAG binding potential (Loos et al., 2008; Proost et al., 
2008; Struyf et al., 2009). Nitration has so far been less studied but has also been 
reported as a down regulator of chemokine function (Molon et al., 2011). 
Establishing which chemokines can be modified by such mechanisms is crucial. 
Examining how these modifications interact together, and determining if some are 
inhibitory of others, are additional vital findings for fully understanding in vivo 
chemokine function but are outside the scope of this study.  
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Although multiple studies have examined the functional effects of chemokine 
modification, few have determined if modification can effect detection. Nitration is 
currently the only modification shown to prevent detection by commercially 
available antibodies however all modifications which alter function will have 
important implications for studies looking at chemokine levels. All protein 
modifications have the potential to alter epitope and therefore change which 
antibodies can detect the protein. Studies using such antibodies may not be seeing 
all chemokine present in the situation.  
An increasing number of studies look at chemokines as biomarkers but until it is 
known which forms of chemokine are being detected, and therefore their function, 
accurate conclusions as to how these chemokines are involved in disease cannot be 
made. Until very recently links between chemokine modification and clinical 
significance had not been made. Counterintuitive findings that increased CXCL10 
levels in hepatitis C patients were associated with worsened prognosis have now 
been explained with the discovery that significant amounts of the CXCL10 present 
in such cases is in a truncated, antagonistic form (Riva et al., 2014). This highlights 
the importance of establishing which chemokine forms are present in each 
situation; studies that have only measured the amount of chemokine in tissue may 
not reflect the true biological potency. 
As discussed in section 1.3, the prototypical chemokines chosen to be the focus of 
this study are CCL2, CCL5 and CXCL8, with CCL2 being studied in most depth. 
These are all chemokines known to be important during both inflammation and 
transplantation for monocyte, T cell and neutrophil recruitment respectively. The 
sequences of these three chemokines are shown in Figure 4-1 with some of the 
potential targets of both nitration and citrullination highlighted.  
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4.1.1 SPECIFIC AIMS  
This chapter aimed to investigate post-translational modifications which can occur 
to chemokines. Specifically, experiments were carried out to: 
 Determine if chemokines are subject to nitration, focussing on CCL2 
 Establish methods for detection of nitrated chemokines 
 Examine the potential for CCL5 citrullination 
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Figure 4-1 Amino acid sequences for CCL2, CCL5 and CXCL8 
Sequences for the three chemokines examined. Highlighted are cysteine residues involved in 
disulphide bonds (underlined), some potential targets for modification  by peroxynitrite (tyrosine – 
red, tryptophan – green) and potential targets for citrullination (arginine – blue). Sequences from 
(Uniprot). 
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4.2 SPECIFIC MATERIALS AND METHODS 
4.2.1 ELISAS 
Several ELISAs were used in this chapter using the basic method outlined in 
section 2.5.1.1.  
For direct ELISAs, 10ng protein was bound to the plate. 3-nitrotyrosine detection 
was with anti-nitrotyrosine (1/1000, 2hr; Millipore, 06-284) and anti-rabbit-HRP 
(1/5000, 2hr, Sigma). CXCL8 and CCL5 detection was using components of R&D 
duosets and CCL2 detection was with R&D Systems antibodies MAB2791 and AB-
279-NA. 
A specific nCCL5 ELISA was developed. Plates were coated with rabbit anti-
nitrotyrosine polyclonal antibody (5µg/ml) and the detection antibody used was 
the biotinylated goat anti-CCL5 from an R&D Duoset. Development was with TMB. 
4.2.2 LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY 
The exact residues modified by peroxynitrite in CCL2 were identified by mass 
spectrometry. Trypsin digest was performed prior to LC-MS/MS and analysed 
using Mascot (Matrix Science) as in Maassen and Hennig, 2011. MS was carried out 
by Dr Joe Gray, Pinnacle Laboratory, Newcastle University.  
4.2.3 PEPTIDE SYNTHESIS 
4.2.3.1 General principles 
Peptide synthesis involves the formation of an amide bond between the carboxyl 
group and the amino group on adjacent amino acids in the peptide sequence. Solid-
phase peptide synthesis (SPPS) is now the normal laboratory method for chemical 
peptide synthesis and was used in this study (Merrifield, 1963). Contrary to the 
biosynthesis of peptides, chemical synthesis is from the C-terminal. In this method 
of synthesis the growing peptide chain is immobilised by covalent attachment to a 
resin, this allows unused amino acids and by-products of the reaction to be washed 
away easily. In this study rink amide resin was used to create a C-terminal amide, 
similar to if the peptide was within a protein.  
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In order to stop unwanted reactions occurring, protecting groups are necessary on 
both the side chains and the amino terminus of each amino acid, for example tBu 
and Fmoc respectively. Peptides are synthesised by repeated cycles of coupling the 
next amino acid to the end of the immobilised chain, washing away free amino 
acid, deprotecting the N-terminus of the newly attached amino acid to prepare it 
for addition of subsequent amino acids, and a second wash step. Washing is 
important as each amino acid is added in major excess to increase yield. It is not 
until the synthesis is complete that side chains are deprotected using strong acid. 
4.2.3.2 Method 
a) Reagents 
All reagents were purchased from Sigma unless otherwise stated. Peptide 
synthesis grade dimethylformamide (DMF) was purchased from AGTC 
Bioproducts. All resins and amino acid derivatives were purchased from 
Novabiochem. PyBOP® was purchased from Mimotopes and Apollo Scientific. 
Fritted polypropylene reaction vessels were used for all reactions and resin 
swelling, with DMF as the reaction solvent. For peptide couplings PyBOP was used 
as the activator. Amino acid side chain functionality was protected as follows: 
Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, 
Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH. The resin used was high loading Rink 
Amide (100-200 mesh) with a specific loading of 0.71g/mol. Pre-swelling of the 
resin was carried out in dichloromethane (DCM) for a minimum of 1hr, followed by 
washing with DMF. The resin was washed in DCM and then shrunk in diethyl ether 
before TFA cleavage. Mass spectra were collected on a Waters TQD mass 
spectrometer (LC-MS/MS). 
All peptide synthesis and related mass spectrometry was carried out in the 
Department of Chemistry, Durham University, UK with the help of Dr Steven Cobb, 
Mr Alex Hudson and Mr Sam Lear. 
b) Synthesis 
Fragments of CCL2 containing possible nitration sites were synthesised (ASYRR 
and QKWVQ). Automated SPPS was carried out on a CEM Liberty1 single-channel 
microwave peptide synthesiser equipped with a Discover microwave unit. All 
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reactions were carried out using the 30ml polytetrafluoroethylene reaction vessel, 
with microwave heating and agitation by bubbling nitrogen. Couplings were 
carried out using Fmoc-protected amino acid (5 equivalents), PyBOP (10 
equivalents) and N,N-Diisopropylethylamine (DIPEA; 20equiv, 2M solution in N-
Methyl-2-pyrrolidone). The reaction vessel was drained after each cycle and fresh 
reagents were added. Microwave-assisted couplings at 0.1mmol scale were carried 
out for 10min at 75°C and 25W power. The Fmoc group was removed by a single 
treatment with a piperidine solution (20% v/v in DMF) at 75°C (45W) for 3min. 
c) Cleavage 
Peptide-resin was treated with 1.90ml TFA, 50µl dH2O and 0.05ml triisopropylsilyl 
for 3hr at RT. The resin was then removed by filtration the filtrate was evaporated 
under reduced pressure. 20ml ice-cold diethyl ether was added and the suspension 
was centrifuged. After centrifugation the supernatant was removed. Ice-cold 
diethyl ether was added and the process was repeated to yield solid peptide. The 
resulting solid peptide was dissolved in dH2O and lyophilized to yield crude 
product peptide as a white powder. 
4.2.4 GEL ELECTROPHORESIS  
SDS-PAGE was used to visualise protein following nitration, a similar method to 
that described in section 3.2.4.5. 
1mm thick gels were cast using a Hoefer dual gel caster (Amersham Bioscience). A 
10% running gel contained: 3.95ml dH2O, 3.35ml 30% acrylamide, 2.5ml 1.5M Tris 
pH6.8, 100µl 10% SDS in dH2O, 100µl 10% ammonium persulphate (APS) in dH2O, 
4µl TEMED. 5% stacking gel contained: 1.7ml dH2O, 415µl 30% acrylamide, 315µl 
1M Tris pH8.8, 25µl 10% SDS, 25µl 10% APS, 2.5µl TEMED. The running gel was 
poured and left to set with a layer of butanol. Alcohol was then washed off 
removed and stacking gel with a 10 well comb added.  
Samples were boiled for 5min in loading buffer (10x loading buffer - 0.625M Tris, 
10% SDS, 50% glycerol, 0.005% Bromophenol Blue, pH6.8) before loading. Gels 
were run at 70V in running buffer (25mM Tris base, 250mM glycine, 0.1% SDS, 
pH8.3). 
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Protein bands were then visualised using SimplyBlue SafeStain (Invitrogen), using 
the microwave protocol in the manufacturer’s instructions.   
4.2.5 CITRULLINATION 
Citrullination work was carried out in the Laboratory of Molecular Immunology, 
Rega Institute, Katholieke Universiteit Leuven, Belgium with the help of Prof. Paul 
Proost and Dr Eva Moelants. 
4.2.5.1 Basic principles 
Citrullination is difficult to detect as it only gives a 1Da mass increase and the loss 
of one positive charge. The modification is therefore difficult, if not impossible, to 
detect by mass spectrometry. A 1Da shift will fall within the isotope peak range of 
the uncitrullinated protein if the sample is mixed. Citrullination increases the 
hydrophobicity of the protein, and therefore its retention time on a HPLC column, 
which may allow detection if the mass spectrometer is sufficiently sensitive. In this 
study citrullinated chemokine was further modified to allow detection. 
The citrulline side chain has a distinctive ureido group (-NC(=O)N-) which is the 
target of reactions for specific identification of citrulline. At low pH, modification 
with antipyrine and 2,3-butanedione leads to a mass gain of 238Da per citrulline 
residue, as described in (Holm et al., 2006; Stensland et al., 2009). Reaction of 2,3-
butanedione with the ureido group of citrulline forms a reactive imidazolone 
derivate (M+50), followed by the nucleophilic addition of antipyrine (M+188) to 
this imidazolone ring, as shown in Figure 4-2. Citrulline residues modified in this 
way are sufficiently different to arginine to be detected by mass spectrometry and 
antibodies can be raised against the modified residue. 
4.2.5.2 CCL5 citrullination and modification 
Citrullination was performed as described in Moelants et al., 2011. CCL5 was 
incubated with PAD (from rabbit skeletal muscle; Sigma, P1584) for 90mins at 
37°C at an enzyme–substrate molar ratio of 1:10. Incubations with PAD were 
carried out in 40mM Tris with 2mM CaCl2 (pH7.4). Citrullinated CCL5 was then 
chemically modified using 50mM antipyrine (Fluka), 16% TFA and 12.5mM 2,3-
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butanedione (Fluka) and incubated for 2hr at 37°C in the dark. The reaction 
mixture is highly acidic and so needed to be neutralised before use in further 
experiments. This was achieved by dialysis using Slide-A-Lyzer MINI Dialyse Units, 
2000 MWCO (Thermo Scientific) overnight in 0.05% Tween/PBS (pH7.4) at RT in 
the dark. 
Before modification was performed ELISA were carried out to ensure that the 
highly acidic conditions for modification did not destroy the epitope of the anti-
CCL5 antibodies used in the subsequent sandwich ELISAs to allow detection of the 
modified chemokine.  
 
Figure 4-2 Chemical modification of citrulline by antipyrine and 2,3-butanedione.  
Reaction of peptidylcitrulline with 50mM antipyrine and 12.5mM 2,3-butanedione at low pH 
results in a total mass gain of +238. 
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4.2.5.3 Citrulline-specific ELISA 
Citrullination was quantified using a specific sandwich ELISA based on that 
developed for CXCL8 (Moelants et al., 2011). The coating antibody used was a 
mouse monoclonal anti-CCL5 antibody (1µg/ml in PBS; from Duoset, R&D 
Systems). Chemically modified citrullinated CCL5 was detected using specific 
polyclonal antibodies against chemically modified citrulline residues, generated in 
rabbit by Moelants et al., 2011, and a secondary anti-rabbit IgG-HRP antibody 
(1/2500; Jackson ImmunoResearch Laboratories). The ELISA was developed using 
TMB.  
A normal CCL5 Duoset (R&D Systems), as described in the chemokine purification 
section, was also performed to show CCL5 is not lost during modification and 
dialysis (see Table 6). 
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4.3 RESULTS               
4.3.1 CHEMOKINE NITRATION 
Chemokine expression has been shown in chapter 3 to be increased by oxidative 
stress. To see if this oxidative environment can also modify chemokines directly 
CCL2, CCL5 and CXCL8 were incubated with peroxynitrite and nitration measured. 
Direct ELISAs using an antibody against 3-nitrotyrosine show peroxynitrite can 
nitrate tyrosine residues in all three chemokines (Figure 4-3 and Figure 4-4) 
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Figure 4-3 Nitration of CCL2 by peroxynitrite  
Direct ELISA using a polyclonal antibody against 3-nitrotyrosine shows following peroxynitrite 
incubation tyrosine residues in CCL2 are nitrated. CCL2 – wild type chemokine, nCCL2 – chemokine 
following modification.  t-test, p = 0.0033, representative of three experiments.  
 
 
Figure 4-4 Nitration of CCL5 and CXCL8 by peroxynitrite  
Direct ELISA using a polyclonal antibody against 3-nitrotyrosine shows following peroxynitrite 
incubation tyrosine residues in CCL5 and CXCL8 are nitrated. t-test, p = 0.009, representative of 
three experiments.  
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CCL2 was focused on to establish the exact residues modified by peroxynitrite; this 
was determined using trypsin digest and LC-MS/MS. Both tyrosines (Tyr13 and 
Tyr28; Figure 4-5 and Figure 4-6) and the tryptophan (Trp59; Figure 4-7) in CCL2 
were all targets of nitration by peroxynitrite. Methionine oxidation was also found 
but, as this is a common artefact during mass spectrometry, cannot be attributed to 
modification by peroxynitrite (Morand et al., 1993).  
To further confirm the targets of nitration in CCL2, peptides were synthesised of 
the five residues surrounding the second tyrosine and the tryptophan in the CCL2 
sequence. Peptides have an acetyl capped N-terminus and C-terminal amide to 
mimic the sequence being within a protein as closely as possible. Synthesis was by 
SPSS and purity of the synthesis determined by mass spectrometry (Figure 4-8 and 
Figure 4-9). These peptides were then subject to modification by peroxynitrite, and 
subsequent nitration detected by mass spectrometry. Figure 4-8 shows tyrosine 
nitration, peroxynitrite incubation increased the half mass peak by 22.5Da (369.7 - 
347.2 = 22.5), an overal increase in 45Da. Tryptophan nitration was also detected 
(Figure 4-9) confirming that both these residues are targets of modification. 
 
Figure 4-5 MS/MS spectra of CCL2 peptide including Tyr13  
Peroxynitrite modified CCL2 was analysed by LC-MS/MS following trypsin digest to establish which 
residues were modified. Shown is the peptide containing Tyr13 (-.QPDAINAPVTCCYNFTNR.K). a) 
unmodified (714.3) b) tyrosine nitration (729.6). n=2   
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Figure 4-6 MS/MS spectra of CCL2 peptide including Tyr28  
Peroxynitrite modified CCL2 was analysed by LC-MS/MS following trypsin digest to establish which 
residues were modified. Shown is the peptide containing Tyr28 (R.LASYR.R). a) unmodified 
(305.17), b)tyrosine nitration (327.66). n=2  
 
 
Figure 4-7 MS/MS spectra of CCL2 peptide including Trp59   
Peroxynitrite modified CCL2 was analysed by LC-MS/MS following trypsin digest to establish which 
residues were modified. Shown is the peptide containing Trp59 (K.WVQDSMDHLDK.Q). a) 
unmodified (458.5), b) methionine oxidation (463.87 and 695.3; can occur during MS), c) 
methionine oxidation with tryptophan nitration (478.87). n=2  
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Figure 4-8 Synthesis and nitration of the peptide ASYRR 
a) Peptide structure (exact mass 692.37) and electrospray ionisation mass spectrometry (ESI-MS) 
plot showing correct peptide synthesis.  
b) Peptide structure (exact mass 737.36) and ESI-MS plot showing nitration of the peptide 
following incubation with peroxynitrite.  
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Figure 4-9 Synthesis and nitration of the peptide QKWVQ 
a) Peptide structure (exact mass 728.40) and electrospray ionisation mass spectrometry (ESI-MS) 
plot showing correct peptide synthesis 
b) Peptide structure (exact mass 773.38) and ESI-MS plot showing nitration of the peptide 
following incubation with peroxynitrite.  
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Chemokine nitration was found to alter protein recognition by some antibodies. 
For CCL2, both the monoclonal and polyclonal antibodies tested could not detect 
the nitrated form of the protein, as shown in Figure 4-10. Similar findings were 
found for CXCL8 (Figure 4-11) as neither a sandwich ELISA using both monoclonal 
and polyclonal antibodies against CXCL8, nor a direct ELISA using the same 
polyclonal, could detect the nitrated form of the chemokine. For CCL5 however the 
epitope damage was not as severe as although the monoclonal antibody tested 
could not detect the nitrated form, the polyclonal could. Figure 4-12a shows a 
sandwich ELISA for CCL5 is unable to efficiently detect the nitrated form of the 
chemokine. A second sandwich ELISA was developed using an anti-3-nitrotyrosine 
antibody as the capture antibody and the same anti-CCL5 polyclonal detection 
antibody. Figure 4-12b shows this ELISA can specifically detect nCCL5 and so the 
anti-CCL5 polyclonal used in this instance is able to detect the nitrated form of the 
chemokine.  
CCL2 MAb CCL2 PAb
0.00
0.05
0.10
0.15 CCL2
nCCL2
**
**
O
D
 4
5
0
/5
9
5
 
Figure 4-10 CCL2 nitration by peroxynitrite prevents detection by ELISA  
By direct ELISA both the R&D monoclonal (MAb; MAB2791) and polyclonal (PAb; AB-279-NA) 
antibody can detect wild type CCL2 but cannot detect the nitrated form (nCCL2). Statistics - t-test, 
MAb - p =0.0014, PAb - p =0.0062. Representative of three experiments.  
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Figure 4-11 CXCL8 nitration by peroxynitrite prevents detection by ELISA 
By a) sandwich ELISA (Duoset) and b) direct ELISA (using polyclonal from Duoset), wild type 
CXCL8 can be detected but the nitrated form cannot. Negative control (diluent only) displayed by 
dotted line. Representative of three experiments.  
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Figure 4-12 Detection of nitrated CCL5 by ELISA 
CCL5 incubated with peroxynitrite was analysed on two sandwich ELISAs. a) CCL5 Duoset (R&D 
Systems), b) polyclonal anti-3-nitrotyrosine capture antibody with biotinylated polyclonal anti-
CCL5 detection antibody. Representative of three experiments.  
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To ensure loss of epitope was not due to protein loss two methods were used, and 
for these experiments BSA was used instead of chemokine. Firstly, total protein 
level was assessed using a BCA assay (Figure 4-13). This showed that total protein 
levels were the same with or without peroxynitrite. To assess protein degradation, 
SDS-PAGE was performed. As seen in Figure 4-14, protein is not degraded using 
this method of nitration as equal levels of protein are present in the corresponding 
lanes.  
0.1 0.4
0.00
0.05
0.10
0.15
0.20
0.25
BSA
nBSA
mg/ml
O
D
5
9
5
 
Figure 4-13 Protein levels following nitration  
BCA assay kit was used to confirm no loss of protein following nitration. BSA was incubated with 
peroxynitrite for 10min, dialysed, then protein levels measured by BCA assay. n=2 
 
 
 
Figure 4-14 SDS-PAGE of BSA following nitration  
SDS-PAGE was used to confirm no degradation of protein following nitration. BSA was incubated 
with 1mM peroxynitrite for 10min at 37°C, run on a 10% SDS-PAGE and stained with SimplyBlue 
SafeStain (Invitrogen). Representative image of three experiments.  
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To determine whether nitrated chemokine could be detected in an in vivo setting, 
the ELISAs used in Figure 4-12 were used to test chemokine previously isolated 
from platelet samples in Prof Paul Proost’s lab. The platelets were taken from 
healthy volunteers between 1988-1995 but no further information was available. 
Figure 4-15 shows that CCL5 was present in all batches tested but in no samples 
were detectable levels of nitrated tyrosine found. 
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
0
200
400
600
Heparin Sepharose
Fraction
C
C
L
5
 n
g
/m
l
0.001 0.01 0.1 1 10 100
0.0
0.2
0.4
0.6
CCL5 g/ml
O
D
4
9
2
26 28 30 32 34
0
500
1000
1500
2000
HPLC
Fraction
C
C
L
5
 n
g
/m
l
0.1 1 10 100
0.0
0.2
0.4
0.6
0.8
1.0
nCCL5 g/ml
O
D
4
9
2
20 25 30 35
0
20
40
60
80
100
HPLC
Fraction
n
C
C
L
5
 n
g
/m
l
a)
b)
d)
c)
e)
 
Figure 4-15 CCL5 isolated from platelets does not have detectable levels of nitration 
a & b show levels of CCL5 present in several batches of platelet samples purified by heparin-
sepharose and then HPLC columns. c) example standard curve used for CCL5 concentration 
calculations. CCL5 Duoset (R&D Systems) was used for CCL5 detection.  
d & e used a specific nCCL5 ELISA to determine levels of nitration in the samples. d) nCCL5 
concentrations in HPLC fractions, e) standard curve. 
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4.3.2 CHEMOKINE CITRULLINATION 
Previously, CXC chemokines have been shown to be targets of citrullination by 
PAD. This preliminary study shows that CCL5 is also a target of these enzymes. As 
citrullination is only a 1Da change in mass this cannot easily be detected but 
further specific chemical modification of the citrulline creates a detectable 
difference. The modification process requires strongly acidic conditions; Figure 
4-16 shows these conditions do not alter epitope and so sandwich ELISAs can be 
used for the detection of the modified chemokine.  Antibodies have been made 
against modified citrulline and can be used in ELISAs, allowing the detection of 
citrullinated chemokine. Figure 4-17a shows an enzyme:substrate ratio of 1:10 is 
sufficient for citrullination of CCL5 but 1:100 is too low for detectable modification. 
The modification citrullination is the result of enzymatic modification of arginine 
residues by PAD enzymes. To establish the potential for chemokine citrullination 
in the models used in this study, the presence of such enzymes was determined in 
liver and kidney epithelial cell lines (H69 and HKC8 respectively) and primary 
neutrophils and PBMC. There are five forms of human PAD and PAD2 and PAD4 
were chosen for analysis using qPCR as they have previously been detected in liver 
and kidney (Moelants et al., 2012). These results show that PAD4 was present at 
low levels in both epithelial cell lines but PAD2 was absent. RNA of both enzymes 
was present in both neutrophils and PBMCs (Figure 4-18). 
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Figure 4-16 Incubation of CCL5 with TFA does not impair detection 
Detection of CCL5 following incubation with TFA using a CCL5 Duoset (R&D Systems). Detection 
was using TMB and OD from blank samples subtracted. Performed in duplicate. 
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Figure 4-17 CCL5 citrullination 
CCL5 incubated with 1:10 or 1:100 enzyme:substrate molar ratio of PAD for 90mins then the 
citrulline modified using antipyrine and 2,3-butanedione. a) ELISA using anti-CCL5 capture 
antibody and detected using an antibody specific for modified citrulline. b) CCL5 sandwich ELISA. 
Negative control (diluent only) displayed by dotted line. E/S 1:10 representative of four 
experiments.  
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Figure 4-18 Presence of PAD in epithelium 
a) Taqman qPCR amplification plots showing PAD2 (red), PAD4 (blue) and GAPDH (green) gene 
expression in H69 and HKC8 cell lines and primary PBMC and neutrophils. b) delta Ct values 
relative to GAPDH. n=2 
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4.4 DISCUSSION 
The regulation of chemokines is a complex process, especially within the 
inflammatory environment, and one which is not fully understood. The findings in 
this chapter of new targets of post-translational modification, namely the less well 
studied nitration and citrullination, further add to the complexities.  
All three prototypical inflammatory chemokines assayed were found to be nitrated 
following incubation with peroxynitrite. For CCL5 and CXCL8, the current lack of 
mass spectrometry data means that the exact residues modified are unknown, but 
3-nitrotyrosine formation occurs, as shown by ELISA. In the case of CCL2, more 
detailed analysis was performed and Tyr13, Tyr28 and Trp59 were all found to be 
nitrated. This is in contrast to a previous study which only identified nitrated 
tryptophan in human CCL2 (Molon et al., 2011). Neither study found oxidised 
histidine residues or other modifications which peroxynitrite could be predicted to 
cause (Pacher et al., 2007). 
As discussed in the introduction to this chapter, assessing mechanisms for the 
detection of both modified and wild type chemokines is important. Nitrated CCL2 
was unable to be detected by either antibody tested, although the loss of epitope of 
the monoclonal antibody used can be easily explained, the complete loss of 
detection by a polyclonal is harder to comprehend. Protein degradation is one 
explanation for this loss of antibody recognition and for this reason additional 
experiments were carried to establish if peroxynitrite incubation causes such 
degradation. The results show that it is loss of antibody sensitivity and not protein 
degradation which prevents the detection of nCCL2. This again is consistent with 
findings reported by (Molon et al., 2011), but due to a lack of details in the 
methods section of this paper, the antibody used is unknown and therefore it is 
unsure whether these are the same findings or further adding to the number of 
commercially available antibodies which cannot detect nCCL2. Similar findings for 
CXCL8 and CCL5 show that the lack of detection of nitrated chemokines with some 
currently produced antibodies is not a finding exclusive to CCL2. The observation 
that the polyclonal antibody tested for nCCL5 detection was able to detect the 
nitrated form of the chemokine further supports evidence that it is epitope loss 
and not protein degradation and highlights the need for a thorough screen of 
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available antibodies. It is crucial to determine which forms of chemokines are 
being detected with which antibody based detection techniques and if large 
quantities of chemokine are potentially being missed. The difference in detection 
difficulties between CCL2 and CXCL8, and CCL5 highlight that this is not a ‘one fits 
all’ problem. 
Although attempts to identify nitrated chemokine from biological samples were 
unsuccessful this is not entirely surprising and does not prove that chemokine 
nitration does not occur in vivo. This study was carried out as a test for the newly 
developed nCCL5 ELISA, for which chemokine in a soluble form is needed. 
Previously isolated CCL5 was the only chemokine source readily available at the 
time. However this had been purified from the platelets of healthy individuals and 
therefore there it is unlikely there were high concentrations of peroxynitrite and 
other reactive species present to cause nitration. Some of the samples were 20 
years old and the stability of nitration at -80 for this length of time is unknown. It is 
therefore possible that samples were originally nitrated although detection is no 
longer possible. To fully test this ELISA as a method for nCCL5 detection, 
chemokine from an inflammatory environment in a soluble form needs to be used, 
for example synovial fluid from a patient with rheumatoid arthritis or urine from a 
patient with an inflammatory kidney disease.  
Chemokine nitration has previously been identified in vivo for CCL2 by IHC and 
ELISA (Molon et al., 2011), although the antibody used in this study did not give 
positive results by ELISA or western blot in our hands (data not shown). One 
explanation for this could potentially be that Molon et al., 2011 identified Trp59 as 
the sole site of nitration, and three sites have been found in this study. The 
antibody may be specific for nitration only at one position and so unable to detect 
more heavily nitrated CCL2. In vivo detection of nitrated protein in sites rich in 
chemokines has been shown in chapter 3 and also in numerous other studies of 
transplantation and inflammatory environments (Macmillan-Crow et al., 1996; 
Moon et al., 2008) and so chemokine modification is likely to occur. 
Citrullination is the other modification studied in this chapter and so far work has 
focused on CXC chemokines and other cytokines including TNF-α (Loos et al., 
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2008; Proost et al., 2008; Loos et al., 2009; Struyf et al., 2009; Moelants et al., 
2013b). The findings in this study show that CC chemokines can also be targets of 
modification by PAD. Although no functional work has yet been carried out on this 
modified chemokine, previous work on citrullination would suggest that 
modification of arginine residues in this manner would lead to a decrease in in vivo 
function due to a decrease in GAG binding ability and potentially receptor binding 
as well. Further work is needed to determine if citrullination is also a 
downregulator of proinflammatory CC chemokines. The results of the PCR data 
support previous findings of PAD expression in liver and kidney cells and in 
leukocytes (Moelants et al., 2012). Although PAD2 has previously been found in 
liver and kidney it may not be specifically expressed in the epithelium and so not 
present in the cell lines tested.  
Data in this chapter demonstrates that nitration, a post-translational modification 
which occurs during inflammation and IRI, occurs to chemokines. Not only does 
this modification occur to the chemokines evaluated, but also impairs their 
detection. CCL5 has been shown to be subject to citrullination, another 
inflammation associated post-translational modification. Overall, this adds to the 
complexity of chemokine regulation and highlights the need for determining which 
forms of chemokine are being detected when establishing chemokine presence, or 
absence, especially in an inflammatory environment.              
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5 FUNCTIONAL EFFECTS OF CHEMOKINE NITRATION 
5.1 INTRODUCTION 
The biological behaviour of chemokines within the inflammatory environment is 
often assumed to be that of wild type chemokines, as assessed in vitro. However 
due to the complexities of both inflammation and chemokine regulation, this is not 
necessarily the case. Chemokine levels in a disease do not always correlate to 
chemokine function within that environment.  
Chapter 3 demonstrated that chemokines can be modified during stress (section 
3.3.3), and within the highly oxidative environments of inflammation and IRI, 
protein nitration can occur (section 3.3.4). Section 4.3.1 went on to show 
chemokines can be targets of such nitration by reactive nitrogen species but the 
function of these modified chemokines is yet to be assessed. This is the aim of this 
chapter. Not only do the mechanisms for chemokine modification need to be 
established, but the function of these modified chemokines also needs to be 
characterised. In vitro observation of the modified chemokines however is not 
sufficient. Confirming that these modifications occur in vivo and are not altered by 
GAG binding, or other post-translational modifications is also important (Sadir et 
al., 2004; Ellyard et al., 2007; Proost et al., 2008).  
Chemokines with altered function have been detected in inflammatory disease. For 
example CXCL10 truncation abrogates function (Proost et al., 2001; Van den Steen 
et al., 2003a). Truncated CXCL10 has been found in hepatitis C patients (Casrouge 
et al., 2011; Ragab et al., 2013; Riva et al., 2014). These highlight the need to 
determine the function of chemokines present in disease, as truncated CXCL10 was 
identified in a study which aimed to resolve the paradox that high CXCL10 levels 
correlated with low response to therapy in hepatitis C patients; the CXCL10 
present is an antagonist. Other chemokine modifications during disease have also 
been suggested, for example, citrullination of CXCL12 during Crohn’s disease, a 
modification which abrogates function (Struyf et al., 2009), and chemokine 
truncation in multiple cancers as reviewed by Van Damme et al., 2004. Not all 
modifications decrease chemokine function. N-terminal cleavage of ELR+ CXC 
chemokines predominantly enhances neutrophil recruitment. For example, CXCL7 
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cleavage is necessary for function (Walz and Baggiolini, 1990) and CXCL8 (6-77) is 
more active than the full length form (Van Damme et al., 1988). Pathogens can also 
modify chemokines to evade the immune system and so evaluating the function of 
these chemokines and processes for modification may also help with infection 
control and prevention (Mikolajczyk-Pawlinska et al., 1998; Edwards et al., 2005; 
Kurupati et al., 2010; Moelants et al., 2014).  
The proportion of chemokines which undergo modification is unknown, and there 
are multiple post-translational modifications identified which are yet to be 
examined for their effect on chemokines, including acetylation and carbamylation. 
Few studies have examined the level of modification which occurs but one showed 
that truncated CCL5 makes up less than 10% of the CCL5 produced by platelets, 
but in whole blood this percent rises to 60 (Struyf et al., 1998a). Other cell types 
are also able to produce large amounts of the modified chemokine with 95% and 
100% of CCL5 produced by diploid fibroblasts and sarcoma cells respectively 
being truncated (Struyf et al., 1998a).  
Even if the proportion of chemokines modified is relatively low, the effects can still 
be significant. Chemokines which are still able to bind the receptor but not signal 
can be antagonistic to the other ‘normal’ chemokines present (Proost et al., 2001), 
as can chemokines which are able to bind and signal normally but are unable bind 
GAGs. In such cases chemokine gradients cannot be formed but receptor 
desentisiation can occur resulting in an anti-inflammatory effect (O'Boyle et al., 
2009; Ali et al., 2010). Modified chemokines may also be able to form homo- or 
hetero-oligomers with wild type chemokines, potentially further altering function.     
All this evidence highlights the need to establish the function of chemokines within 
the inflammatory environment and not merely the simple presence of the proteins. 
For example, any biopsy stained for chemokines is only seeing part of the story; in 
vivo function cannot be established by antibody staining. This is especially 
important in inflammatory conditions where many modifications are possible. 
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5.1.1 SPECIFIC AIMS  
This chapter examined the alteration in chemokine biology following nitration by 
peroxynitrite, focusing on CCL2. Specifically these aspects were examined: 
 Chemotaxis - bare membrane, transendothelial and in vivo 
 Receptor binding and intracellular signalling 
 GAG binding 
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5.2 SPECIFIC MATERIALS AND METHODS 
5.2.1 RADIOLIGAND BINDING ASSAY 
Radioligand competition assays were performed to assess differences in CCR2 
binding between CCL2 and nCCL2. These are competition assays in which 
radiolabelled CCL2, in this case labelled with 125I, is used as a tracer to compete 
with unlabelled chemokine to determine ligand affinity for the receptor. For these 
experiments the affinities of CCL2 and nCCL2 for CCR2b were determined. The 
higher the radiation level at the end of the experiment, the less unlabelled protein 
is bound and so the lower the affinity of the chemokine for its receptor.   
200,000 HEK-CCR2b per tube were resuspended in 30µl binding buffer (1mM 
CaCl2, 5mM MgCl2, 50mM HEPES, 0.5% BSA, pH7.2). 100µl CCL2 or nCCL2 in 
binding buffer was then added at a final concentration of 0.1-650nM. Finally a 
tracer amount of [125I]-CCL2 (Perkin Elmer) in 20µl binding buffer was added and 
tubes incubated on ice with agitation for 2hr. Cells were then washed twice using 
wash buffer (binding buffer with 0.5M NaCl) before resuspending cells in 1ml 
dH2O. A negative control with no un-labelled chemokine added was also 
performed. Counts per minute (CPM) were measured using a gamma counter 
(Perkin Elmer; Medical Physics department, Royal Victoria Infirmary, Newcastle, 
UK) with the help of J Lloyd and E Howell and background radiation readings 
subtracted from results. All radiation work was performed in the designated 
radiation laboratory. Experiments were performed three times in triplicate and 
IC50 values calculated using ‘one site competition analysis’ in GraphPad Prism 5.0.   
5.2.2 PROTEOME PROFILER ANTIBODY ARRAYS 
To see if CCL2 and nCCL2 trigger different intracellular signalling pathways in 
THP-1 Proteome ProfilerTM antibody arrays (R&D Systems) were used. The kits 
used in this study were the human phospho-MAPK array and the human phospho-
kinase array and were carried out according to the manufacturer’s instructions. 
Briefly, membranes which are pre-spotted with capture antibodies were blocked 
and then incubated with a mix of cell lysate and biotinylated-detection antibody 
overnight. After washing, membranes were incubated with streptavidin-HRP 
followed by chemi-luminescent reagent and manually developed. Densitometry 
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analysis was performed using Photoshop, and the density value normalised to 
reference spots on each membrane, minus the negative control value was plotted. 
5.2.2.1 Cell Stimulation and Lysis 
THP-1 were allowed to settle out of suspension overnight as previous work found 
centrifugation caused high levels of background MAPK activation (Chaffey, 2004). 
Cells were then gently resuspended at approximately 2.5x10-6 cells per ml in 
serum free RPMI for 2hr at 37°C prior to a 5min incubation (O'Boyle et al., 2007) 
with or without 10nM chemokine. Cell lysate was then prepared as per kit 
instructions. Briefly, cells were washed with PBS and resuspended at 1 x 107 
cells/ml in lysis buffer. For lysis to occur samples were incubated at 4°C for 30min 
with agitation before centrifuging for 5min at 14 000xg. To ensure equal sample 
loading, protein levels were then determined using a BCA assay and compared to a 
standard curve (Figure 5-1), as described in section 2.7, and 250µg protein added 
to each membrane. 
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Figure 5-1 BCA protein assay standard curve 
Example standard curve from a BCA assay used to determine the protein concentration in cell 
lysates. 
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5.2.3 HEPARIN BINDING ASSAYS 
5.2.3.1 Development of solid-phase heparin binding assay 
Solid phase heparin assays were performed to establish alteration in heparin 
binding between wild type and nitrated CCL2. These assays are ELISA based 
assays, similar to the basic protocol described in section 2.5.1, but instead of a 
capture antibody, plates are coated with heparin. Due to technical difficulties there 
were many stages in the development of these assays. 
First, Immulon 4HBX microtitre plates were coated overnight with 250µg/ml poly-
L-lysine (Sigma) at 4°C to create a positively charged surface for heparin to bind to 
(all volumes are 100µl). Heparin (25µg/ml, Sigma) was then incubated for 2hr at 
RT before blocking with 1% BSA/PBS for 1hr. 10-1000ng/ml CCL2 was added for 
1hr and then detected using a polyclonal anti-CCL2 antibody (1/1500, 2hr, RT; AB-
279-NA, R&D Systems) and anti-goat-HRP (1/5000, 2hr, RT; A5420, Sigma). The 
assay was developed using OPD but there was no detectable signal. 
In order to determine if the failure to detect bound CCL2 was due to a lack of 
heparin binding, 1,9-Dimethyl-methylene blue (DMMB) solution (35mM NaCl, 
40mM  glycine, 40M DMMB, pH3.0) was used. This should change from blue to 
purple in the presence of GAGs. Poly-L-lysine however was found to prevent this 
colour change occurring, presumably by interfering with the charge which is 
important for the colour change, so this method could not be used to check that 
heparin was bound to the plate.  
To establish if the lack of detection was a problem with the antibodies used a 
direct ELISA was performed, using the basic protocol described in section 2.5.1.1. 
Reagents from a CXCL12 Duoset kit (R&D Systems) were used as a positive control. 
CCL2 detection was performed as above. The assay was developed using both OPD 
and TMB, stopped using 1M H2SO4 and read at 492nm and 450/595nm 
respectively. The results showed that the detection system used does detect both 
CCL2 and CXCL12 in a direct ELISA and that TMB (R&D Systems – from Duoset) is 
a more sensitive development method (Figure 5-2). 
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To further investigate if heparin immobilisation was the problem a 4HBX plate 
coated with poly-L-lysine and a Heparin/GAG binding plate (Iduron) were 
compared. Both plates were incubated with heparin overnight prior to performing 
a similar binding assay as first performed. Protocol alterations were made as 
follows, as recommended by Iduron for use with plates. Plates were coated with 
100µl heparin per well – 25µg/ml in standard assay buffer (SAB; 100nM NaCl, 
50mM sodium acetate, 0.2% v/v Tween 20, pH7.2) and incubated overnight at RT. 
Plates were then washed three times in SAB prior to blocking with 150µl/well, 1% 
BSA/PBS for 1hr at 37°C. Plates were washed before 100µl/well chemokine in 1%  
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Figure 5-2 Direct ELISA for CCL2 and CXCL12 
By direct ELISA both CCL2 and CXCL12 could be detected using OPD and TMB showing the 
antibodies and detection methods are suitable for the detection of chemokine. No primary antibody 
(NPA) controls are shown.   
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Figure 5-3 Comparison of heparin binding strategies 
HBX plates coated with poly-L-lysine and GAG binding plates (Iduron) were compared for their 
ability to bind heparin, and subsequently chemokine. No primary antibody (NPA) controls are 
shown.   
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BSA/PBS added for 2hr at 37°C. Suitable detection antibodies were used and 
developed using TMB. CXCL12 was detectable on both plates within minutes. After 
1hr there was no visible detection of CCL2 above background (Figure 5-3).  
If the anti-CCL2 antibody used detected an epitope which overlapped with the 
heparin binding site the antibody would either be unable to bind, or would 
compete off the heparin and both CCL2 and antibody would wash off, either way 
would result in no detection. For this reason a second CCL2 antibody was tested 
(MAB2791, R&D Systems). Using this antibody heparin bound CCL2 was detected 
(Figure 5-4).  
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Figure 5-4 Detection of heparin bound CCL2 
CCL2 bound to immobilised heparin can be detected using the monoclonal antibody (MAB2791, 
R&D Systems) with appropriate secondary antibody and TMB. 
 
5.2.3.2 Optimised method  
Heparin/GAG binding plate (Iduron) was coated with 100µl heparin per well – 
25µg/ml in SAB and incubated overnight at RT. Plates were then washed three 
times in SAB prior to blocking with 150µl/well, 1% BSA/PBS for 1hr at 37°C. Plates 
were washed before 100µl/well chemokine in 1% BSA/PBS was added for 2hr at 
37°C. Plates were then washed prior to incubation with detection antibody. For 
CCL2 this was MAB2791, R&D Systems, 0.5µg/ml in block buffer for 2hr at RT. 
After washing, detection antibody was added for 2hr at RT (anti-mouse IgG-HRP, 
Sigma; 1/5000). For nCCL2 the detection antibodies were anti-3-nitrotyrosine 
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(1/1000; Millipore) and anti-rabbit IgG-HRP (Sigma; 1/5000). The assay was then 
developed using TMB, 100µl/well, and stopped with 50µl 1M H2SO4. Plates were 
then read at 450nm with 595nm correction. 
5.2.4 SURFACE PLASMON RESONANCE  
5.2.4.1 General principles 
Surface plasmon resonance (SPR) is a powerful and reproducible technique used 
to study the interaction between molecules without the need for labelling and is 
the phenomenon used by Biacore systems. The technique involves immobilising 
one molecule (ligand) onto the surface of a sensor chip, and then flowing the other 
molecule of interest (analyte) over the surface. Binding of the molecules to the 
sensor surface generates a response which is proportional to the bound mass, and 
can be sensitive to changes of a few picograms per mm2. As binding events are 
monitored in real time a range of interaction characteristics can be determined.  
Biacore chips consist of a glass slide coated with a 50nm layer of gold, acting as an 
electrically conducting surface; SPR occurs when polarised light hits this surface. 
Electron charge density waves called plasmons are generated, reducing the light 
reflected at a specific angle (the resonance angle) in proportion to the mass bound 
to the chip surface (see Figure 5-5). The interface must be in conditions of total 
internal reflection for SPR to occur. Alterations in binding can therefore be read 
out in resonance units (RU). 
All SPR work was performed in the Institut de Biologie Structurale, Grenoble, 
France with the help of Dr Hugues Lortat-Jacob using a Biacore 3000. The running 
buffer used was HBS-P (10mM HEPES pH7.4, 150mM NaCl, 0.005% P20). Unless 
stated all reagents are from GE Healthcare. 
5.2.4.1 Streptavidin Immobilisation 
The surface of Biacore chips are coated with a matrix of covalently attached 
carboxymethylated dextran, an unbranched carbohydrate polymer which is 
flexible, allowing movement of the attached ligand. For the experiments in this 
study a CM4 chip was used. This has a lower level of carboxymethylation than  
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Figure 5-5 Surface plasmon resonance  
Upper panel - schematic of surface plasmon resonance. GAG is immobilised to the gold plated 
sensor surface using dextran and streptavidin. As the chemokine (analyte) binds to the GAG, the 
refractive index shifts and the SPR angle alters. The movement is the signal monitored, and the 
change over time forms the sensorgram. 
Lower panel - sensogram cartoon showing alteration in RU with association and dissociation of the 
(chemokine) analyte. The more analyte binds to the chip surface, the larger the increase in RU.     
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other chips, resulting in reduced ligand immobilisation and a lower surface charge 
density. This helps to reduce the non-specific binding of positively charged 
molecules, for example chemokines, and is beneficial when investigating kinetics 
as low levels of ligand immobilisation levels are optimal. There are several 
methods for covalent attachment to the chip surface, for streptavidin amine 
coupling is used. This is stable, allowing the chip to be reused multiple times. For 
coupling the surface must first be activated with 50µl 0.2M 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) and 50µl 0.05M N-hydroxysuccinimide 
(NHS). This activates the carboxyl groups on the chip surface, forming reactive 
succinimide esters which can spontaneously react with nucleophilic groups such 
as amines, in this case covalently attaching streptavidin to the chip surface. 
The immobilisation process is shown in Figure 5-6. 50µl streptavidin (0.2 mg/ml, 
Sigma, in 10mM acetate buffer, pH 4.2) was injected over the activated surface. The 
buffer must be below the isoelectic point of the ligand, but needs to be above the 
pKa of the surface (pH3.5), in this case pH4.5 was used as the pI of streptavidin is 
~pH5. Once streptavidin is immobilised, 1M ethanolamine HCl, pH8.5, is injected 
as it deactivates any of the remaining active groups and removes any unbound 
ligand which would interfere with subsequent heparin immobilisation. 
 
Figure 5-6 Streptavidin immobilisation 
Trace showing the activation of a CM4 chip using EDC and NHS, followed by streptavidin 
immobilisation and deactivation by ethanolamine. 
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5.2.4.2 GAG Immobilisation 
a) GAG Biotinylation  
Heparin and heparan sulphate were biotinylated to allow immobilisation on to the 
chip by streptavadin. Mono-biotinylation at the reducing end of the GAG is 
important for correct presentation when immobilised.  
Biotinylation was performed by H. Lortat-Jacob as described previously (Sadir et 
al., 2001; Saesen et al., 2013). Briefly, 1mM heparin (9kDa; Sigma) or heparan 
sulphate (12kDa; Sigma) in PBS was reacted with 10mM biotin-LC-hydrazide for 
24hr at RT. This was then dialysed against water to remove any unreacted biotin, 
and freeze dried for storage. 
b) Immobilisation 
Biotinylated heparin and heparan sulphate were immobilised as follows. 5-
20µg/ml biotinylated heparin in 300mM NaCl, was injected at 10µl/min for 30sec 
followed by a 2M NaCl wash to remove unbound heparin. Injections were repeated 
until a total RU of 50-150 was achieved (see Figure 5-7). For heparan sulphate 
immobilisation, a 5µl injection of 50µg/ml biotinylated heparan sulphate was 
injected at a flow rate of 5µl/min. The surface was again washed with 2M NaCl and 
injections repeated until an RU increase of 200 reached.     
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Figure 5-7 Heparin immobilisation 
Plot showing immobilisation of heparin to the streptavidin coated chip. Two injections were 
needed to reach the RU increase required. The increase in RU from baseline is shown by the red 
lines. 
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5.2.4.3 Chemokine SPR 
Following preparation of the chip surface, SPR was performed to compare the GAG 
binding properties of CCL2 and nCCL2. 
A range of chemokine concentrations (66-500nM) were flowed across the chip at 
25µl/min for 5mins followed by a 500sec dissociation phase.  
RU from a flow cell coated with streptavidin only was subtracted from the results 
from GAG coated flow cells and analysis was performed using BIAevaluation 4.1. 
5.2.5 IN VIVO CHEMOTAXIS 
In vivo chemotaxis assays were performed using the air pouch model outlined in 
section 2.8.2. Eight-week old female BALB/c mice (Charles River, UK) were used 
for generation of air pouches and animal work was performed by Prof. Simi Ali and 
technicians in the Comparative Biology Centre, Newcastle University. On day 6, 
each pouch was injected with 1ml PBS containing either 10μg CCL2, nCCL2 or PBS 
alone. After 18hr recruited cells were recovered by lavaging the pouch. The 
exudates were centrifuged (500xg, 5min) and cell pellets resuspended in 1% 
FBS/PBS. Resuspended cells were then split into tubes to allow cells to be both 
counted and identified. Cells were counted by haemocytometer, or stained for 
mCD3 and mCD45 and analysed by flow cytometry. Figure 5-8 shows the gating 
strategy used to identify cell populations in the pouch and was performed with the 
help of Dr Chris Lamb. The percentage of each population was established and 
multiplied by the total number of cells in each pouch to calculate the total number 
of, for example, CD45+ cells which have migrated into the pouch.  
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Figure 5-8 Flow cytometry gating strategy for the air pouch chemotaxis assay 
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5.3 RESULTS 
5.3.1 EFFECT OF NITRATION ON BARE MEMBRANE CHEMOTAXIS  
The previous chapter demonstrated that incubation with peroxynitrite leads to the 
nitration of chemokines. This chapter shows how nitration alters the function of 
these chemokines. Figure 5-9 and Figure 5-10 show CCL2 nitration decreases its 
ability to recruit both monocytes and T cells in bare membrane chemotaxis assays. 
Two sources of chemokine were used, Almac (synthetic) and Peprotech 
(recombinant), to confirm these findings. For monocyte chemotaxis although 
minor differences were seen between the two CCL2 sources these were only 
statistically significant at 1nM nCCL2 (p=0.0019). For T cell recruitment there was 
no overall differences between Almac and Peprotech although in some 
experiments slight differences were seen. For example in the one shown in Figure 
5-10 Almac CCL2 and nCCL2 has significantly higher increase in recruitment at 
1nM. Of note is that nitration of CCL2 in these experiments does not completely 
abrogate function even though it is decreased in comparison to wild type.    
An increasing concentration of peroxynitrite used for CCL2 modification increases 
the reduction of monocyte recruitment (Figure 5-11). At high concentrations 
however there is a risk that some protein degradation could occur and so this 
decrease may not be specifically due to an increase in nitration.   
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Figure 5-9 The functional effect of CCL2 nitration on monocyte recruitment 
Chemotaxis using PBMC with both wt and peroxynitrite modified CCL2 (nCCL2) from both Almac 
and Peprotech was performed. Cells were placed in a 3µm filter above a chemokine containing well, 
incubated at 37°C for 90min, then migrated cells counted. Graph shows migrated cells adhered to 
the filter per high power field (mean of 5 fields per filter shown). No chemokine control displayed 
by dotted line. Representative data of three experiments, performed in triplicate.  
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Figure 5-10 The functional effect of CCL2 nitration on T cell recruitment 
Chemotaxis using PBMC with both wt and peroxynitrite modified CCL2 (nCCL2) from both Almac 
and Peprotech was performed. Cells were placed in a 3µm filter above a chemokine containing well, 
incubated at 37°C for 90min, then migrated cells counted. Graph shows cells migrated into the 
lower well as a ratio to beads by flow cytometry. No chemokine control displayed by dotted line. 
Representative data of three experiments, performed in triplicate. 
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Figure 5-11 The effect of peroxynitrite concentration on CCL2 nitration and the functional 
effect on monocyte recruitment 
CCL2 was incubated with 1 or 10mM peroxynitrite for 10min at 37°C prior to chemotaxis using 
PBMC. Cells were placed in a 3µm filter above a chemokine containing well, incubated at 37°C for 
90min, then migrated cells counted. Graph shows migrated cells adhered to the filter per high 
power field (mean of 5 fields per filter shown). No chemokine control displayed by dotted line. 
Representative data of three experiments, performed in triplicate. 
 
To determine if this decrease in function following nitration was a finding specific 
to CCL2 or a more wide-ranging effect, the other chemokines examined in Chapter 
4 were also tested. Like CCL2, nitration of CCL5 significantly decreased its ability to 
recruit both monocytes and T cells at a range of chemokine concentrations (Figure 
5-12). Unlike CCL2, function was completely lost following nitration, a much more 
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severe effect on function than was found with CCL2. Figure 5-13 shows CXCL8 
function is also decreased following nitration. At 10nM there is no recruitment of 
neutrophils in response to nCXCL8. 
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Figure 5-12 The functional effect of CCL5 nitration on monocyte and T cell recruitment 
Chemotaxis using PBMC with both wt and peroxynitrite modified CCL5 (nCCL5) was performed. 
Cells were placed in a 3µm filter above a chemokine containing well, incubated at 37°C for 90min, 
then migrated cells counted. Left – Graph shows migrated monocytes adhered to the filter per high 
power field (mean of 5 fields per filter shown). Right - Graph shows T cells migrated into the lower 
well as a ratio to beads by flow cytometry. No chemokine control displayed by dotted line. 
Representative data of three experiments, performed in triplicate. 
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Figure 5-13 The functional effect of CXCL8 nitration on neutrophil recruitment 
Chemotaxis using neutrophils with both wt and peroxynitrite modified CXCL8 (nCXCL8) was 
performed. Cells were placed in a 3µm filter above a well containing 10nM chemokine, incubated at 
37°C for 90min, then migrated cells counted. Graph shows cells migrated into the lower chamber 
and counted by haemocytometer. No chemokine control displayed by dotted line. Combined data of 
three expreiments, performed in triplicate.  
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5.3.2 EFFECTS OF NITRATION ON SINGLE RECEPTORS   
To establish if the effect of nitration on cell recruitment was mediated through 
chemokine receptors, chemotaxis assays were performed using transfected cells 
expressing only the chemokine receptor of interest. Figure 5-14 confirms the 
expression of CCR2b, the receptor for CCL2, on HEK transfectants. Chemotaxis 
assays showed that at 10nM, HEK-CCR2b recruitment was significantly impaired 
following CCL2 nitration (Figure 5-15). This suggests that the decrease in T cell 
and monocyte recruitment is mediated through this receptor.  
 
Figure 5-14 CCR2 expression on HEK-CCR2b transfectants  
Representative flow cytometry staining of wild type HEK (left) and HEK-CCR2b transfectants 
(right) for CCR2 (black) and isotype control (red). 
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Figure 5-15 The functional effect of CCL2 nitration on HEK-CCR2b recruitment 
Chemotaxis using HEK-CCR2b with both wt and peroxynitrite modified CCL2 (nCCL2) was 
performed. Cells were placed in a fibronectin coated 8µm filter above a chemokine containing well, 
incubated at 37°C for 6hr, then migrated cells counted. Graph shows migrated cells adhered to the 
filter per high power field (mean of 5 fields per filter shown). No chemokine control displayed by 
dotted line. Representative data of three experiments, performed in triplicate. * p = 0.0198  
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There is precedent for post-translational modification changing the receptor usage 
of the chemokine. For this reason chemotaxis assays with CHO-CCR5 were also 
performed with CCL2 and nCCL2. Receptor expression on the transfectants was 
confirmed in Figure 5-16 and chemotaxis in Figure 5-17 shows neither CCL2 nor 
its nitrated form can recruit cells through CCR5. This assay also demonstrated 
decreased recruitment of cells in response to nCCL5 compared to CCL5 (Figure 
5-17) showing that, as with CCL2/CCR2, at least some of the decrease in PBMC 
recruitment is mediated through this receptor.   
 
Figure 5-16 CCR5 expression on CHO-CCR5 transfectants  
Representative flow cytometry staining of wild type CHO (left) and CHO -CCR5 transfectants (right) 
for CCR5 (black) and isotype control (red). 
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Figure 5-17 The functional effect of nitration on CHO-CCR5 recruitment 
Chemotaxis using CHO-CCR5 with both wt and peroxynitrite modified CCL2 and CCL5 was 
performed. Cells were placed in a fibronectin coated 8µm filter above a well containing 10nM 
chemokine, incubated at 37°C for 5hr, then migrated cells counted. Graph shows migrated cells 
adhered to the filter per high power field (mean of 5 fields per filter shown). No chemokine control 
displayed by dotted line. Representative data of three experiments, performed in triplicate. t-test, 
*** p=0.0005. 
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To determine if the decrease in recruitment of HEK-CCR2b in response to nCCL2 
compared to CCL2 was due to a decrease in CCR2b binding, radioligand binding 
assays were performed. Figure 5-18 shows nCCL2 binds the receptor with a ten-
fold lower affinity than the wild type form of the chemokine. The assay was 
performed three times in triplicate and the details of each repeat are shown in 
Figure 5-18. Although there is variation between the repeats an approximate ten-
fold decrease was found each time. In two of the three repeats the measurements 
at 10nM are significantly different by t-test. Overall however, the IC50 values of 
CCL2 and nCCL2 are not statistically different.       
10-11 10-10 10-9 10-8 10-7 10-6
0
500
1000
1500
CCL2
nCCL2
Chemokine (M)
C
o
u
n
ts
 p
e
r 
m
in
u
te
 
 CCL2 nCCL2 
Repeat 1 2 3 1 2 3 
IC50 1.56x10-9 6.30x10-10 3.33x10-9 1.90x10-8 8.18x10-9 3.65x10-8 
95% CI 
Upper 
 
2.43x10-11 
 
4.43x10-11  
 
1.50x10-9  
 
5.72x10-12 
 
5.77x10-10 
 
1.12x10-8  
Lower 1.00x10-7 8.97x10-9 7.39x10-9 6.30x10-5 1.16x10-7 1.19x10-7 
 
Figure 5-18 The effect of CCL2 nitration on CCR2 binding 
Radioligand binding assays comparing the ability of CCL2 and nCCL2 to bind CCR2. Assays were 
carried out using HEK-CCR2b, and 125I-CCL2 used as a tracer. Graph shows nitration decreases 
receptor binding ten-fold (IC50 CCL2=3nM, nCCL2=36nM). Representative of three experiments. 
Table gives details of the individual repeats with the 95% confidence intervals (CI). 
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5.3.3 EFFECTS OF NITRATION ON INTRACELLULAR SIGNALLING 
To establish if there were differences in downstream signalling following THP-1 
stimulation with either CCL2 or nCCL2, Proteome Profiler arrays were performed. 
THP-1 express the appropriate receptor, CCR2, as demonstrated in Figure 5-19. An 
example from the phospho-kinase array is shown in Figure 5-20. No significant 
alterations were found in intracellular signalling between CCL2 and nCCL2 
although for most proteins examined phosphorylation is above that of PBS, the 
negative control. Although there do appear to be some differences, for example to 
AMPKα1, the difference is small and unlikely to be biologically significant.  
 
 
Figure 5-19 CCR2 expression on THP-1  
Representative flow cytometry staining of THP-1 for CCR2 (black) and isotype control (red). 
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5.3.4 EFFECTS OF NITRATION ON GAG INTERACTIONS 
GAG binding is an important property of chemokines for in vivo function. If 
nitration altered the ability of CCL2 to interact with GAGs was assessed by two 
methods. Solid-phase heparin binding assays (Figure 5-21) indicated that nCCL2 
did not bind to immobilised heparin. Due to the complications of detecting nCCL2 
using antibodies, as discussed in sections 5.2.3 and shown in Figure 4-10, the same 
method of detection could not be used for both CCL2 and nCCL2. This means direct 
comparison could not be made between the two results. To eliminate this problem, 
Biacore, an antibody free technique, was used. Biacore confirmed that nCCL2 does 
not bind to heparin unlike the wild type form (Figure 5-22). A decreased alteration 
in RU was seen with a decrease in heparin density on the chip surface for both 
forms (Figure 5-23). The same lack of binding of nitrated CCL2 is also seen with 
heparan sulphate (Figure 5-24), a more physiologically important GAG.    
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Figure 5-21 Solid-phase heparin binding assays with CCL2 and nCCL2 
Solid-phase heparin assays were performed with CCL2 and nCCL2, and bound chemokine detected 
using anti-CCL2 or anti-3-nitrotyrosine (3-NT) antibodies. Representative of two experiments. 
Functional Effects of Nitration 
157 
 
200 400 600
0
100
200
300
400
0nM
66nM CCL2
98nM CCL2
148nM CCL2
222nM CCL2
333nM CCL2
500nM CCL2
Time (s)
R
U
200 400 600
0
100
200
300
400
0nM
66nM nCCL2
98nM nCCL2
148nM nCCL2
222nM nCCL2
333nM nCCL2
500nM nCCL2
Time (s)
R
U
 
Figure 5-22 Alteration in higher density heparin interaction following CCL2 nitration 
Biacore was used to assess the alteration in heparin interaction following CCL2 nitration. 66-
500nM chemokine was flowed over immobilised heparin (142RU bound) and the alteration in 
resonance units (RU) shown. Upper – CCL2, Lower – nCCL2. Representative data of two 
experiments 
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Figure 5-23 Alteration in lower density heparin interaction following CCL2 nitration 
Biacore was used to assess the alteration in heparin interaction following CCL2 nitration. 66-
500nM chemokine was flowed over immobilised heparin (50RU bound) and the alteration in 
resonance units (RU) shown. Upper – CCL2, Lower – nCCL2. Representative data of two 
experiments 
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Figure 5-24 Alteration in heparan sulphate interaction following CCL2 nitration 
Biacore was used to assess the alteration in heparan sulphate interaction following CCL2 nitration. 
66-500nM chemokine was flowed over immobilised heparan sulphate (237RU bound) and the 
alteration in resonance units (RU) shown. Upper – CCL2, Lower – nCCL2. Representative data of 
two experiments 
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5.3.5 TRANSENDOTHELIAL CHEMOTAXIS 
The chemotaxis assays performed so far in this study have been using a bare 
membrane system. Transendothelial chemotaxis assays are a more physiological 
approach to studying chemokine function as cells need to cross the endothelium in 
vivo for extravasation. In this system chemokines need to bind GAGs as well as 
activate appropriate receptors for cell migration to occur. Figure 5-25 shows that 
in such assays CCL2 nitration abolishes the recruitment of monocytes, a more 
substantial loss in activity than was found in bare membrane assays which is 
consistent with the loss of GAG binding.  
 
 
Figure 5-25 The functional effect of CCL2 nitration on monocyte recruitment across an 
endothelial layer 
Transendothelial chemotaxis using PBMC with both wt and peroxynitrite modified CCL2 (nCCL2) 
was performed. Cells were placed in a 3µm filter with an endothelial monolayer above a chemokine 
containing well, incubated at 37°C for 90min, then migrated cells counted. a) Graph shows migrated 
cells adhered to the filter per high power field (mean of 5 fields per filter shown). No chemokine 
control displayed by dotted line. Representative data of three experiments, performed in triplicate. 
** p=0.0029, **** p<0.0001 b) representative images of migrated cells at 10nM. 
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5.3.6 IN VIVO CHEMOTAXIS 
CCL2 nitration has been shown to impair function in both bare membrane and 
transendothelial assays. To see if nitration also decreases cell recruitment 
compared to wildtype CCL2 in vivo an air pouch chemotaxis model was performed. 
An initial pilot study was performed which indicated a decrease in the function of 
nCCL2 compared to CCL2. Cell counts are shown in Figure 5-26. Due to low animal 
numbers and animal death, along with anomalies in the PBS control, this did not 
reach significance and so robust conclusions could not be drawn.  
The experiment was therefore repeated with larger groups of eight mice and data 
agrees with the previous assay that nitration inhibits CCL2 function. Total cell 
counts from each pouch are shown in Figure 5-27. Data from lavages contaminated 
with blood have been excluded. Recruitment in response to CCL2 is significantly 
higher than to both PBS and nCCL2, with nCCL2 and PBS not being statistically 
significant. Using flow cytometry analysis the number of migrated CD3+ and CD45+ 
cells was calculated. Figure 5-28a shows CD45+ cells are the majority of cells 
migrated into the pouch, consisting of both T cells (Figure 5-28b) and monocytes 
(Figure 5-28c). All three cell populations follow the same pattern, with nitration 
preventing recruitment. Another observation from these experiments is that the 
spread of data is always less for nCCL2 than the other two groups. Although not 
statistically different to PBS, the negative control, the mean recruitment in the 
nCCL2 group is lower than that of the PBS treated group in all cases.      
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Figure 5-26 Cell counts from initial air pouch experiment  
Total cell migration into air pouches 18hr after intrapouch administration of 10µg CCL2, nCCL2 or 
PBS only control. Cells were counted by haemocytometer. Each symbol represents an animal. 
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Figure 5-27 The functional effect of CCL2 nitration on cell recruitment in vivo  
Total cell migration into air pouches 18hr after intrapouch administration of 10µg CCL2, nCCL2 or 
PBS only control. Cells were counted by haemocytometer. Statistics - one-tailed t-test - * p=0.04, ** 
p=0.0024, ns p=0.28. Each symbol represents an animal. 
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Figure 5-28 Effects of CCL2 nitration on the migration of different cell types in vivo    
Cells migrated into air pouches 18hr after intrapouch administration of 10µg CCL2, nCCL2 or PBS 
only control. Cell populations were identified by flow cytometry and absolute cell numbers 
calculated using data from haemocytometer counts. a) CD45+ migrated cells, b) CD3+CD45+ cells, c) 
monocytes identified by both CD45 positivity and FSC/SSC characteristics. Each symbol represents 
an animal.  
Functional Effects of Nitration 
164 
 
5.4 DISCUSSION 
The function of chemokines is tightly regulated, especially during times of stress. 
This chapter has shown the profound effects of chemokine nitration on chemokine 
function, a modification identified in chapter 4 which could potentially occur 
during oxidative stress. 
All three prototypical inflammatory chemokines found to be nitrated following 
incubation with peroxynitrite in chapter 4, namely CCL2, CCL5 and CXCL8, have 
decreased cell recruiting ability compared to the wild type proteins. For CCL2, in 
bare membrane transwell assays, the chemotactic potential for both T cells and 
monocytes following nitration is greatly reduced but the chemokine still has some 
function. The soluble diffusion gradient necessary for cell migration in this assay 
has still been formed but the chemokine has lost some function. The largest 
decrease being seen for T cell recruitment at 50nM where nitration decreases 
recruitment by 74%, however nCCL2 still causes recruitment significantly above 
the negative control (p=0.0182). For CCL5 and CXCL8 however the loss of function 
is more severe. Nitrated CCL5 and CXCL8 do not cause migration significantly 
different to the no chemokine control. This suggests that though no selectivity has 
been shown for which chemokines are able to be modified by peroxynitrite, the 
magnitude of the effects are varied. The reasons for this have not been elucidated 
but CCL5 contains more potential modification sites than CCL2 which may be a 
factor. Although both CCL2 and CCL5 have one tryptophan, CCL2 only has two 
tyrosines whereas CCL5 has five. In all cases assayed so far, nitration can be 
described as an anti-inflammatory modification. 
These findings for CCL2 are in some aspects inconsistent with findings by Molon et 
al. 2011 which found that, like this study, T cells do not migrate in response to 
nCCL2 but states that CD14+ cells do respond. However closer examination of the 
data in that paper shows that although there is no alteration in CD14+ cell response 
at 10nM chemokine, there is a significant decrease in response to nCCL2 compared 
to wild type at lower concentrations. This is the opposite of my findings which only 
gave a significant decrease in monocyte recruitment at 10nM or higher, a contrast 
to T cells in which significant differences could be seen at all chemokine 
concentrations.     
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The nitrated chemokines used in this study are potentially a mix of proteins with 
varied levels of nitration. Although this does not allow the exact determination of 
which residues are crucial for function this heterogeneous mix is arguably more 
physiological. It is very unlikely in vivo that all chemokine would be subject to the 
same level of modification. The half-life of radicals is generally short and the 
diffusion distance small, so chemokines not immobilised to, or present near, the 
site of RNS production may not be modified. Also, an area which has not been 
examined in this study is which other situations and modifications can modulate 
nitration. For example, if CCL2 is bound to heparin is it still subject to nitration? 
GAG binding has previously been shown to prevent enzymatic modifications such 
as the CD26 cleavage of CXCL12 (Sadir et al., 2004) which, although a different 
type of modification to the chemical reaction achieved with RNS, highlights how 
other aspects of in vivo biology can alter post-translational modification.    
To see if the decrease in migration in response to nCCL2 was mediated through the 
receptor CCR2b, migration assays using HEK transfectants were performed. These 
showed decreased recruitment at 10nM showing that at least some of the lack of 
function is mediated through the receptor. CCL2 can also bind the isoform CCR2a 
but this receptor has a lower level of surface expression due to cytoplasmic 
retention (Wong et al., 1997). For this reason CCR2b was chosen as the isoform to 
use in this study. Similar chemotaxis experiments were performed with nCCL5 and 
cells transfected with CCR5, one of the three CCL5 receptors. These experiments 
again showed decreased migration was mediated through the appropriate 
receptor and, fitting with the PBMC chemotaxis data, the effect of nitration is more 
severe for CCL5 than CCL2. Other CCL5 receptors have yet to be examined.  
Other post-translational modifications of chemokines have been shown to not only 
alter function through the appropriate receptors for wild type chemokine but to 
also have the ability to alter receptor usage.  For example CD26 cleaved CCL4 can 
still bind CCR5 but unlike the full form can also bind CCR1 and CCR2 (Guan et al., 
2002). For this reason chemotaxis assays with CCR5 transfectants were also 
performed with CCL2 and nCCL2. CCL2 nitration does not change its ability to bind 
CCR5 but this does not rule out the possibility that binding to other receptors is 
altered. However, the PBMC and HEK-CCR2b chemotaxis assays gave similar 
Functional Effects of Nitration 
166 
 
results suggesting the effects seen are mainly CCR2b dependent. It is therefore 
unlikely that binding to other receptors has been affected by nitration.  
To determine if the decrease in function was due to a lack of receptor binding, 
radioligand binding assays were performed. These showed that CCL2 nitration 
causes a 10 fold decrease in CCR2b binding but due to variation between repeats, 
overall the two forms were not statistically different. Previous studies suggest that 
although this level of decrease in receptor binding will effect chemotaxis, it is not 
sufficient to abrogate function and for antagonism (Paavola et al., 1998) and so the 
biological importance of such a decrease even if significance had been reached 
would be limited. Two crucial receptors which are yet to be examined are ACKR1 
and ACKR2. If nCCL2 also has decreased binding to these atypical receptors it 
could be predicted that there will be higher levels of the chemokine present as it 
cannot be sequestered. This may have profound effects on the in vivo biology. 
Previous work from our group and others demonstrates that chemokine receptors 
display biased agonism (O'Boyle et al., 2007; Zidar et al., 2009). For example CCR2, 
the receptor of most interest for this study, has four ligands. CCL8 activates 
different signalling pathways to the other three ligands, CCL2, CCL7 and CCL13. 
CCL8 cannot inhibit adenylate cyclase, does not induce nuclear translocation of 
ERK1 and has a delayed response in Akt activation compared to the other three 
ligands (O'Boyle et al., 2007). To determine if CCL2 nitration could also alter the 
downstream signalling pathways activated through CCR2, signalling arrays were 
performed. These assays show a general increase in phosphorylation following 
stimulation but there were no differences between CCL2 and nCCL2. It is however 
of note that phosphorylation is not uniformly an ‘on’ switch and can be used to 
downregulate signalling. Although the nitrated form of the chemokine does not 
bind the receptor with such high affinity as the wild type, it may be that at 10nM 
there is sufficient chemokine present to activate the ‘threshold’ number of 
receptors needed for signalling; a binary response and therefore not so sensitive to 
a small decrease in binding. This data is only n=1, due to experimental cost, and the 
assays performed are not fully quantitative so further work is needed to determine 
if there are differences in signalling and the biological implications of this data.     
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GAG interaction is an important aspect of chemokine biology and how nitration 
alters this was assessed by both solid-phase heparin binding assays and Biacore. 
Both these techniques show that nCCL2 is unable to bind heparin. It is of note that 
Biacore also shows that nCCL2 is unable to bind the less sulphated GAG heparan 
sulphate, which is more biologically relevant than heparin. This data suggests that 
even though nCCL2 is able to bind CCR2b, albeit with less affinity than the wild 
type protein, it will not function in vivo due to an inability to bind GAGs.  
Biacore is a very complex and powerful technique which can in some 
circumstances be used to determine the Kd of interactions. In this instance 
however it was not possible. Nitration caused a complete loss of binding so no 
kinetic data could be determined. For CCL2, binding was achieved but no kinetic 
models could successfully be fitted to the data. This is most likely due to the 
complexities of CCL2-GAG interactions. CCL2 can be present as a monomer, dimer 
and in larger oligomers and these multiple forms means that establishing kinetics 
is difficult. There are two distinct ‘on’ phases seen in Figure 5-22 - Figure 5-24, an 
initial rapid increase in RU, followed by a more gradual phase, suggestive that 
more than one form is present. These multiple phases could be rapid binding of 
pre-formed dimers or higher structures followed by slower binding of monomers. 
With further optimisation kinetics may be found for CCL2, and have previously 
been found by other groups (Piccinini et al., 2010; Salanga et al., 2014). This was 
not optimised during this study as the purpose of the experiment was to establish 
differences between the wild type and nitrated forms and not necessarily to 
determine exact kinetics.   
GAG density has been shown in some cases to affect chemokine binding so levels of 
immobilised heparin were assessed. However as discussed, affinities could not be 
determined and so differences between the heparin densities could not be shown. 
Wild type CCL2 affinity would not be expected to alter greatly between GAG 
densities however if the decrease in binding following nitration was due to a 
decrease in oligomerisation potential, the affinity would be expected to decrease 
on low density surfaces (Salanga et al., 2014). In this study very little binding was 
found following nitration even on higher density surfaces so this phenomenon is 
unlikely to be seen.   
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Difficulties in setting up the solid-phase heparin assay as described in section 
5.2.3.1 are interesting from the technical aspect. The polyclonal anti-CCL2 antibody 
(AB-279-NA, R&D Systems) originally tested was unable to detect heparin bound 
chemokine. Monoclonal antibodies have been specifically designed to investigate 
chemokine-GAG interactions (Burns et al., 1998) but polyclonal antibodies 
interfering with GAG binding have not been reported. As GAG bound chemokine is 
a vital context physiologically it is an important observation. This is similar to the 
concepts in the results Figure 4-10 - Figure 4-12  showing that due to chemokine 
post-translational modification, not all chemokine can be detected by antibodies 
and so physiologically relevant chemokine is being missed. These findings 
highlight, potentially more importantly that chemokine, with most likely ‘normal’ 
function also cannot be detected if it is GAG bound and functional.  
The residues nitrated in CCL2 were established in chapter 4, but exactly which 
modified residues are responsible for the alteration in function is unknown. Tyr13 
is one of the residues modified and has previously been shown to be crucial for 
CCL2 function. It is involved in receptor binding and signalling (Beall et al., 1996; 
Paavola et al., 1998; Jarnagin et al., 1999) and so modification of this residue could 
explain the decrease in receptor binding and bare membrane chemotaxis. As 
discussed earlier however the nitrated CCL2 used in this study is likely to be a 
heterogeneous mix of levels of nitration and so the exact involvement of this and 
other residues cannot be confirmed.  
The residues directly involved in GAG binding are positively charged amino acids 
such as arginine and lysine, neither of which is subject to nitration. Studies 
modifying such residues in CCL2 cause a decrease in GAG binding and therefore in 
vivo function (Chakravarty et al., 1998; Lau et al., 2004). Post-translational 
modifications such as citrullination which alter the charge of arginine residues also 
have profound effects on GAG binding (Proost et al., 2008). One potential 
explanation for nitration altering GAG binding is by disrupting dimerisation. As 
discussed in section 1.3.4 dimerisation is crucial for GAG binding. P8A and Y13A 
are obligate monomers with decreased GAG binding potential (Lau et al., 2004; 
Handel et al., 2008; Salanga et al., 2014), however the loss of GAG binding in these 
studies was not as severe as found following nitration. Dimerisation therefore is 
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unlikely to be the sole explanation for decreased function. Figure 5-29 highlights 
the position of Tyr 13 along the dimer interface and as Tyr 13 is subject to 
nitration this residue could again be the explanation for decreased function. If 
nitration affects the dimerisation ability of Tyr13, either by altering hydrogen 
bonding potential or altering the conformation of the protein then GAG binding 
will be affected.       
Another explanation for the substantial loss of GAG interaction could potentially be 
that nitration unfolds the protein. The chemokine however cannot be completely 
unfolded as there is at least some retention of receptor binding. Modification of 
Trp59, a residue found to be nitrated, could be predicted to cause protein 
unfolding and structure distortion (Personal communication with Prof Tracy 
Handel at the Gordon Research Conference, 2014). If this occurred but left the N-
terminal region structurally intact, the N-terminus would be predicted to still bind 
the receptor, with lower efficacy, but loss of general structure would prevent 
dimerisation and therefore GAG interaction. Detailed structural and biochemical 
analysis needs to be performed to determine exactly how nitration affects CCL2 
function, and that of other chemokines.   
 
Figure 5-29 CCL2 dimer structure  
Cartoon of a CCL2 dimer with potential nitration sites highlighted. Tyr13 from both monomers can 
be seen along the dimer interface. Monomers - yellow and grey, GAG binding sites – green, nitration 
sites - blue and red. 
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To confirm that loss of GAG binding following nitration causes the predicted loss of 
function, transendothelial chemotaxis assays, a more physiologically relevant 
variation of the technique requiring apical presentation of the chemokine for cell 
migration were performed. These showed complete abrogation of CCL2 function 
following nitration, a much more severe effect than was seen in the bare 
membrane assays. This confirms the GAG interaction data which suggests nitration 
prevents chemotaxis across the endothelium, a requirement for in vivo chemotaxis, 
due to lack of GAG binding. 
Establishing the in vivo implications of CCL2 nitration were the final experiments 
in this study. These assays confirmed all the data discussed so far that nitration 
abrogates the chemotactic potential of CCL2. Other interesting observations from 
this assay are the high level of basal recruitment into pouches in the absence of 
chemokine, and the differences seen between PBS and nCCL2 groups. The creation 
of a murine air pouch is in itself a proinflammatory event. It is therefore 
unsurprising that relatively large numbers of cells were recovered from the PBS air 
pouches. Numbers are comparable to previous similar studies from our group (Ali 
et al., 2005b; O'Boyle et al., 2009). The large spread of data seen in the PBS and 
CCL2 group is potentially because of variation during air pouch creation. As 
mentioned, creating an air pouch is inflammatory and the positioning of the needle 
or other experimental variations may alter the level of background inflammation 
induced, and the natural production of murine chemokines and associated cell 
recruitment. For nCCL2 treated mice however the spread of data is always less and 
also the mean value is lower than that of the PBS control. This decrease compared 
to control could be explained if nCCL2 causes heterologous receptor 
desensitisation, which may decrease both the spread of data and the level of 
background recruitment. It is actively anti-inflammatory, not just lacking 
proinflammatory properties. Further experiments need to be performed to 
determine if this phenomenon does occur in response to nCCL2. 
Overall the data in this chapter meets the three aims. If protein nitration, a 
modification which can occur during inflammation, occurs to chemokines, the 
function of the chemokines affected is reduced. Function decreased in all three 
forms of chemotaxis assay performed: bare membrane, transendothelial and in 
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vivo. This functional abrogation in the latter two is predominantly due to a 
decrease in GAG interaction and not mediated through the receptor CCR2b. 
Chemokine nitration is potentially a mechanism for self-regulation, preventing 
excessive cell recruitment during inflammation.  
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6 FINAL DISCUSSION 
6.1 SUMMARY OF AIMS AND OUTCOMES 
 To determine how tissue stress effects the production of the chemokines 
CCL2, CCL5, CXCL8 and CXCL10 
The tissue and stress specific nature of chemokine responses is known. Chapter 3 
established the range of responses of liver and kidney epithelium, the cell lines 
H69 and HKC8 respectively, to a number of tissue stresses. These stresses are 
either present during inflammation and transplantation, for example ROS, or non-
physiological models of stress, such as PMA. Results from qPCR experiments 
showed CXCL8 had the greatest capacity for induction both in terms of fold 
increase and the range of stimuli which could upregulate it; CCL5 demonstrated 
little increase at the time points assayed.  
The chemokines produced during stress were functional, as verified by both in 
vitro and in vivo chemotaxis assays. The effects of such a mix of chemokines can be 
blocked using the CXCR3 agonist PS372424, but not a CXCR3 blocking antibody, 
fitting with a previous study showing PS372424 can cause heterologous receptor 
desensitisation and therefore block chemotactic responses to chemokines, beyond 
those which are ligands to CXCR3. The chemokines within this mix may have 
undergone post-translational modification and therefore do not have ‘normal’ 
function. This was demonstrated by the purification of truncated CCL5 from HKC8 
cells which had been subject to oxidative stress.  
The concurrent presence of chemokines and nitro-oxidative stress was also 
demonstrated by immunohistochemical detection of CCL2 and 3-NT. These were 
found in liver, both in inflammatory conditions and ischaemia. Importantly, 
dramatically increased levels of 3-NT were found in a murine model of kidney IRI, 
a cause of injury known to considerably increase chemokine production.           
 To investigate which chemokines are subject to post-translational 
modification. Specifically if CCL2, CCL5 and CXCL8 undergo the oxidative 
stress associated modification, nitration, and if CCL5 citrullination occurs 
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Chemokines are induced and present during periods of oxidative stress. The first 
section of chapter 4 aimed to assess if chemokines are subject to nitration by 
incubation with the RNS peroxynitrite. Results show that CCL2, CCL5 and CXCL8 
can all undergo nitration, and that in CCL2 the residues modified are the two 
tyrosines and the tryptophan. Nitration alters our ability to detect all three 
chemokines by disrupting the epitope recognised by several commercially 
available antibodies.  
Studies of citrullination, another inflammation associated post-translational 
modification, have so far focussed on CXC chemokines. Here CCL5 was also found 
to be a target of PAD enzymes. Such enzymes are expressed by the liver and kidney 
epithelial cell lines used in other areas of this study and so citrullination could be 
predicted to occur in these cells, dependant on calcium levels.          
 Characterise the functional effects of nitration, focussing on CCL2 
Chemokine modification by peroxynitrite has been shown and chapter 5 
established the functional implications of the modification. In bare membrane 
chemotaxis assays all three chemokines tested showed decreased chemotactic 
potential following nitration. More detailed further studies were then performed 
using CCL2. These showed that although the decrease in chemotaxis seen in bare 
membrane assays could be attributed to CCR2b, as shown by chemotaxis with 
appropriate transfectants, a biologically significant decrease in receptor binding 
was not seen. No difference in intracellular signalling was detected but robust 
conclusions cannot be drawn from the signalling assays performed in this study 
due to lack of repetition.  
Nitration also disrupted the GAG binding potential of CCL2, detected by solid-
phase binding assays and Biacore. This lack of GAG interaction lead to a complete 
loss of function in transendothelial chemotaxis assays. Crucially, this was also seen 
in an in vivo air pouch model of chemotaxis where migration of both T cells and 
monocytes was lost.    
 
Discussion 
174 
 
6.2 IMPLICATIONS 
Chemokines are the key regulators of inflammation, controlling both its initiation 
and resolution. Fine tuning of the chemokine response is therefore crucial for the 
prevention of unnecessary and prolonged inflammation. As many diseases have an 
inflammatory aspect, it is not surprising that the chemokine system is a major 
focus for drug development. Unfortunately due the complexities of the chemokine 
system few of these drugs have made it to market (Horuk, 2009; Roy et al., 2014). 
Although many drugs appear to work in vitro and in animal models, few make it 
through phase II clinical trials. This is for a multitude of reasons, including lack of 
efficacy and unpredicted off-target effects. This highlights the need for greater 
knowledge of the basic biology of human chemokines. This study attempted to 
unravel more of the complexities of chemokine regulation that may occur in the 
inflammatory environment. 
The results of this study are summarised in Figure 6-1. Oxidative, as well as other 
forms of stress stimulate epithelial cells to produce increased levels of chemokine. 
This is not however an on/off response, as both the cell type and stimulus affect 
the chemokine upregulated. The chemokines produced in such situations however 
do not necessarily have an easily predicted function. As well as altering chemokine 
levels, stress can also modify both the levels and function of multiple enzymes and 
molecules which are capable of post-translational chemokine modification. PAD 
and CD26 are the enzymes responsible for such modifications that were assessed 
in this study. Although no evidence has been provided here that either of the 
enzymes is increased in epithelium during inflammation, PAD, the enzyme 
responsible for citrullination, is regulated by calcium levels which are known to 
increase during oxidative stress. CD26, a protease which can cleave chemokines, 
for example trimming the two N-terminal amino acids from CCL5, is expressed on 
T cells and other cells in inflammatory infiltrate (Morimoto and Schlossman, 
1998). Therefore even if it is not directly transcriptionally regulated by stress, the 
levels of the enzyme at sites during inflammation are increased.  
The effects of the co-incubation of chemokines with the RNS peroxynitrite is the 
main focus of this study. Levels of nitration by this reactive species have been 
shown to increase dramatically in the transplant and inflammation associated 
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situations examined. This study has shown nitration, caused by peroxynitrite, to be 
an anti-inflammatory modification, downregulating chemokine function. It could 
therefore be proposed that even though chemokine production is upregulated by 
oxidative stress, the increase in overall chemokine function would not be as great 
as predicted. This suggests a feedback loop wherein the same stimulus which 
increases chemokine production, also decreases chemokine function. This is a 
similar auto-inhibitory concept to a study of CCL8 which showed the same 
stimulus, in this case IL-1β and IFNγ, which increases CCL8 production, also 
increases proteolytic cleavage of the chemokine. This cleavage  results in an 
antagonist form of CCL8 (Struyf et al., 1998b). Overall, despite there being an 
increase in protein, the levels of functional chemokine do not increase to the same 
extent.  
The majority of studies carried out so far which assess the involvement of 
chemokines in disease assume the function of the chemokines detected to be 
‘normal’. Not only is this an over simplification of the situation, especially in vivo, 
but may be a confounding factor for the failure of chemokine based drug trials. The 
functional ability and therefore the potential biological role of each chemokine 
during disease needs to be fully established. Due to the chemokine specific effects 
of each modification, no general paradigm can be drawn; systematic analysis is 
needed. This analysis is needed not just in terms of alteration of function following 
modification but also alteration of detection. The majority of current detection 
methods do not differentiate between different forms of chemokine.  
Findings in this study show that nitration can, in some instances, prevent 
chemokine detection and highlight the need to establish which methods are able to 
identify which chemokines. Both commercial CCL2 antibodies tested were unable 
to bind nCCL2, however the situation is not universal as one CCL5 antibody could 
detect the nitrated form of this chemokine. Generalisations therefore should not be 
made. Studies using such antibodies to detect chemokine levels in inflammatory 
environments, for example Robertson et al., 2000, are therefore not ‘seeing’ the 
whole picture. This is arguably not important for the nitration modifications 
discovered in this study as although the nitrated chemokines generally cannot be 
detected, they also have decreased function. Other modifications however may  
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Figure 6-1 Chemokine regulation during inflammation 
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Chemokine biology is complex especially during times of stress, this figure summaries the findings 
of this study and some ideas for future work.  
a) Following tissue stress the transcription and production of numerous chemokines increases, as 
does the potential for chemokine post-translational modification. Data presented in this thesis 
shows nitration of CCL2, CCL5 and CXCL8 can occur although its presence is yet to be determined in 
vivo. CCL5 is also subject to citrullination, and N-terminal processing by CD26.  
b) CCL2 nitration abrogates function in vivo. The effects are predominantly due to an inability to 
interact with GAGs and therefore transendothelial migration cannot occur.  
c) Other non-GAG binding chemokines are able to not only desensitise the appropriate chemokine 
receptor but also others. If nCCL2 can desensitise receptors other than CCR2, and therefore have 
more extensive anti-inflammatory effects, this will have profound implications for in vivo 
chemokine regulation during times of stress.    
 
 
retain function but are unable to be detected and vice versa. Ensuring antibodies 
used can detect GAG bound chemokine is also important. It is imperative to 
determine the function and true levels of chemokines present otherwise roles in 
disease will be missed.  
Further analysis of the role of chemokines in disease is necessary and may help to 
explain certain paradoxes found between clinical outcome and chemokine levels. 
For example the finding that increased CXCL10 truncation is found in hepatitis C 
patients, and explains why increased levels of the chemokine correlate with 
decreased response to treatment, the opposite would be predicted (Riva et al., 
2014).  
In many studies transcription does not fully correlate with protein levels (Li et al., 
2014). There are numerous stages of regulation throughout protein production for 
example during translation, but lack of detection of modified proteins may also 
have an effect. The ability of nitration to prevent detection by antibody could 
explain a discrepancy between PCR and detectable protein levels in inflammatory 
environments. This however was not directly evaluated in this study. Although 
cells were treated by peroxynitrite and the subsequent alteration in chemokine 
levels assessed by both qPCR and ELISA, samples were taken 24 or 48hr after 
treatment for protein measurement. Due to the short half-life of peroxynitrite it 
will no longer be active once increased protein production occurs. Chemokine 
nitration is unlikely to occur in such situations without a repeat dose of 
peroxynitrite or co-incubation with cells capable of producing oxidative burst. No 
nCCL5 was found in peroxynitrite treated HKC8 samples when assessed by mass 
spectrometry, however for the reasons described above this finding was not 
Discussion 
178 
 
unexpected. Data in this study emphasise the importance of looking at chemokine 
function and not merely protein transcription or translation, especially if the 
protein levels are determined by antibody based techniques which do not 
differentiate between the forms present. There are reports in the literature of 
antibodies specific for the nitrated form of individual chemokines being developed.  
Work in this study suggests chemokine nitration could be an in vivo method of 
chemokine downregulation, preventing chronic inflammation and associated 
damage. Recent studies also show that chemokine nitration, and subsequent non-
function, may be a mechanism by which cancers can evade the immune system 
(Molon et al., 2011). The only situations evaluated for levels of protein nitration in 
this study are those of increased oxidative stress such as IRI and inflammatory 
liver conditions. However diseases can arise due to a lack of reactive species 
production, for example primary immunodeficiencies such as chronic 
granulomatous disease (CGD). These patients have problems with recurrent 
infection due to defects in the NADPH oxidase in phagocytes. This inhibits 
pathogen killing as they are unable to perform oxidative burst. As well as the 
anticipated problems with infection, there is increasing interest in observations 
that these patients also suffer from increased inflammation (Magnani et al., 2014). 
If nitration is a mechanism for the resolution of inflammation, the inability of these 
patients to produce RNS and therefore allow nitration to occur may go some way 
to explaining this inflammation dysregulation.    
6.3 FUTURE DIRECTIONS  
There are three main areas of future work regarding the biology of nCCL2 to come 
from this study: finding the structure of nCCL2 and so determining exactly how the 
modification disrupts function, establishing if nCCL2 is capable of heterologous 
desensitisation and therefore affecting the function of chemokines other than 
CCL2, and finally finding in vivo presence of nitrated chemokine in a transplant or 
other human inflammatory setting.  
The first area of future work builds on observations relating to the regulation of 
chemokine production by stress. This analysis was predominantly performed 
using qPCR which only gives relative results. Therefore even though the fold 
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increase of chemokine production in response to different stresses has been 
established, the overall importance of the chemokines induced in the epithelial 
cells studied is unknown. It would be interesting to compare changes in chemokine 
levels between rich sources present in inflamed tissues, for example macrophages 
and epithelium. Is a ten-fold increase in chemokine production from epithelium an 
overwhelming increase in protein production? Or is the basal level significantly 
lower than of the infiltrating immune cells that even relatively large upregulation 
by epithelial cells will not be significant pathologically?    
Nitration of the residue Tyr13 is likely to be the modification predominantly 
responsible for the loss of CCL2 function following peroxynitrite incubation due to 
its crucial role in both dimerisation and signalling. This study has only used a 
heterogenous mix of nitration levels and so the exact residues responsible for the 
functional change seen are unknown. For this reason more detailed structural and 
biochemical studies need to be performed. Evaluation of the structural 
consequences of nitration especially on dimerisation and protein unfolding is 
necessary, for example by NMR. Establishing the role of each nitrated residue may 
also help to explain differences found with the study by Molon et al., 2011 which 
only found nitrated tryptophan. 
In vivo chemotaxis assays showed that nCCL2 is unable to induce cell recruitment 
into a murine air pouch. This work should be extended to determine whether 
nitration not only downregulates the function of the chemokine modified, but also 
can have wider anti-inflammatory effects. This is depicted in Figure 6-1c. Previous 
experiments carried out by our group, similar to the air pouch model involving 
PS372424 (section 3.3.2), show that giving a non-GAG binding agonist, 
downregulates recruitment in response to a functional chemokine. To test this, the 
effect of nCCL2 i.v. on recruitment of immune cells to a CCL5 containing air-pouch 
could be assessed. Determining the wider reaching effects of chemokine nitration 
is crucial to understanding its potential role in the regulation in vivo chemokine 
biology. 
Not only does the basic biology of chemokine nitration need to be determined but 
the presence of nitrated chemokine needs to be established in transplantation and 
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other human inflammatory settings discussed in this study. Molon et al., 2011 
found nitrated CCL2 in cancer sections, and this study has shown increased 3-NT in 
transplant situations with increased chemokine production. It is therefore almost 
certain that the modification will occur. Developing a suitable ELISA or refining 
mass spectrometry analysis would help with the finding of such modifications, of 
both CCL2 and other chemokines. An nCCL2 specific antibody has been developed 
and used by Molon et al., 2011. However as mentioned previously the targets of 
nitration found in that study were different to this, and so the suitability of the 
antibody to detect all forms of nCCL2 is uncertain.  
It would also be of interest to determine if this modification is prevented if the 
chemokine is already GAG bound. If so, this would have profound implications for 
the global effects of nitration as a downregulator of chemokine function as 
significant amounts of chemokine could no longer be subject to modification if 
protected by GAG binding.  
6.4 CONCLUSIONS 
Chemokines are crucial for the induction and resolution of inflammation; it is 
therefore not surprising that the methods of their regulation alter during times of 
stress. This study shows that inducers of tissue stress can increase chemokine 
production in a chemokine, tissue and stress specific manner. The chemokines 
produced in such situations are able, unsurprisingly, to induce chemotaxis but the 
chemokine present may not have the predicted functions due to post-translational 
modifications.  
Nitration, a modification caused by reaction with RNS, increases in times of 
oxidative stress for example IRI and inflammation. This is a known protein 
modification but previously little work has established its effects on chemokine 
biology. CCL2, CCL5 and CXCL8 are all targets of nitration and in all three cases is 
an anti-inflammatory modification. Nitration also affects the detection of these 
chemokines in antibody based techniques. For CCL2, the focus of this work, the 
recruitment of both T cells and monocytes is decreased. This is in some part due to 
interaction with the receptor CCR2b but predominantly due to an inability to bind 
GAGs. This interaction is crucial to the in vivo function of chemokines as shown by 
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the lack of cell migration into an air pouch model in response to nCCL2. Overall this 
work demonstrates the complexities of chemokine regulation during inflammation 
and highlights how much more there is to discover. 
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